Hypertension Research (2014) 37, 362–387
© 2014 The Japanese Society of Hypertension All rights reserved 0916-9636/14
www.nature.com/hr

GUIDELINES (JSH 2014)

References

Hypertension Research (2014) **37,** 362–387; doi:10.1038/hr.2014.17

1 The Ministry of Health, Labour, and Welfare. The 2010 National Health and Nutrition Survey in Japan. 2012. Japanese. E-III
2 Miura K (chief investigator). Comprehensive research business on strategies to prevent/treat cardiovascular disease/lifestyle-related diseases such as diabetes mellitus by a scientific grant/subsidy from the Ministry of Health, Labour and Welfare, 'Research on the start of follow-up of the subjects of the 2010 National Health and Nutrition Survey (NIPPON DATA2010) and continuation of NIPPON DATA80/90 follow-up', Comprehensive/project study reports in 2012. 2013. Japanese. E-III
3 Miura K, Nagai M, Ohkubo T. Epidemiology of hypertension in Japan. *Circ J* 2013; **77**: 2226–2231. E-III
4 The Ministry of Health, Labour, and Welfare. Demographics in Japan in 2013. The Ministry of Health, Labour, and Welfare. 2013. Japanese. E-III
5 Kubo M, Kiyohara Y, Kato I, Tanizaki Y, Arima H, Tanaka K, Nakamura H, Okubo K, Iida M. Trends in the incidence, mortality, and survival rate of cardiovascular disease in a Japanese community: the Hisayama study. *Stroke* 2003; **34**: 2349–2354. E-III
6 Kitamura A, Sato S, Kiyama M, Imano H, Iso H, Okada T, Ohira T, Tanigawa T, Yamagishi K, Nakamura M, Konishi M, Shimamoto T, Iida M, Komachi Y. Trends in the incidence of coronary heart disease and stroke and their risk factors in Japan, 1964 to 2003: the Akita-Osaka study. *J Am Coll Cardiol* 2008; **52**: 71–79. E-III
7 Ueshima H. Explanation for the Japanese paradox: prevention of increase in coronary heart disease and reduction in stroke. *J Atheroscler Thromb* 2007; **14**: 278–286. E-III
8 Kimura Y, Takishita S, Muratani H, Kinjo K, Shinzato Y, Muratani A, Fukiyama K. Demographic study of first-ever stroke and acute myocardial infarction in Okinawa. *Japan Intern Med* 1998; **37**: 736–745. E-III
9 Imano H, Kitamura A, Sato S, Kiyama M, Ohira T, Yamagishi K, Noda H, Tanigawa T, Iso H, Shimamoto T. Trends for blood pressure and its contribution to stroke incidence in the middle-aged Japanese population: the Circulatory Risk in Communities Study (CIRCS). *Stroke* 2009; **40**: 1571–1577. E-Ib
10 Rumana N, Kita Y, Turin TC, Murakami Y, Sugihara H, Morita Y, Tomioka N, Okayama A, Nakamura Y, Abbott RD, Ueshima H. Trend of increase in the incidence of acute myocardial infarction in a Japanese population: Takashima AMI Registry, 1990–2001. *Am J Epidemiol* 2008; **167**: 1358–1364. E-III
11 Turin TC, Kokubo Y, Murakami Y, Higashiyama A, Rumana N, Watanabe M, Okamura T. Lifetime risk of acute myocardial infarction in Japan. *Circ Cardiovasc Qual Outcomes* 2010; **3**: 701–703. E-III
12 Turin TC, Kokubo Y, Murakami Y, Higashiyama A, Rumana N, Watanabe M, Okamura T. Lifetime risk of stroke in Japan. *Stroke* 2010; **41**: 1552–1554. E-III
13 Fujiyoshi A, Ohkubo T, Miura K, Murakami Y, Nagasawa SY, Okamura T, Ueshima H, Observational Cohorts in Japan (EPOCH-JAPAN) Research Group. Blood pressure categories and long-term risk of cardiovascular disease according to age group in Japanese men and women. *Hypertens Res* 2012; **35**: 947–953. E-Ia
14 Takashima N, Ohkubo T, Miura K, Okamura T, Murakami Y, Fujiyoshi A, Nagasawa SY, Kadota A, Kita Y, Miyagawa N, Hisamatsu T, Hayakawa T, Okayama A, Ueshima H, NIPPON DATA80 Research Group. Long-term risk of BP values above normal for cardiovascular mortality: a 24-year observation of Japanese aged 30 to 92 years. *J Hypertens* 2012; **30**: 2299–2306. E-Ib
15 Ikeda A, Iso H, Yamagishi K, Inoue M, Tsugane S. Blood pressure and the risk of stroke, cardiovascular disease, and all-cause mortality among Japanese: the JPHC Study. *Am J Hypertens* 2009; **22**: 273–280. E-Ib
16 Arima H, Tanizaki Y, Yonemoto K, Doi Y, Ninomiya T, Hata J, Fukuhara M, Matsumura K, Iida M, Kiyohara Y. Impact of blood pressure levels on different types of stroke: the Hisayama study. *J Hypertens* 2009; **27**: 2437–2443. E-Ib
17 Lawes CM, Rodgers A, Bennett DA, Parag V, Suh I, Ueshima H, MacMahon S, Asia Pacific Cohort Studies Collaboration. Blood pressure and cardiovascular disease in the Asia Pacific region. *J Hypertens* 2003; **21**: 707–716. E-Ia
18 Nippon Data 80 Research Group. Impact of elevated blood pressure on mortality from all causes, cardiovascular diseases, heart disease and stroke among Japanese: 14 year follow-up of randomly selected population from Japanese–Nippon data 80. *J Hum Hypertens* 2003; **17**: 851–857. E-Ib
19 Tanizaki Y, Kiyohara Y, Kato I, Iwamoto H, Nakayama K, Shinohara N, Arima H, Tanaka K, Ibayashi S, Fujishima M. Incidence and risk factors for subtypes of cerebral infarction in a general population: the Hisayama study. *Stroke* 2000; **31**: 2616–2622. E-Ib
20 Fukuhara M, Arima H, Ninomiya T, Hata J, Yonemoto K, Doi Y, Hirakawa Y, Matsumura K, Kitazono T, Kiyohara Y. Impact of lower range of prehypertension on cardiovascular events in a general population: the Hisayama Study. *J Hypertens* 2012; **30**: 893–900. E-Ib
21 Tozawa M, Iseki K, Iseki C, Kinjo K, Ikemiya Y, Takishita S. Blood pressure predicts risk of developing end-stage renal disease in men and women. *Hypertension* 2003; **41**: 1341–1345. E-Ib
22 Yamagata K, Ishida K, Sairenchi T, Takahashi H, Ohba S, Shiigai T, Narita M, Koyama A. Risk factors for chronic kidney disease in a community-based population: a 10-year follow-up study. *Kidney Int* 2007; **71**: 159–166. E-Ib
23 Kanno A, Kikuya M, Ohkubo T, Hashimoto T, Satoh M, Hirose T, Obara T, Metoki H, Inoue R, Asayama K, Shishido Y, Hoshi H, Nakayama M, Totsune K, Satoh H, Sato H, Imai Y. Pre-hypertension as a significant predictor of chronic kidney disease in a general population: the Ohasama Study. *Nephrol Dial Transplant* 2012; **27**: 3218–3223. E-Ib
24 Ninomiya T, Ohara T, Hirakawa Y, Yoshida D, Doi Y, Hata J, Kanba S, Iwaki T, Kiyohara Y. Midlife and late-life blood pressure and dementia in Japanese elderly: the Hisayama study. *Hypertension* 2011; **58**: 22–28. E-Ib
25 Hozawa A, Okamura T, Murakami Y, Kadowaki T, Okuda N, Takashima N, Hayakawa T, Kita Y, Miura K, Nakamura Y, Okayama A, Ueshima H, NIPPON DATA80 Research Group. High blood pressure in middle age is associated with a future decline in activities of daily living. NIPPON DATA80. *J Hum Hypertens* 2009; **23**: 546–552. E-Ib
26 Murakami Y, Hozawa A, Okamura T, Ueshima H, Evidence for Cardiovascular Prevention From Observational Cohorts in Japan Research Group (EPOCH-JAPAN). Relation of blood pressure and all-cause mortality in 180,000 Japanese participants: pooled analysis of 13 cohort studies. *Hypertension* 2008; **51**: 1483–1491. E-Ia
27 Ikeda N, Saito E, Kondo N, Inoue M, Ikeda S, Satoh T, Wada K, Stickley A, Katanoda K, Mizoue T, Noda M, Iso H, Fujino Y, Sobue T, Tsugane S, Naghavi M, Ezzati M, Shibuya K. What has made the population of Japan healthy? *Lancet* 2011; **378**: 1094–1105. E-Ia
28 Turin TC, Murakami Y, Miura K, Rumana N, Kita Y, Hayakawa T, Okamura T, Okayama A, Ueshima H, NIPPON DATA80/90 Research Group. Hypertension and life expectancy among Japanese: NIPPON DATA80. *Hypertens Res* 2012; **35**: 954–958. E-Ib
29 Nakamura Y, Yamamoto T, Okamura T, Kadowaki T, Hayakawa T, Kita Y, Saitoh S, Okayama A, Ueshima H, NIPPON DATA 80 Research Group. Combined cardiovascular risk factors and outcome: NIPPON DATA80, 1980–1994. *Circ J* 2006; **70**: 960–964. E-Ib
30 Nakamura K, Nakagawa H, Sakurai M, Murakami Y, Irie F, Fujiyoshi A, Okamura T, Miura K, Ueshima H, EPOCH-JAPAN Research Group. Influence of smoking combined with another risk factor on the risk of mortality from coronary heart disease and stroke: pooled analysis of 10 Japanese cohort studies. *Cerebrovasc Dis* 2012; **33**: 480–491. E-Ia
31 Kokubo Y, Okamura T, Watanabe M, Higashiyama A, Ono Y, Miyamoto Y, Furukawa Y, Kamide K, Kawanishi K, Okayama A, Yoshimasa Y. The combined impact of blood pressure category and glucose abnormality on the incidence of cardiovascular diseases in a Japanese urban cohort: the Suita Study. *Hypertens Res* 2010; **33**: 1238–1243. E-Ib
32 Ninomiya T, Kiyohara Y, Tokuda Y, Doi Y, Arima H, Harada A, Ohashi Y, Ueshima H, Japan Arteriosclerosis Longitudinal Study Group. Impact of kidney disease and blood pressure on the development of cardiovascular disease: an overview from the Japan Arteriosclerosis Longitudinal Study. *Circulation* 2008; **118**: 2694–2701. E-Ia
33 Kokubo Y, Nakamura S, Okamura T, Yoshimasa Y, Makino H, Watanabe M, Higashiyama A, Kamide K, Kawanishi K, Okayama A, Kawano Y. Relationship between blood pressure category and incidence of stroke and myocardial infarction in an urban Japanese population with and without chronic kidney disease: the Suita Study. *Stroke* 2009; **40**: 2674–2679. E-Ib
34 Takeuchi H, Saitoh S, Takagi S, Ohnishi H, Ohhata J, Isobe T, Shimamoto K. Metabolic syndrome and cardiac disease in Japanese men: applicability of the concept of metabolic syndrome defined by the National Cholesterol Education Program-Adult Treatment Panel III to Japanese men–the Tanno and Sobetsu Study. *Hypertens Res* 2005; **28**: 203–208. E-Ib
35 Iso H, Sato S, Kitamura A, Imano H, Kiyama M, Yamagishi K, Cui R, Tanigawa T, Shimamoto T. Metabolic syndrome and the risk of ischemic heart disease and stroke among Japanese men and women. *Stroke* 2007; **38**: 1744–1751. E-Ib
36 Ninomiya T, Kubo M, Doi Y, Yonemoto K, Tanizaki Y, Rahman M, Arima H, Tsuryuya K, Iida M, Kiyohara Y. Impact of metabolic syndrome on the development of

cardiovascular disease in a general Japanese population: the Hisayama study. *Stroke* 2007; **38**: 2063–2069. E-Ib

37 Noda H, Iso H, Saito I, Konishi M, Inoue M, Tsugane S, JPHC Study Group. The impact of the metabolic syndrome and its components on the incidence of ischemic heart disease and stroke: the Japan public health center-based study. *Hypertens Res* 2009; **32**: 289–298. E-Ib

38 Kokubo Y, Okamura T, Yoshimasa Y, Miyamoto Y, Kawanishi K, Kotani Y, Okayama A, Tomoike H. Impact of metabolic syndrome components on the incidence of cardiovascular disease in a general urban Japanese population: the Suita study. *Hypertens Res* 2008; **31**: 2027–2035. E-Ib

39 Chei CL, Yamagishi K, Tanigawa T, Kitamura A, Imano H, Kiyama M, Sato S, Iso H. Metabolic syndrome and the risk of ischemic heart disease and stroke among middle-aged Japanese. *Hypertens Res* 2008; **31**: 1887–1894. E-Ib

40 Irie F, Iso H, Noda H, Sairenchi T, Otaka E, Yamagishi K, Doi M, Izumi Y, Ota H. Associations between metabolic syndrome and mortality from cardiovascular disease in Japanese general population, findings on overweight and non-overweight individuals. Ibaraki Prefectural Health Study. *Circ J* 2009; **73**: 1635–1642. E-Ib

41 Saito I, Konishi M, Watanabe K, Kondo H, Fujimoto K, Okada. The metabolic syndrome and risk of stroke in a rural community in Japan. *Jpn J Publ Health* 2007; **54**: 677–683. Japanese. E-Ib

42 Kadota A, Hozawa A, Okamura T, Kadowak T, Nakmaura K, Murakami Y, Hayakawa T, Kita Y, Okayama A, Nakamura Y, Kashiwagi A, Ueshima H, NIPPON DATA Research Group. Relationship between metabolic risk factor clustering and cardiovascular mortality stratified by high blood glucose and obesity: NIPPON DATA90, 1990–2000. *Diabetes Care* 2007; **30**: 1533–1538. E-Ib

43 Ohashi Y, Shimamoto K, Sato S, Iso H, Kita Y, Kitamura A, Saito I, Kiyohara Y, Kawano H, Nakagawa H, Toyoshima H, Ando T, Taguri M, Harada A, Ueshima H, Japan Arteriosclerosis Longitudinal Study Group. Association of obesity and other cardiovascular risk factors with stroke: The Japan Arteriosclerosis Longitudinal Study - Existing Cohorts Combined (JALS-ECC). *Jpn J Publ Health* 2011; **58**: 1007–1015. Japanese. E-Ia

44 Miura K, Nakagawa H, Ohashi Y, Harada A, Taguri M, Kushiro T, Takahashi A, Nishinaga M, Soejima H, Ueshima H, Japan Arteriosclerosis Longitudinal Study (JALS) Group. Four blood pressure indexes and the risk of stroke and myocardial infarction in Japanese men and women: a meta-analysis of 16 cohort studies. *Circulation* 2009; **119**: 1892–1898. E-Ia

45 Lawes CM, Bennett DA, Parag V, Woodward M, Whitlock G, Lam TH, Suh I, Rodgers A, Asia Pacific Cohort Studies Collaboration. Blood pressure indices and cardiovascular disease in the Asia Pacific region: a pooled analysis. *Hypertension* 2003; **42**: 69–75. E-Ia

46 Inoue R, Ohkubo T, Kikuya M, Metoki H, Asayama K, Obara T, Hoshi H, Hashimoto J, Totsune K, Satoh H, Kondo Y, Imai Y. Predicting stroke using 4 ambulatory blood pressure monitoring-derived blood pressure indices: the Ohasama Study. *Hypertension* 2006; **48**: 877–882. E-Ib

47 Ohkubo T, Asayama K, Kikuya M, Metoki H, Hoshi H, Hashimoto J, Totsune K, Satoh H, Imai Y, Ohasama Study. How many times should blood pressure be measured at home for better prediction of stroke risk? Ten-year follow-up results from the Ohasama study. *J Hypertens* 2004; **22**: 1099–1104. E-Ib

48 Ohkubo T, Kikuya M, Metoki H, Asayama K, Obara T, Hashimoto J, Totsune K, Hoshi H, Satoh H, Imai Y. Prognosis of'masked'hypertension and'white-coat' hypertension detected by 24-h ambulatory blood pressure monitoring 10-year follow-up from the Ohasama study. *J Am Coll Cardiol* 2005; **46**: 508–515. E-Ib

49 Ohkubo T, Hozawa A, Nagai K, Kikuya M, Tsuji I, Ito S, Satoh H, Hisamichi S, Imai Y. Prediction of stroke by ambulatory blood pressure monitoring versus screening blood pressure measurements in a general population: the Ohasama study. *J Hypertens* 2000; **18**: 847–854. E-Ib

50 Kikuya M, Ohkubo T, Asayama K, Metoki H, Obara T, Saito S, Hashimoto J, Totsune K, Hoshi H, Satoh H, Imai Y. Ambulatory blood pressure and 10-year risk of cardiovascular and noncardiovascular mortality: the Ohasama study. *Hypertension* 2005; **45**: 240–245. E-Ib

51 Intersalt Cooperative Research Group. Intersalt: an international study of electrolyte excretion and blood pressure. Results for 24 hour urinary sodium and potassium excretion. *BMJ* 1988; **297**: 319–328. E-II

52 Stamler J, Elliott P, Chan Q. INTERMAP appendix tables. *J Hum Hypertens* 2003; **17**: 665–675. E-III

53 The Ministry of Health, Labour, and Welfare. The results of the 2011 National Health and Nutrition Survey in Japan. 2013. Japanese. E-III

54 Kojima S, *et al*. Environmental changes during the past 10 to 20 years and changes in cardiovascular disease. A. Dietary changes and cardiovascular disease in agricultural villages in Akita Prefecture, (1) State from 1950 until 1965. In: Komachi Y, *et al* (eds) *Changes in Cardiovascular Disease/Association Between Nutrition and Environment in the Japanese* (in Japanese). Hoken-Dojin-sha: Tokyo, 1987, pp 120–138. E-III

55 The Ministry of Health, Labour, and Welfare. *Dietary Reference Intakes (2010) Report from the Review Board to Prepare the 'Reference Dietary Intake for the Japanese'*. The Ministry of Health, Labour, and Welfare. 2009. Japanese. GL

56 Minister of Health, Labour and Welfare. Ministry of Health. *Labour and Welfare Notification No. 430/Basic Strategies to Comprehensively Promote National Health*. 2012. Japanese.

57 WHO. Guideline: Sodium intake for adults and children. Geneva: World Health Organization (WHO); 2012. GL

58 Yoshiike N, Seino F, Tajima S, Arai Y, Kawano M, Furuhata T, Inoue S. Twenty-year changes in the prevalence of overweight in Japanese adults: the National Nutrition Survey 1976–1995. *Obes Rev* 2002; **3**: 183–190. E-II

59 OECD Health Data. 2012. E-III

60 Rose G. *The Strategy of Preventive Medicine*. Oxford University Press: New York, 1992.

61 Whelton PK, He J, Appel LJ, Cutler JA, Havas S, Kotchen TA, Roccella EJ, Stout R, Vallbona C, Winston MC, Karimbakas JM, National High Blood Pressure Education Program Coordinating Committee. Primary prevention of hypertension: clinical and public health advisory from The National High Blood Pressure Education Program. *JAMA* 2002; **288**: 1882–1888. GL

62 Special Committee for Establishing the Next-Phase National Health Exercise Plan, Regional Health/Health Promotion Nutritional Section, Health Science Council. *Reference Materials on the Promotion of Health Japan 21 (II)*. The Ministry of Health, Labour and Welfare, 2012. Japanese.

63 National High Blood Pressure Education Program Working Group. Report on primary prevention of hypertension. *Arch Intern Med* 1993; **153**: 186–208.

64 Committee on Strategies to Reduce Sodium Intake Food and Nutrition Board, Institute of Medicine. *Strategies to Reduce Salt Intake in the United States*. The National Academies Press: Washington, DC, 2010.

65 Health Service Bureau, Ministry of Health, Labour and Welfare. *Standard Health Checkup/Health Guidance Program (revision)*. The Ministry of Health, Labour, and Welfare, 2013. Japanese.

66 Fagard RH, Staessen JA, Thijs L. Prediction of cardiac structure and function by repeated clinic and ambulatory blood pressure. *Hypertension* 1997; **29**: 22–29. IVb

67 Fagard RH, Van Den Broeke C, De Cort P. Prognostic significance of blood pressure measured in the office, at home and during ambulatory monitoring in older patients in general practice. *J Hum Hypertens* 2005; **19**: 801–807. E-Ib

68 Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, Jones DW, Kurtz T, Sheps SG, Roccella EJ, Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Recommendations for blood pressure measurement in humans and experimental animals: Part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. *Hypertension* 2005; **45**: 142–161. GL

69 O'Brien E, Asmar R, Beilin L, Imai Y, Mallion JM, Mancia G, Mengden T, Myers M, Padfield P, Palatini P, Parati G, Pickering T, Redon J, Staessen J, Stergiou G, Verdecchia P, European Society of Hypertension Working Group on Blood Pressure Monitoring. European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. *J Hypertens* 2003; **21**: 821–848. GL

70 Ménard J, Chatellier G, Day M, Vaur L. Self-measurement of blood pressure at home to evaluate drug effects by the trough: peak ratio. *J Hypertens Suppl* 1994; **12**: S21–S25. V

71 Oikawa T, Obara T, Ohkubo T, Kikuya M, Asayama K, Metoki H, Komai R, Murai K, Hashimoto J, Totsune K, Imai Y, J-HOME Study Group. Characteristics of resistant hypertension determined by self-measured blood pressure at home and office blood pressure measurements: the J-HOME study. *J Hypertens* 2006; **24**: 1737–1743. E-II

72 Imai Y, Munakata M, Tsuji I, Ohkubo T, Satoh H, Yoshino H, Watanabe N, Nishiyama A, Onodera N, Kato J, Sekino M, Aihara A, Kasai Y, Abe K. Seasonal variation in blood pressure in normotensive women studied by home measurements. *Clin Sci (Lond)* 1996; **90**: 55–60. V

73 Fukunaga H, Okubo T, Obara T, Kikuya M, Asayama T, Metoki H, Hashimoto J, Totsune K, Imai Y. Home blood pressure measurement in Japan: Practice by 1,928 physicians and its significance: Investigational study regarding current home blood pressure measurement. *J Blood Pressure* 2006; **13**: 122–128. Japanese. VI

74 Obara T, Okubo T, Kikuya M, Fukunaga H, Murai K, Asayama K, Metoki H, Hashimoto J, Totsune K, Imai Y. Home blood pressure measurement in Japan: Practice by 8,506 outpatients and its significance: Investigational study regarding current home blood pressure measurement. *J Blood Pressure* 2006; **13**: 447–454. Japanese. E-III

75 Imai Y, Otsuka K, Kawano Y, Shimada K, Hayashi H, Tochikubo O, Miyakawa M, Fukiyama K, Japanese Society of Hypertension. Japanese society of hypertension (JSH) guidelines for self-monitoring of blood pressure at home. *Hypertens Res* 2003; **26**: 771–782. GL

76 Imai Y, Kario K, Shimada K, Kawano Y, Hasebe N, Matsuura H, Tsuchihashi T, Ohkubo T, Kuwajima I, Miyakawa M, Japanese Society of Hypertension Committee for Guidelines for Self-monitoring of Blood Pressure at Home. The Japanese Society of Hypertension Guidelines for Self-monitoring of Blood Pressure at Home, 2nd edn. *Hypertens Res* 2012; **35**: 777–795. GL

77 The Japanese Society of Hypertension. *Guidelines Subcommittees of the Japanese Society of Hypertension. Guidelines for the Management of Hypertension JSH2009* (in Japanese). Life Science Publishing Co, Ltd: Tokyo, 2009. GL

78 Kawabe H, Saito I, Saruta T. Influence of repeated measurement on one occasion, on successive days, and on workdays on home blood pressure values. *Clin Exp Hypertens* 2005; **27**: 215–222. V

79 Saito I, Kario K, Kushiro T, Teramukai S, Zenimura N, Hiramatsu K, Kobayashi F, Shimada K. Rationale, study design, baseline characteristics and blood pressure at 16 weeks in the HONEST Study. *Hypertens Res* 2013; **36**: 177–182. V

80 Imai Y, Obara T, Ohkubo T. How many times should we ask subjects to measure blood pressure at home on each occasion? *J Hypertens* 2007; **25**: 1987–1991. VI

81 Kikuya M, Chonan K, Imai Y, Goto E, Ishii M, Research Group to Assess the Validity of Automated Blood Pressure Measurement Devices in Japan. Accuracy and reliability of wrist-cuff devices for self-measurement of blood pressure. *J Hypertens* 2002; **20**: 629–638. III
82 Ishimitsu T, Matsuoka H, Minami J, Kawano Y. Usefulness of home automatic sphygmomanometer in medical care for hypertension. *Ther Res* 1997; **18**: 488–493. Japanese. V
83 Ishii M, Goto E. Accuracy control of home sphygmomanometer. *Ther Res* 1998; **19**: 56–59. Japanese. V
84 Ohkubo T, Imai Y, Tsuji I, Nagai K, Kato J, Kikuchi N, Nishiyama A, Aihara A, Sekino M, Kikuya M, Ito S, Satoh H, Hisamichi S. Home blood pressure measurement has a stronger predictive power for mortality than does screening blood pressure measurement: a population-based observation in Ohasama, Japan. *J Hypertens* 1998; **16**: 971–975. E-Ib
85 Sega R, Facchetti R, Bombelli M, Cesana G, Corrao G, Grassi G, Mancia G. Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population: follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study. *Circulation* 2005; **111**: 1777–1783. E-Ib
86 Stergiou GS, Nasothimiou EG, Kalogeropoulos PG, Pantazis N, Baibas NM. The optimal home blood pressure monitoring schedule based on the Didima outcome study. *J Hum Hypertens* 2010; **24**: 158–164. E-Ib
87 Niiranen TJ, Johansson JK, Reunanen A, Jula AM. Optimal schedule for home blood pressure measurement based on prognostic data: the Finn-Home Study. *Hypertension* 2011; **57**: 1081–1086. E-Ib
88 Hozawa A, Ohkubo T, Nagai K, Kikuya M, Matsubara M, Tsuji I, Ito S, Satoh H, Hisamichi S, Imai Y. Prognosis of isolated systolic and isolated diastolic hypertension as assessed by self-measurement of blood pressure at home: the Ohasama study. *Arch Intern Med* 2000; **160**: 3301–3306. E-Ib
89 Asayama K, Ohkubo T, Kikuya M, Metoki H, Hoshi H, Hashimoto J, Totsune K, Satoh H, Imai Y. Prediction of stroke by self-measurement of blood pressure at home versus casual screening blood pressure measurement in relation to the Joint National Committee 7 classification: the Ohasama study. *Stroke* 2004; **35**: 2356–2361. E-Ib
90 Asayama K, Ohkubo T, Kikuya M, Metoki H, Obara T, Hoshi H, Hashimoto J, Totsune K, Satoh H, Imai Y. Use of 2003 European Society of Hypertension-European Society of Cardiology guidelines for predicting stroke using self-measured blood pressure at home: the Ohasama study. *Eur Heart J* 2005; **26**: 2026–2031. E-Ib
91 Nishinaga M, Takata J, Okumiya K, Matsubayashi K, Ozawa T, Doi Y. High morning home blood pressure is associated with a loss of functional independence in the community-dwelling elderly aged 75 years or older. *Hypertens Res* 2005; **28**: 657–663. E-II
92 Agarwal R, Andersen MJ. Prognostic importance of clinic and home blood pressure recordings in patients with chronic kidney disease. *Kidney Int* 2006; **69**: 406–411. E-Ib
93 Stergiou GS, Baibas NM, Kalogeropoulos PG. Cardiovascular risk prediction based on home blood pressure measurement: the Didima study. *J Hypertens* 2007; **25**: 1590–1596. E-Ib
94 Imai Y, Obara T, Asamaya K, Ohkubo T. The reason why home blood pressure measurements are preferred over clinic or ambulatory blood pressure in Japan. *Hypertens Res* 2013; **36**: 661–672. VI
95 Imai Y, Abe K, Sasaki S, Minami N, Munakata M, Sekino H, Nihei M, Yoshinaga K. Determination of clinical accuracy and nocturnal blood pressure pattern by new portable device for monitoring indirect ambulatory blood pressure. *Am J Hypertens* 1990; **3**: 293–301. V
96 Imai Y, Sasaki S, Minami N, Munakata M, Hashimoto J, Sakuma H, Sakuma M, Watanabe N, Imai K, Sekino H, Abe K. The accuracy and performance of the A & D TM 2421, a new ambulatory blood pressure monitoring device based on the cuff-oscillometric method and the Korotkoff sound technique. *Am J Hypertens* 1992; **5**: 719–726. V
97 Kuwajima I, Nishinaga M, Kanamaru A. The accuracy and clinical performance of a new compact ambulatory blood pressure monitoring device, the ES-H531. *Am J Hypertens* 1998; **11**: 1328–1333. V
98 Shimada K, Imai Y, Kario K, Kawano Y. Kimura G, Kuwajima I, Yamamoto Y, JCS Joint working *Group. Guidelines for the Clinical Use of 24 hour Ambulatory Blood Pressure Monitoring (ABPM)(JCS 2010). Guidelines for Diagnosis and Treatment of Cardiovascular Diseases*. Japanese Circulation Society: Japanese, 2009. GL
99 Sokolow M, Werdegar D, Kain HK, Hinman AT. Relationship between level of blood pressure measured casually and by portable recorders and severity of complications in essential hypertension. *Circulation* 1966; **34**: 279–298. E-II
100 Mancia G, Zanchetti A, Agabiti-Rosei E, Benemio G, De Cesaris R, Fogari R, Pessina A, Porcellati C, Rappelli A, Salvetti A, Trimarco B, Agebiti-Rosei E, Pessino A. Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. SAMPLE Study Group. Study on Ambulatory Monitoring of Blood Pressure and Lisinopril Evaluation. *Circulation* 1997; **95**: 1464–1470. E-II
101 Verdecchia P, Porcellati C, Schillaci G, Borgioni C, Ciucci A, Battistelli M, Guerrieri M, Gatteschi C, Zampi I, Santucci A, Santucci C, Reboldi G. Ambulatory blood pressure. An independent predictor of prognosis in essential hypertension. *Hypertension* 1994; **24**: 793–801. E-1b
102 Staessen JA, Thijs L, Fagard R, O'Brien ET, Clement D, de Leeuw PW, Mancia G, Nachev C, Palatini P, Parati G, Tuomilehto J, Webster J, Systolic Hypertension in Europe Trial Investigators. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. *JAMA* 1999; **282**: 539–546. E-Ib
103 Suzuki Y, Kuwajima I, Aono T, Kanemaru A, Nishinaga M, Shibata H, Ozawa T. Prognostic value of nighttime blood pressure in the elderly: a prospective study of 24-hour blood pressure. *Hypertens Res* 2000; **23**: 323–230. E-Ib
104 Agarwal R, Andersen MJ. Blood pressure recordings within and outside the clinic and cardiovascular events in chronic kidney disease. *Am J Nephrol* 2006; **26**: 503–510. E-Ib
105 Arima H, Tanizaki Y, Kiyohara Y, Tsuchihashi T, Kato I, Kubo M, Tanaka K, Ohkubo K, Nakamura H, Abe I, Fujishima M, Iida M. Validity of the JNC VI recommendations for the management of hypertension in a general population of Japanese elderly: the Hisayama study. *Arch Intern Med* 2003; **163**: 361–366. E-Ib
106 Ueda K, Omae T, Hasuo Y, Kiyohara Y, Fujii I, Wada J, Kato I, Kawano H, Shinkawa A, Omura T, Fujishima M. Prognosis and outcome of elderly hypertensives in a Japanese community: results from a long-term prospective study. *J Hypertens* 1988; **6**: 991–997. E-Ib
107 Shimamoto K. Origin, diagnosis and treatment of circulatory diseases. Recent approaches. II. *Hypertension* 1. New trends in control and treatment of hypertension JNC-VI and the present state in Japan. *J Jpn Soc Intern Med* 1999; **88**: 401–405. VI
108 MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, Abbott R, Godwin J, Dyer A, Stamler J. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. *Lancet* 1990; **335**: 765–774. E-Ib
109 Vasan RS, Larson MG, Leip EP, Evans JC, O'Donnell CJ, Kannel WB, Levy D. Impact of high-normal blood pressure on the risk of cardiovascular disease. *New Engl J Med* 2001; **345**: 1291–1297. E-Ib
110 Shimamoto K, Kita T, Mabuchi H, Matsuzaki M, Matsuzawa Y, Nakaya N, Oikawa S, Saito Y, Sasaki J, Itakura H, J-LIT Study Group. The risk of cardiovascular events in Japanese hypertensive patients with hypercholesterolemia: sub-analysis of the Japan Lipid Intervention Trial (J-LIT) Study, a large-scale observational cohort study. *Hypertens Res* 2005; **28**: 879–887. E-Ib
111 Vasan RS, Larson MG, Leip EP, Kannel WB, Levy D. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study. *Lancet* 2001; **358**: 1682–1686. E-Ib
112 The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. *Arch Intern Med* 1997; **157**: 2413–2446. GL
113 Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ, National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. *JAMA* 2003; **289**: 2560–2572. GL
114 European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. *J Hypertens* 2003; **21**: 1011–1053. GL
115 Guidelines Subcommittees of the Japanese Society of Hypertension. *Guidelines for the Management of Hypertension (JSH 2004) (in Japanese)*. The Japanese Society of Hypertension: Tokyo, 2004. GL
116 Imai Y, Ohkubo T, Tsuji I, Nagai K, Satoh H, Hisamichi S, Abe K. Prognostic value of ambulatory and home blood pressure measurements incomparisonto screening blood pressure measurements: a pilot study in Ohasama. *Blood Press Monit* 1996; **1**(Suppl 2): S51-S58. E-Ib
117 Niiranen TJ, Asayama K, Thijs L, Johansson JK, Ohkubo T, Kikuya M, Boggia J, Hozawa A, Sandoya E, Stergiou GS, Tsuji I, Jula AM, Imai Y, Staessen JA, International Database of Home blood pressure in relation to Cardiovascular Outcome Investigators. Outcome-driven thresholds for home blood pressure measurement: international database of home blood pressure in relation to cardiovascular outcome. *Hypertension* 2013; **61**: 27–34. E-Ib
118 Guidelines Subcommittee. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. *J Hypertens* 1999; **17**: 151–183. GL
119 Kikuya M, Hansen TW, Thijs L, Björklund-Bodegård K, Kuznetsova T, Ohkubo T, Richart T, Torp-Pedersen C, Lind L, Ibsen H, Imai Y, Staessen JA, International Database on Ambulatory blood pressure monitoring in relation to Cardiovascular Outcomes Investigators. Diagnostic thresholds for ambulatory blood pressure monitoring based on 10-year cardiovascular risk. *Circulation* 2007; **115**: 2145–2152. E-Ia
120 Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F, The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *J Hypertens* 2013; **31**: 1281–1357. GL
121 Franklin SS, Khan SA, Wong ND, Larson MG, Levy D. Is pulse pressure useful in predicting risk for coronary heart Disease? The Framingham heart study. *Circulation* 1999; **100**: 354–360. E-Ib
122 Benetos A, Zureik M, Morcet J, Thomas F, Bean K, Safar M, Ducimetière P, Guize L. A decrease in diastolic blood pressure combined with an increase in systolic blood

pressure is associated with a higher cardiovascular mortality in men. *J Am Coll Cardiol* 2000; **35**: 673–680. E-Ib
123 Staessen JA, Gasowski J, Wang JG, Thijs L, Den Hond E, Boissel JP, Coope J, Ekbom T, Gueyffier F, Liu L, Kerlikowske K, Pocock S, Fagard RH. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. *Lancet* 2000; **355**: 865–872. I
124 Shirasaki O, Terada H, Niwano K, Nakanishi T, Kanai M, Miyawaki Y, Souma T, Tanaka T, Kusunoki T. The Japan Home-health Apparatus Industrial Association: investigation of home-use electronic sphygmomanometers. *Blood Press Monit* 2001; **6**: 303–307. VI
125 Minister's Secretariat/Statistics and Information Department Ministry of Health and Welfare. Summary of a survey regarding needs for health/welfare-associated service in 1997. http://www1.mhlw.go.jp/toukei/h9kenkou_8/. E-III
126 Pickering TG, Shimbo D, Haas D. Ambulatory blood-pressure monitoring. *New Engl J Med* 2006; **354**: 2368–2374. VI
127 Kario K, Shimada K, Schwartz JE, Matsuo T, Hoshide S, Pickering TG. Silent and clinically overt stroke in older Japanese subjects with white-coat and sustained hypertension. *J Am Coll Cardiol* 2001; **38**: 238–245. E-Ib
128 Ugajin T, Hozawa A, Ohkubo T, Asayama K, Kikuya M, Obara T, Metoki H, Hoshi H, Hashimoto J, Totsune K, Satoh H, Tsuji I, Imai Y. White-coat hypertension as a risk factor for the development of home hypertension: the Ohasama study. *Arch Intern Med* 2005; **165**: 1541–1546. E-Ib
129 Verdecchia P, Reboldi GP, Angeli F, Schillaci G, Schwartz JE, Pickering TG, Imai Y, Ohkubo T, Kario K. Short- and long-term incidence of stroke in white-coat hypertension. *Hypertension* 2005; **45**: 203–208. E-Ia
130 Mancia G, Facchetti R, Bombelli M, Grassi G, Sega R. Long-term risk of mortality associated with selective and combined elevation in office, home, and ambulatory blood pressure. *Hypertension* 2006; **47**: 846–853. E-Ib
131 Pickering TG, Eguchi K, Kario K. Masked hypertension: a review. *Hypertens Res* 2007; **30**: 479–488. VI
132 Matsui Y, Eguchi K, Ishikawa J, Hoshide S, Shimada K, Kario K. Subclinical arterial damage in untreated masked hypertensive subjects detected by home blood pressure measurement. *Am J Hypertens* 2007; **20**: 385–391. E-II
133 Hara A, Ohkubo T, Kondo T, Kikuya M, Aono Y, Hanawa S, Shioda K, Miyamoto S, Obara T, Metoki H, Inoue R, Asayama K, Hirose T, Totsune K, Hoshi H, Izumi S, Satoh H, Imai Y. Detection of silent cerebrovascular lesions in individuals with'masked'and'white-coat'hypertension by home blood pressure measurement: the Ohasama study. *J Hypertens* 2009; **27**: 1049–1055. E-II
134 Björklund K, Lind L, Zethelius B, Andrén B, Lithell H. Isolated ambulatory hypertension predicts cardiovascular morbidity in elderly men. *Circulation* 2003; **107**: 1297–1302. E-Ib
135 Bobrie G, Chatellier G, Genes N, Clerson P, Vaur L, Vaisse B, Menard J, Mallion JM. Cardiovascular prognosis of'masked hypertension'detected by blood pressure self-measurement in elderly treated hypertensive patients. *JAMA* 2004; **291**: 1342–1349. E-Ib
136 Kario K. Diagnosis of true uncontrolled hypertension using both home and ambulatory blood pressure monitoring. *J Hum Hypertens* 2013. E-II
137 Kario K, Pickering TG, Umeda Y, Hoshide S, Hoshide Y, Morinari M, Murata M, Kuroda T, Schwartz JE, Shimada K. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. *Circulation* 2003; **107**: 1401–1406. E-Ib
138 Metoki H, Ohkubo T, Kikuya M, Asayama K, Obara T, Hashimoto J, Totsune K, Hoshi H, Satoh H, Imai Y. Prognostic significance for stroke of a morning pressor surge and a nocturnal blood pressure decline: the Ohasama study. *Hypertension* 2006; **47**: 149–154. E-Ib
139 Kario K. Morning surge in blood pressure and cardiovascular risk: evidence and perspectives. *Hypertension* 2010; **56**: 765–773. VI
140 Kario K, Yano Y, Matsuo T, Hoshide S, Eguchi K, Shimada K. Additional impact of morning haemostatic risk factors and morning blood pressure surge on stroke risk in older Japanese hypertensive patients. *Eur Heart J* 2011; **32**: 574–580. E-1b
141 Ohira T, Tanigawa T, Tabata M, Imano H, Kitamura A, Kiyama M, Sato S, Okamura T, Cui R, Koike KA, Shimamoto T, Iso H. Effects of habitual alcohol intake on ambulatory blood pressure, heart rate, and its variability among Japanese men. *Hypertension* 2009; **53**: 13–19. E-II
142 Kario K, Ishikawa J, Pickering TG, Hoshide S, Eguchi K, Morinari M, Hoshide Y, Kuroda T, Shimada K. Morning hypertension: the strongest independent risk factor for stroke in elderly hypertensive patients. *Hypertens Res* 2006; **29**: 581–587. E-Ib
143 Asayama K, Ohkubo T, Kikuya M, Obara T, Metoki H, Inoue R, Hara A, Hirose T, Hoshi H, Hashimoto J, Totsune K, Satoh H, Imai Y. Prediction of stroke by home'-morning'versus'evening'blood pressure values: the Ohasama study. *Hypertension* 2006; **48**: 737–743. E-Ib
144 Matsui Y, Eguchi K, Shibasaki S, Ishikawa J, Shimada K, Kario K. Morning hypertension assessed by home monitoring is a strong predictor of concentric left ventricular hypertrophy in patients with untreated hypertension. *J Clin Hypertens (Greenwich)* 2010; **12**: 776–783. E-II
145 Chonan K, Kikuya M, Araki T, Fujiwara T, Suzuki M, Michimata M, Hashimoto J, Ohkubo T, Hozawa A, Yamamoto N, Miyawaki Y, Matsubara M, Imai Y. Device for the self-measurement of blood pressure that can monitor blood pressure during sleep. *Blood Press Monit* 2001; **6**: 203–205. E-II
146 Shirasaki O, Kuwabara M, Saito M, Tagami K, Washiya S, Kario K. Development and clinical application of a new technique for detecting 'sleep blood pressure surges' in sleep apnea patients based on a variable desaturation threshold. *Hypertens Res* 2011; **34**: 922–928. E-II
147 Ishikawa J, Hoshide S, Eguchi K, Ishikawa S, Shimada K, Kario K, Japan Morning Surge-Home Blood Pressure Study Investigators Group. Nighttime home blood pressure and the risk of hypertensive target organ damage. *Hypertension* 2012; **60**: 921–928. E-II
148 Nagai M, Hoshide S, Ishikawa J, Shimada K, Kario K. Ambulatory blood pressure as an independent determinant of brain atrophy and cognitive function in elderly hypertension. *J Hypertens* 2008; **26**: 1636–1641. E-II
149 Yano Y, Inokuchi T, Hoshide S, Kanemaru Y, Shimada K, Kario K. Association of poor physical function and cognitive dysfunction with high nocturnal blood pressure level in treated elderly hypertensive patients. *Am J Hypertens* 2011; **24**: 285–291. E-II
150 Hoshide S, Ishikawa J, Eguchi K, Ojima T, Shimada K, Kario K. Masked nocturnal hypertension and target organ damage in hypertensives with well-controlled self-measured home blood pressure. *Hypertens Res* 2007; **30**: 143–149. E-II
151 Kario K, Matsuo T, Kobayashi H, Imiya M, Matsuo M, Shimada K. Nocturnal fall of blood pressure and silent cerebrovascular damage in elderly hypertensive patients. Advanced silent cerebrovascular damage in extreme dippers. *Hypertension* 1996; **27**: 130–135. E-II
152 Kario K, Pickering TG, Matsuo T, Hoshide S, Schwartz JE, Shimada K. Stroke prognosis and abnormal nocturnal blood pressure falls in older hypertensives. *Hypertension* 2001; **38**: 852–857. E-Ib
153 Ohkubo T, Hozawa A, Yamaguchi J, Kikuya M, Ohmori K, Michimata M, Matsubara M, Hashimoto J, Hoshi H, Araki T, Tsuji I, Satoh H, Hisamichi S, Imai Y. Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-h blood pressure: the Ohasama study. *J Hypertens* 2002; **20**: 2183–2189. E-Ib
154 Eguchi K, Pickering TG, Schwartz JE, Hoshide S, Ishikawa J, Ishikawa S, Shimada K, Kario K. Short sleep duration as an independent predictor of cardiovascular events in Japanese patients with hypertension. *Arch Intern Med* 2008; **168**: 2225–2231. E-Ib
155 Kabutoya T, Hoshide S, Ishikawa J, Eguchi K, Shimada K, Kario K. The effect of pulse rate and blood pressure dipping status on the risk of stroke and cardiovascular disease in Japanese hypertensive patients. *Am J Hypertens* 2010; **23**: 749–755. E-Ib
156 Watanabe N, Imai Y, Nagai K, Tsuji I, Satoh H, Sakuma M, Sakuma H, Kato J, Onodera-Kikuchi N, Yamada M, Abe F, Hisamichi S, Abe K. Nocturnal blood pressure and silent cerebrovascular lesions in elderly Japanese. *Stroke* 1996; **27**: 1319–1327. E-II
157 Siennicki-Lantz A, Reinprecht F, Axelsson J, Elmståhl S. Cerebral perfusion in the elderly with nocturnal blood pressure fall. *Eur J Neurol* 2007; **14**: 715–720. E-Ib
158 Guo H, Tabara Y, Igase M, Yamamoto M, Ochi N, Kido T, Uetani E, Taguchi K, Miki T, Kohara K. Abnormal nocturnal blood pressure profile is associated with mild cognitive impairment in the elderly: the J-SHIPP study. *Hypertens Res* 2010; **33**: 32–36. E-II
159 Jerrard-Dunne P, Mahmud A, Feely J. Circadian blood pressure variation: relationship between dipper status and measures of arterial stiffness. *J Hypertens* 2007; **25**: 1233–1239. E-II
160 Viera AJ, Lin FC, Hinderliter AL, Shimbo D, Person SD, Pletcher MJ, Jacobs DR Jr. Nighttime blood pressure dipping in young adults and coronary artery calcium 10–15 years later: the coronary artery risk development in young adults study. *Hypertension* 2012; **59**: 1157–1163. E-Ib
161 Hata Y, Kimura Y, Muratani H, Fukiyama K, Kawano Y, Ashida T, Yokouchi M, Imai Y, Ozawa T, Fujii J, Omae T. Office blood pressure variability as a predictor of brain infarction in elderly hypertensive patients. *Hypertens Res* 2000; **23**: 553–560. E-II
162 Hata Y, Muratani H, Kimura Y, Fukiyama K, Kawano Y, Ashida T, Yokouchi M, Imai Y, Ozawa T, Fujii J, Omae T. Office blood pressure variability as a predictor of acute myocardial infarction in elderly patients receiving antihypertensive therapy. *J Hum Hypertens* 2002; **16**: 141–146. E-Ib
163 Rothwell PM, Howard SC, Dolan E, O'Brien E, Dobson JE, Dahlöf B, Sever PS, Poulter NR. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. *Lancet* 2010; **375**: 895–905. E-Ib
164 Parati G, Pomidossi G, Albini F, Malaspina D, Mancia G. Relationship of 24-hour blood pressure mean and variability to severity of target-organ damage in hypertension. *J Hypertens* 1987; **5**: 93–98. E-II
165 Kikuya M, Hozawa A, Ohokubo T, Tsuji I, Michimata M, Matsubara M, Ota M, Nagai K, Araki T, Satoh H, Ito S, Hisamichi S, Imai Y. Prognostic significance of blood pressure and heart rate variabilities: the Ohasama study. *Hypertension* 2000; **36**: 901–906. E-Ib
166 Mancia G, Bombelli M, Facchetti R, Madotto F, Corrao G, Trevano FQ, Grassi G, Sega R. Long-term prognostic value of blood pressure variability in the general population: results of the Pressioni Arteriose Monitorate e Loro Associazioni Study. *Hypertension* 2007; **49**: 1265–1270. E-Ib
167 Kikuya M, Ohkubo T, Metoki H, Asayama K, Hara A, Obara T, Inoue R, Hoshi H, Hashimoto J, Totsune K, Satoh H, Imai Y. Day-by-day variability of blood pressure and heart rate at home as a novel predictor of prognosis: the Ohasama study. *Hypertension* 2008; **52**: 1045–1050. E-Ib
168 Johansson JK, Niiranen TJ, Puukka PJ, Jula AM. Prognostic value of the variability in home-measured blood pressure and heart rate: the Finn-Home Study. *Hypertension* 2012; **59**: 212–218. E-Ib
169 Kannel WB, Kannel C, Paffenbarger RS Jr, Cupples LA. Heart rate and cardiovascular mortality: the Framingham Study. *Am Heart J* 1987; **113**: 1489–1494. E-Ib
170 Palatini P, Benetos A, Grassi G, Julius S, Kjeldsen SE, Mancia G, Narkiewicz K, Parati G, Pessina AC, Ruilope LM, Zanchetti A, European Society of Hypertension.

Identification and management of the hypertensive patient with elevated heart rate: statement of a European Society of Hypertension Consensus Meeting. *J Hypertens* 2006; **24**: 603–610. GL
171 Palatini P, Thijs L, Staessen JA, Fagard RH, Bulpitt CJ, Clement DL, de Leeuw PW, Jaaskivi M, Leonetti G, Nachev C, O'Brien ET, Parati G, Rodicio JL, Roman E, Sarti C, Tuomilehto J, Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Predictive value of clinic and ambulatory heart rate for mortality in elderly subjects with systolic hypertension. *Arch Intern Med* 2002; **162**: 2313–2321. E-Ib
172 Hozawa A, Ohkubo T, Kikuya M, Ugajin T, Yamaguchi J, Asayama K, Metoki H, Ohmori K, Hoshi H, Hashimoto J, Satoh H, Tsuji I, Imai Y. Prognostic value of home heart rate for cardiovascular mortality in the general population: the Ohasama study. *Am J Hypertens* 2004; **17**: 1005–1010. E-Ib
173 Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R, BEAUTIFUL investigators. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. *Lancet* 2008; **372**: 817–821. E-Ib
174 Paul L, Hastie CE, Li WS, Harrow C, Muir S, Connell JM, Dominiczak AF, McInnes GT, Padmanabhan S. Resting heart rate pattern during follow-up and mortality in hypertensive patients. *Hypertension* 2010; **55**: 567–574. E-Ib
175 The Committee of the Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus. Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus: Revision for International Harmonization of HbA1c in Japan. *J Jpn Diabetes Soc* 2012; **55**: 485–504. Japanese. GL
176 Momiyama Y, Kawaguchi A, Kajiwara I, Ohmori R, Okada K, Saito I, Konishi M, Nakamura M, Sato S, Kokubo Y, Mannami T, Adachi H, Kario K, Iso H, Ohsuzu F, Tsushima M. Prognostic value of plasma high-sensitivity C-reactive protein levels in Japanese patients with stable coronary artery disease: the Japan NCVC-Collaborative Inflammation Cohort (JNIC) Study. *Atherosclerosis* 2009; **207**: 272–276. E-Ib
177 Ishikawa J, Tamura Y, Hoshide S, Eguchi K, Ishikawa S, Shimada K, Kario K. Low-grade inflammation is a risk factor for clinical stroke events in addition to silent cerebral infarcts in Japanese older hypertensives: the Jichi Medical School ABPM Study, wave 1. *Stroke* 2007; **38**: 911–917. E-Ib
178 Shimizu M, Ishikawa J, Yano Y, Hoshide S, Shimada K, Kario K. The relationship between the morning blood pressure surge and low-grade inflammation on silent cerebral infarct and clinical stroke events. *Atherosclerosis* 2011; **219**: 316–321. E-Ib
179 Tanaka F, Makita S, Onoda T, Tanno K, Ohsawa M, Itai K, Sakata K, Onodera M, Koeda Y, Kawarura K, Terayama Y, Yoshida Y, Ogawa A, Okayama A, Nakamura M, Iwate-KENCO Study Group. Prehypertension subtype with elevated C-reactive protein: risk of ischemic stroke in a general Japanese population. *Am J Hypertens* 2010; **23**: 1108–1113. E-Ib
180 Rose KM, Eigenbrodt ML, Biga RL, Couper DJ, Light KC, Sharrett AR, Heiss G. Orthostatic hypotension predicts mortality in middle-aged adults: the Atherosclerosis Risk In Communities (ARIC) Study. *Circulation* 2006; **114**: 630–636. E-Ib
181 Kario K, Eguchi K, Hoshide S, Hoshide Y, Umeda Y, Mitsuhashi T, Shimada K. U-curve relationship between orthostatic blood pressure change and silent cerebrovascular disease in elderly hypertensives: orthostatic hypertension as a new cardiovascular risk factor. *J Am Coll Cardiol* 2002; **40**: 133–141. E-II
182 Kario K, Shimada K, Pickering TG. Abnormal nocturnal blood pressure falls in elderly hypertension: clinical significance and determinants. *J Cardiovasc Pharmacol* 2003; **41**(Suppl 1): S61–S66. V
183 Dauphinot V, Gosse P, Kossovsky MP, Schott AM, Rouch I, Pichot V, Gaspoz JM, Roche F, Barthelemy JC. Autonomic nervous system activity is independently associated with the risk of shift in the non-dipper blood pressure pattern. *Hypertens Res* 2010; **33**: 1032–1037. E-Ib
184 Liao D, Cooper L, Cai J, Toole JF, Bryan NR, Hutchinson RG, Tyroler HA. Presence and severity of cerebral white matter lesions and hypertension, its treatment, and its control. The ARIC Study. Atherosclerosis Risk in Communities Study. *Stroke* 1996; **27**: 2262–2270. E-II
185 Debette S, Markus HS. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. *BMJ* 2010; **341**: c3666. E-Ia
186 Kobayashi S, Okada K, Koide H, Bokura H, Yamaguchi S. Subcortical silent brain infarction as a risk factor for clinical stroke. *Stroke* 1997; **28**: 1932–1939. E-Ib
187 Vermeer SE, Hollander M, van Dijk EJ, Hofman A, Koudstaal PJ, Breteler MM, Rotterdam Scan Study. Silent brain infarcts and white matter lesions increase stroke risk in the general population: the Rotterdam Scan Study. *Stroke* 2003; **34**: 1126–1129. E-Ib
188 Naka H, Nomura E, Takahashi T, Wakabayashi S, Mimori Y, Kajikawa H, Kohriyama T, Matsumoto M. Combinations of the presence or absence of cerebral microbleeds and advanced white matter hyperintensity as predictors of subsequent stroke types. *Am J Neuroradiol* 2006; **27**: 830–835. E-Ib
189 Sachs GA, Carter R, Holtz LR, Smith F, Stump TE, Tu W, Callahan CM. Cognitive impairment: an independent predictor of excess mortality: a cohort study. *Ann Intern Med* 2011; **155**: 300–308. E-Ib
190 Yamanaka G, Otsuka K, Hotta N, Murakami S, Kubo Y, Matsuoka O, Takasugi E, Yamanaka T, Shinagawa M, Nunoda S, Nishimura Y, Shibata K, Saitoh H, Nishinaga M, Ishine M, Wada T, Okumiya K, Matsubayashi K, Yano S, Ishizuka S, Ichihara K, Cornélissen G, Halberg F. Depressive mood is independently related to stroke and cardiovascular events in a community. *Biomed Pharmacother* 2005; **59**(Suppl 1): S31–S39. E-Ib
191 Sairenchi T, Iso H, Yamagishi K, Irie F, Okubo Y, Gunji J, Muto T, Ota H. Mild retinopathy is a risk factor for cardiovascular mortality in Japanese with and without hypertension: the Ibaraki Prefectural Health Study. *Circulation* 2011; **124**: 2502–2511. E-Ib
192 Kawasaki R, Xie J, Cheung N, Lamoureux E, Klein R, Klein BE, Cotch MF, Sharrett AR, Shea S, Wong TY, MESA. Retinal microvascular signs and risk of stroke: the Multi-Ethnic Study of Atherosclerosis (MESA). *Stroke* 2012; **43**: 3245–3251. E-Ib
193 Salles GF, Cardoso CR, Fiszman R, Muxfeldt ES. Prognostic impact of baseline and serial changes in electrocardiographic left ventricular hypertrophy in resistant hypertension. *Am Heart J* 2010; **159**: 833–840. E-Ib
194 Sundström J, Lind L, Arnlöv J, Zethelius B, Andrén B, Lithell HO. Echocardiographic and electrocardiographic diagnoses of left ventricular hypertrophy predict mortality independently of each other in a population of elderly men. *Circulation* 2001; **103**: 2346–2351. E-Ib
195 Gosse P, Jan E, Coulon P, Cremer A, Papaioannou G, Yeim S. ECG detection of left ventricular hypertrophy: the simpler, the better? *J Hypertens* 2012; **30**: 990–996. E-II
196 Schillaci G, Battista F, Pucci G. A review of the role of electrocardiography in the diagnosis of left ventricular hypertrophy in hypertension. *J Electrocardiol* 2012; **45**: 617–623. VI
197 Salles GF, Cardoso CR, Fiszman R, Muxfeldt ES. Prognostic significance of baseline and serial changes in electrocardiographic strain pattern in resistant hypertension. *J Hypertens* 2010; **28**: 1715–1723. E-Ia
198 Pierdomenico SD, Cuccurullo F. Risk reduction after regression of echocardiographic left ventricular hypertrophy in hypertension: a meta-analysis. *Am J Hypertens* 2010; **23**: 876–881. E-Ib
199 Gerdts E, Cramariuc D, de Simone G, Wachtell K, Dahlöf B, Devereux RB. Impact of left ventricular geometry on prognosis in hypertensive patients with left ventricular hypertrophy (the LIFE study). *Eur J Echocardiogr* 2008; **9**: 809–815. III
200 Zile MR, Gottdiener JS, Hetzel SJ, McMurray JJ, Komajda M, McKelvie R, Baicu CF, Massie BM, Carson PE, I-PRESERVE Investigators. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. *Circulation* 2011; **124**: 2491–2501. E-Ib
201 Sudoh T, Kangawa K, Minamino N, Matsuo H. A new natriuretic peptide in porcine brain. *Nature* 1988; **332**: 78–81. VI
202 JCS Joint Working Group. Guidelines for diagnosis and treatment of cardiovascular diseases 2007–2008 JCS Joint Working Groups Report. Guidelines for Noninvasive Diagnosis of Coronary Artery Lesions. *Circ J* 2009; **73**(suppl III). Japanese. GL
203 Japanese Society of Nephrology. Evidence-based practice guideline for the treatment of CKD. *Clin Exp Nephrol* 2009; **13**: 537–566. GL
204 Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A, Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. *Am J Kidney Dis* 2009; **53**: 982–992. IVb
205 Horio M, Imai E, Yasuda Y, Watanabe T, Matsuo S, Collaborators Developing the Japanese Equation for Estimated GFR. GFR estimation using standardized serum cystatin C in Japan. *Am J Kidney Dis* 2013; **61**: 197–203. IVb
206 Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. *Kidney Int Suppl* 2013; **3**: 1–150. GL
207 The Joint Committee of 'The Japan Academy of Neurosonology' and 'The Japan Society of Embolus Detection and Treatment' on Guideline for Neurosonology. [Carotid Ultrasound Examination]. *Neurosonology* 2006; **19**: 49–69. Japanese. GL
208 O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr, Cardiovascular Health Study Collaborative Research Group. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. *New Engl J Med* 1999; **340**: 14–22. E-Ib
209 Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. *Circulation* 2007; **115**: 459–467. E-Ia
210 Wang JG, Staessen JA, Li Y, Van Bortel LM, Nawrot T, Fagard R, Messerli FH, Safar M. Carotid intima-media thickness and antihypertensive treatment: a meta-analysis of randomized controlled trials. *Stroke* 2006; **37**: 1933–1940. I
211 Crouse JR 3rd, Raichlen JS, Riley WA, Evans GW, Palmer MK, O'Leary DH, Grobbee DE, Bots ML, METEOR Study Group. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. *JAMA* 2007; **297**: 1344–1353. II
212 Geng DF, Jin DM, Wu W, Fang C, Wang JF. Effect of alpha-glucosidase inhibitors on the progression of carotid intima-media thickness: a meta-analysis of randomized controlled trials. *Atherosclerosis* 2011; **218**: 214–219. I
213 Mathiesen EB, Johnsen SH, Wilsgaard T, Bønaa KH, Løchen ML, Njølstad I. Carotid plaque area and intima-media thickness in prediction of first-ever ischemic stroke: a 10-year follow-up of 6584 men and women: the Tromsø Study. *Stroke* 2011; **42**: 972–978. E-Ib
214 Polak JF, Pencina MJ, Pencina KM, O'Donnell CJ, Wolf PA, D'Agostino RB Sr. Carotid-wall intima-media thickness and cardiovascular events. *New Engl J Med* 2011; **365**: 213–221. E-Ib
215 Inaba Y, Chen JA, Bergmann SR. Carotid plaque, compared with carotid intima-media thickness, more accurately predicts coronary artery disease events: a meta-analysis. *Atherosclerosis* 2012; **220**: 128–133. E-Ia
216 Murabito JM, Evans JC, Larson MG, Nieto K, Levy D, Wilson PW, Framingham Study. The ankle-brachial index in the elderly and risk of stroke, coronary disease, and death: the Framingham Study. *Arch Intern Med* 2003; **163**: 1939–1942. E-Ib
217 Newman AB, Sutton-Tyrrell K, Rutan GH, Locher J, Kuller LH. Lower extremity arterial disease in elderly subjects with systolic hypertension. *J Clin Epidemiol* 1991; **44**: 15–20. E-II

218 Farkas K, Járai Z, Kolossváry E, Ludányi A, Clement DL, Kiss I, ERV Study Group. High prevalence of peripheral arterial disease in hypertensive patients: the Evaluation of Ankle-Brachial Index in Hungarian Hypertensives screening program. *J Hypertens* 2012; **30**: 1526–1532. E-II

219 Rooke TW, Hirsch AT, Misra S, Sidawy AN, Beckman JA, Findeiss LK, Golzarian J, Gornik HL, Halperin JL, Jaff MR, Moneta GL, Olin JW, Stanley JC, White CJ, White JV, Zierler RE, American College of Cardiology Foundation, American Heart Association, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society for Vascular Medicine, Society for Vascular Surgery. 2011 ACCF/AHA focused update of the guideline for the management of patients with peripheral artery disease (updating the 2005 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society for Vascular Medicine, and Society for Vascular Surgery. *Catheter Cardiovasc Interv* 2012; **79**: 501–531. GL

220 Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, ESH-ESC Task Force on the Management of Arterial Hypertension. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. *J Hypertens* 2007; **25**: 1751–1762. GL

221 Yamashina A, Tomiyama H, Takeda K, Tsuda H, Arai T, Hirose K, Koji Y, Hori S, Yamamoto Y. Validity, reproducibility, and clinical significance of noninvasive brachial-ankle pulse wave velocity measurement. *Hypertens Res* 2002; **25**: 359–364. E-III

222 Tomiyama H, Yamashina A, Arai T, Hirose K, Koji Y, Chikamori T, Hori S, Yamamoto Y, Doba N, Hinohara S. Influences of age and gender on results of noninvasive brachial-ankle pulse wave velocity measurement–a survey of 12517 subjects. *Atherosclerosis* 2003; **166**: 303–309. E-II

223 Ohnishi H, Saitoh S, Takagi S, Ohata J, Isobe T, Kikuchi Y, Takeuchi H, Shimamoto K. Pulse wave velocity as an indicator of atherosclerosis in impaired fasting glucose: the Tanno and Sobetsu study. *Diabetes Care* 2003; **26**: 437–440. E-II

224 Munakata M, Konno S, Miura Y, Yoshinaga K, J-TOPP Study Group. Prognostic significance of the brachial-ankle pulse wave velocity in patients with essential hypertension: final results of the J-TOPP study. *Hypertens Res* 2012; **35**: 839–842. III

225 Shirai K, Hiruta N, Song M, Kurosu T, Suzuki J, Tomaru T, Miyashita Y, Saiki A, Takahashi M, Suzuki K, Takata M. Cardio-ankle vascular index (CAVI) as a novel indicator of arterial stiffness: theory, evidence and perspectives. *J Atheroscler Thromb* 2011; **18**: 924–938. VI

226 Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. *BMJ* 2009; **338**: b1665. I

227 Bejan-Angoulvant T, Saadatian-Elahi M, Wright JM, Schron EB, Lindholm LH, Fagard R, Staessen JA, Gueyffier F. Treatment of hypertension in patients 80 years and older: the lower the better? A meta-analysis of randomized controlled trials. *J Hypertens* 2010; **28**: 1366–1372. I

228 Asayama K, Ohkubo T, Yoshida S, Suzuki K, Metoki H, Harada A, Murakami Y, Ohashi Y, Ueshima H, Imai Y, Japan Arteriosclerosis Longitudinal Study (JALS) group. Stroke risk and antihypertensive drug treatment in the general population: the Japan arteriosclerosis longitudinal study. *J Hypertens* 2009; **27**: 357–364. E-Ia

229 Inoue R, Ohkubo T, Kikuya M, Metoki H, Asayama K, Obara T, Hirose T, Hara A, Hoshi H, Hashimoto J, Totsune K, Satoh H, Kondo Y, Imai Y. Stroke risk in systolic and combined systolic and diastolic hypertension determined using ambulatory blood pressure. The Ohasama study. *Am J Hypertens* 2007; **20**: 1125–1131. E-Ib

230 Barengo NC, Hu G, Kastarinen M, Antikainen R, Tuomilehto J. The effects of awareness, treatment and control of hypertension on future stroke incidence in a community-based population study in Finland. *J Hypertens* 2009; **27**: 1459–1465. E-Ib

231 Barengo NC, Kastarinen M, Antikainen R, Nissinen A, Tuomilehto J. The effects of awareness, treatment and control of hypertension on cardiovascular and all-cause mortality in a community-based population. *J Hum Hypertens* 2009; **23**: 808–816. E-Ib

232 Arima H, Chalmers J, Woodward M, Anderson C, Rodgers A, Davis S, Macmahon S, Neal B, PROGRESS Collaborative Group. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. *J Hypertens* 2006; **24**: 1201–1208. III

233 Ishikawa S, Kario K, Kayaba K, Gotoh T, Nago N, Nakamura Y, Tsutsumi A, Kajii E, Jichi Medical School (JMS) Cohort Study Group. Continued high risk of stroke in treated hypertensives in a general population: the Jichi Medical School Cohort study. *Hypertens Res* 2008; **31**: 1125–1133. E-Ib

234 Okayama A, Kadowaki T, Okamura T, Hayakawa T, Ueshima H, NIPPON DATA80 Research Group. Age-specific effects of systolic and diastolic blood pressures on mortality due to cardiovascular diseases among Japanese men (NIPPON DATA80). *J Hypertens* 2006; **24**: 459–462. E-Ib

235 Shimamoto K, Fujita T, Ito S, Naritomi H, Ogihara T, Shimada K, Tanaka H, Yoshiike N, J-HEALTH Study Committees. Impact of blood pressure control on cardiovascular events in 26,512 Japanese hypertensive patients: the Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J-HEALTH) study, a prospective nationwide observational study. *Hypertens Res* 2008; **31**: 469–478. E-Ib

236 Lever AF, Ramsay LE. Treatment of hypertension in the elderly. *J Hypertens* 1995; **13**: 571–579. VI

237 ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *JAMA* 2002; **288**: 2981–2997. II

238 Moser M, Hebert PR. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. *J Am Coll Cardiol* 1996; **27**: 1214–1218. I

239 Psaty BM, Smith NL, Siscovick DS, Koepsell TD, Weiss NS, Heckbert SR, Lemaitre RN, Wagner EH, Furberg CD. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. *JAMA* 1997; **277**: 739–745. I

240 Verdecchia P, Staessen JA, Angeli F, de Simone G, Achilli A, Ganau A, Mureddu G, Pede S, Maggioni AP, Lucci D, Reboldi G, Cardio-Sis investigators. Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. *Lancet* 2009; **374**: 525–533. II

241 Gueyffier F, Boutitie F, Boissel JP, Pocock S, Coope J, Cutler J, Ekbom T, Fagard R, Friedman L, Perry M, Prineas R, Schron E. Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. A meta-analysis of individual patient data from randomized, controlled trials. The INDANA Investigators. *Ann Intern Med* 1997; **126**: 761–767. III

242 Sairenchi T, Iso H, Irie F, Fukasawa N, Yamagishi K, Kanashiki M, Saito Y, Ota H, Nose T. Age-specific relationship between blood pressure and the risk of total and cardiovascular mortality in Japanese men and women. *Hypertens Res* 2005; **28**: 901–909. E-Ib

243 Conen D, Ridker PM, Buring JE, Glynn RJ. Risk of cardiovascular events among women with high normal blood pressure or blood pressure progression: prospective cohort study. *BMJ* 2007; **335**: 432. E-Ib

244 Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, Stoyanovsky V, Antikainen RL, Nikitin Y, Anderson C, Belhani A, Forette F, Rajkumar C, Thijs L, Banya W, Bulpitt CJ, HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. *New Engl J Med* 2008; **358**: 1887–1898. II

245 Ninomiya T, Kiyohara Y, Kubo M, Tanizaki Y, Doi Y, Okubo K, Wakugawa Y, Hata J, Oishi Y, Shikata K, Yonemoto K, Hirakata H, Iida M. Chronic kidney disease and cardiovascular disease in a general Japanese population: the Hisayama Study. *Kidney Int* 2005; **68**: 228–236. E-Ib

246 Rahman M, Ford CE, Cutler JA, Davis BR, Piller LB, Whelton PK, Wright JT Jr, Barzilay JI, Brown CD, Colon PJ Sr, Fine LJ, Grimm RH Jr, Gupta AK, Baimbridge C, Haywood LJ, Henriquez MA, Ilamaythi E, Oparil S, Preston R, ALLHAT Collaborative Research Group. Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated GFR. *Clin J Am Soc Nephrol* 2012; **7**: 989–1002. IVa

247 Arnlöv J, Evans JC, Meigs JB, Wang TJ, Fox CS, Levy D, Benjamin EJ, D'Agostino RB, Vasan RS. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. *Circulation* 2005; **112**: 969–975. E-Ib

248 Nakayama M, Metoki H, Terawaki H, Ohkubo T, Kikuya M, Sato T, Nakayama K, Asayama K, Inoue R, Hashimoto J, Totsune K, Hoshi H, Ito S, Imai Y. Kidney dysfunction as a risk factor for first symptomatic stroke events in a general Japanese population–the Ohasama study. *Nephrol Dial Transplant* 2007; **22**: 1910–1915. E-Ib

249 Irie F, Iso H, Sairenchi T, Fukasawa N, Yamagishi K, Ikehara S, Kanashiki M, Saito Y, Ota H, Nose T. The relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population. *Kidney Int* 2006; **69**: 1264–1271. E-Ib

250 Hallan SI, Matsushita K, Sang Y, Mahmoodi BK, Black C, Ishani A, Kleefstra N, Naimark D, Roderick P, Tonelli M, Wetzels JF, Astor BC, Gansevoort RT, Levin A, Wen CP, Coresh J, Chronic Kidney Disease Prognosis Consortium. Age and association of kidney measures with mortality and end-stage renal disease. *JAMA* 2012; **308**: 2349–2360. E-Ia

251 Asayama K, Ohkubo T, Sato A, Hara A, Obara T, Yasui D, Metoki H, Inoue R, Kikuya M, Hashimoto J, Hoshi H, Satoh H, Imai Y. Proposal of a risk-stratification system for the Japanese population based on blood pressure levels: the Ohasama study. *Hypertens Res* 2008; **31**: 1315–1322. E-Ib

252 Mahmoodi BK, Matsushita K, Woodward M, Blankestijn PJ, Cirillo M, Ohkubo T, Rossing P, Sarnak MJ, Stengel B, Yamagishi K, Yamashita K, Zhang L, Coresh J, de Jong PE, Astor BC, Chronic Kidney Disease Prognosis Consortium. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis. *Lancet* 2012; **380**: 1649–1661. E-Ia

253 Fox CS, Matsushita K, Woodward M, Bilo HJ, Chalmers J, Heerspink HJ, Lee BJ, Perkins RM, Rossing P, Sairenchi T, Tonelli M, Vassalotti JA, Yamagishi K, Coresh J, de Jong PE, Wen CP, Nelson RG, Chronic Kidney Disease Prognosis Consortium. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. *Lancet* 2012; **380**: 1662–1673. E-Ia

254 de Leeuw PW, Ruilope LM, Palmer CR, Brown MJ, Castaigne A, Mancia G, Rosenthal T, Wagener G. Clinical significance of renal function in hypertensive patients at high risk: results from the INSIGHT trial. *Arch Intern Med* 2004; **164**: 2459–2464. III

255 Turnbull F, Neal B, Algert C, Chalmers J, Chapman N, Cutler J, Woodward M, MacMahon S, Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. *Arch Intern Med* 2005; **165**: 1410–149. I
256 PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or ransient ischaemic attack. *Lancet* 2001; **358**: 1033–1041. II
257 UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. *BMJ* 1998; **317**: 703–713. II
258 Bangalore S, Kumar S, Lobach I, Messerli FH. Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and bayesian random-effects meta-analyses of randomized trials. *Circulation* 2011; **123**: 2799–27810. I
259 Casas JP, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD, MacAllister RJ. Effect of inhibitors of the renin–angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. *Lancet* 2005; **366**: 2026–2033. I
260 Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Erdine S, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Lindholm LH, Viigimaa M, Adamopoulos S, Agabiti-Rosei E, Ambrosioni E, Bertomeu V, Clement D, Erdine S, Farsang C, Gaita D, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O'Brien E, Ponikowski P, Redon J, Ruschitzka F, Tamargo J, van Zwieten P, Waeber B, Williams B, Management of Arterial Hypertension of the European Society of Hypertension, European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *J Hypertens* 2007; **25**: 1105–1187. GL
261 Japan Atherosclerosis Society (JAS). Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases (in Japanese). 2012. GL
262 Onishi H, Saito S, Akasaka K, Miura T, Shimamoto K. Examination regarding the ability of risk stratification in the JSH2009 Guidelines to predict cardiovascular events in the regional general population: Tanno-Sobetsu Study. *J Clin Exp Med* 2013; **245**: 675–676. Japanese. E-II
263 Ninomiya T, Kiyohara H. Prognostic factors to be used for risk stratification and reassessment of these factors, (1) Metabolic syndrome, Clinical Hypertension Workbook—Next approach beyond evidence—2nd volume, Risk stratification in hypertensive patients. Edited by Tsuchihashi T, Oya Y, and Kario N, Osaka, Iyaku (Medicine and Drug) Journal, 2012, pp 58–64. Japanese. VI
264 Dolan E, Stanton A, Thijs L, Hinedi K, Atkins N, McClory S, Den Hond E, McCormack P, Staessen JA, O'Brien E. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. *Hypertension* 2005; **46**: 156–161. E-Ib
265 Hansen TW, Jeppesen J, Rasmussen S, Ibsen H, Torp-Pedersen C. Ambulatory blood pressure and mortality: a population-based study. *Hypertension* 2005; **45**: 499–504. E-Ib
266 Hansen TW, Kikuya M, Thijs L, Björklund-Bodegård K, Kuznetsova T, Ohkubo T, Richart T, Torp-Pedersen C, Lind L, Jeppesen J, Ibsen H, Imai Y, Staessen JA, IDACO Investigators. Prognostic superiority of daytime ambulatory over conventional blood pressure in four populations: a meta-analysis of 7,030 individuals. *J Hypertens* 2007; **25**: 1554–1564. E-Ia
267 Hodgkinson J, Mant J, Martin U, Guo B, Hobbs FD, Deeks JJ, Heneghan C, Roberts N, McManus RJ. Relative effectiveness of clinic and home blood pressure monitoring compared with ambulatory blood pressure monitoring in diagnosis of hypertension: systematic review. *BMJ* 2011; **342**: d3621.E-Ia
268 Ingelsson E, Björklund-Bodegård K, Lind L, Arnlöv J, Sundström J. Diurnal blood pressure pattern and risk of congestive heart failure. *JAMA* 2006; **295**: 2859–2866. E-Ib
269 Niiranen TJ, Hänninen MR, Johansson J, Reunanen A, Jula AM. Home-measured blood pressure is a stronger predictor of cardiovascular risk than office blood pressure: the Finn-Home study. *Hypertension* 2010; **55**: 1346–1351. E-Ib
270 Ishikawa J, Carroll DJ, Kuruvilla S, Schwartz JE, Pickering TG. Changes in home versus clinic blood pressure with antihypertensive treatments: a meta-analysis. *Hypertension* 2008; **52**: 856–864. E-Ia
271 Appel LJ, Champagne CM, Harsha DW, Cooper LS, Obarzanek E, Elmer PJ, Stevens VJ, Vollmer WM, Lin PH, Svetkey LP, Stedman SW, Young DR, Writing Group of the PREMIER Collaborative Research Group. Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial. *JAMA* 2003; **289**: 2083–2093. II
272 Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. *Br Med J (Clin Res Ed)* 1985; **291**: 97–104. II
273 Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, Ménard J, Rahn KH, Wedel H, Westerling S, HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. *Lancet* 1998; **351**: 1755–1762. II
274 Liu L, Zhang Y, Liu G, Li W, Zhang X, Zanchetti A, FEVER Study Group. The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. *J Hypertens* 2005; **23**: 2157–2172. II
275 Zanchetti A, Grassi G, Mancia G. When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal. *J Hypertens* 2009; **27**: 923–934. IVa
276 Berry JD, Dyer A, Cai X, Garside DB, Ning H, Thomas A, Greenland P, Van Horn L, Tracy RP, Lloyd-Jones DM. Lifetime risks of cardiovascular disease. *New Engl J Med* 2012; **366**: 321–329. IVa
277 Yasui D, Asayama K, Ohkubo T, Kikuya M, Kanno A, Hara A, Hirose T, Obara T, Metoki H, Inoue R, Totsune K, Hoshi H, Satoh H, Imai Y. Stroke risk in treated hypertension based on home blood pressure: the Ohasama study. *Am J Hypertens* 2010; **23**: 508–514. IVa
278 Yasui D, Asayama K, Takada N, Ohkubo T, Kikuya M, Hara A, Hirose T, Obara T, Metoki H, Inoue R, Totsune K, Hoshi H, Satoh H, Staessen JA, Imai Y. Evaluating home blood pressure in treated hypertensives in comparison with the referential value of casual screening of blood pressure: the Ohasama study. *Blood Press Monit* 2012; **17**: 89–95. IVb
279 Asayama K, Ohkubo T, Metoki H, Obara T, Inoue R, Kikuya M, Thijs L, Staessen JA, Imai Y, Hypertension Objective Treatment Based on Measurement by Electrical Devices of Blood Pressure (HOMED-BP). Cardiovascular outcomes in the first trial of antihypertensive therapy guided by self-measured home blood pressure. *Hypertens Res* 2012; **35**: 1102–1110. II
280 Noguchi Y, Asayama K, Staessen JA, Inaba M, Ohkubo T, Hosaka M, Satoh M, Kamide K, Awata T, Katayama S, Imai Y, the HOMED-BP study group. Predictive power of home blood pressure and clinic blood pressure in hypertensive patients with impaired glucose metabolism and diabetes. *J Hypertens* 2013; **31**: 1593–1602. IVa
281 Messerli FH, Mancia G, Conti CR, Hewkin AC, Kupfer S, Champion A, Kolloch R, Benetos A, Pepine CJ. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? *Ann Intern Med* 2006; **144**: 884–893. E-Ib
282 Rothwell PM, Howard SC, Spence JD, Carotid Endarterectomy Trialists' Collaboration. Relationship between blood pressure and stroke risk in patients with symptomatic carotid occlusive disease. *Stroke* 2003; **34**: 2583–2590. E-Ia
283 Ueshima H. NIPPON DATA 80. *J Blood Pressure* 2000; **7**: 421–426. Japanese. VI
284 Sleight P, Redon J, Verdecchia P, Mancia G, Gao P, Fagard R, Schumacher H, Weber M, Böhm M, Williams B, Pogue J, Koon T, Yusuf S, ONTARGET investigators. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. *J Hypertens* 2009; **27**: 1360–1369. III
285 Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, Simons-Morton DG, Basile JN, Corson MA, Probstfield JL, Katz L, Peterson KA, Friedewald WT, Buse JB, Bigger JT, Gerstein HCIsmail-Beigi F, ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. *New Engl J Med* 2010; **362**: 1575–1585. II]
286 Cooper-DeHoff RM, Gong Y, Handberg EM, Bavry AA, Denardo SJ, Bakris GL, Pepine CJ. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. *JAMA* 2010; **304**: 61–68. IVa
287 Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. *Lancet* 2002; **360**: 1903–1913. E-Ia
288 Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, Bray GA, Vogt TM, Cutler JA, Windhauser MM, Lin PH, Karanja N, DASH Collaborative Research Group. A clinical trial of the effects of dietary patterns on blood pressure. *New Engl J Med* 1997; **336**: 1117–1124. II
289 Whelton PK, Appel LJ, Espeland MA, Applegate WB, Ettinger WH Jr, Kostis JB, Kumanyika S, Lacy CR, Johnson KC, Folmar S, Cutler JA, TONE Collaborative Research Group. Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). *JAMA* 1998; **279**: 839–846. II
290 Hayashi T, Tsumura K, Suematsu C, Okada K, Fujii S, Endo G. Walking to work and the risk for hypertension in men: the Osaka Health Survey. *Ann Intern Med* 1999; **131**: 21–26. IVa
291 Svetkey LP, Pollak KI, Yancy WS Jr, Dolor RJ, Batch BC, Samsa G, Matchar DB, Lin PH. Hypertension improvement project: randomized trial of quality improvement for physicians and lifestyle modification for patients. *Hypertension* 2009; **54**: 1226–1233. II
292 Neaton JD, Grimm RH Jr, Prineas RJ, Stamler J, Grandits GA, Elmer PJ, Cutler JA, Flack JM, Schoenberger JA, McDonald R, Lewis CE, Liebson PR, Treatment of Mild Hypertension Study Research Group. Treatment of Mild Hypertension Study. Final results. *JAMA* 1993; **270**: 713–724. II
293 Singer DR, Markandu ND, Cappuccio FP, Miller MA, Sagnella GA, MacGregor GA. Reduction of salt intake during converting enzyme inhibitor treatment compared with addition of a thiazide. *Hypertension* 1995; **25**: 1042–1044. II
294 Saito I, Saruta T. Effect of education through a periodic newsletter on persistence with antihypertensive therapy. *Hypertens Res* 2003; **26**: 159–162. III
295 Yoshida K, Matsuoka H, Omae T, Fujii J. Patient-hospital relationship and quality of life in elderly patients with hypertension. *Hypertens Res* 1995; **18**: 77–83. IVb
296 Croog SH, Levine S, Testa MA, Brown B, Bulpitt CJ, Jenkins CD, Klerman GL, Williams GH. The effects of antihypertensive therapy on the quality of life. *New Engl J Med* 1986; **314**: 1657–1664. II
297 Kaplan NM. Anxiety-induced hyperventilation. A common cause of symptoms in patients with hypertension. *Arch Intern Med* 1997; **157**: 945–948. V

298 Mena-Martin FJ, Martin-Escudero JC, Simal-Blanco F, Carretero-Ares JL, Arzua-Mouronte D, Herreros-Fernandez V. Health-related quality of life of subjects with known and unknown hypertension: results from the population-based Hortega study. *J Hypertens* 2003; **21**: 1283–1289. IVb
299 Dimenäs ES, Wiklund IK, Dahlöf CG, Lindvall KG, Olofsson BK, De Faire UH. Differences in the subjective well-being and symptoms of normotensives, borderline hypertensives and hypertensives. *J Hypertens* 1989; **7**: 885–890. IVb
300 Mikami H, Ogihara T. Quality of life in the pharmacologically treated elderly patients. *Jpn J Geriat* 1999; **7**: 1657–1664. Japanese. VI
301 Grimm RH Jr, Grandits GA, Cutler JA, Stewart AL, McDonald RH, Svendsen K, Prineas RJ, Liebson PR. Relationships of quality-of-life measures to long-term lifestyle and drug treatment in the Treatment of Mild Hypertension Study. *Arch Intern Med* 1997; **157**: 638–648. II
302 Degl'Innocenti A, Elmfeldt D, Hofman A, Lithell H, Olofsson B, Skoog I, Trenkwalder P, Zanchetti A, Wiklund I. Health-related quality of life during treatment of elderly patients with hypertension: results from the Study on COgnition and Prognosis in the Elderly (SCOPE). *J Hum Hypertens* 2004; **18**: 239–2345. II
303 Bremner AD. Antihypertensive medication and quality of life–silent treatment of a silent killer? *Cardiovasc Drugs Ther* 2002; **16**: 353–364. VI
304 Bane C, Hughes CM, Cupples ME, McElnay JC. The journey to concordance for patients with hypertension: a qualitative study in primary care. *Pharm World Sci* 2007; **29**: 534–540. IVb
305 Saito I. Factors and strategies: Adherence. *J Blood Pressure* 2010; **17**: 217–219. Japanese. VI
306 Ashida T. White coat hypertension, Therapeutic strategies for poor compliance. *Cardioangiology* 2003; **53**: 236–244. Japanese. VI
307 Saito I. Compliance and blood pressure control, Influence of the number of antihypertensive drugs on compliance. *J Blood Pressure* 2006; **13**: 1019–1025. Japanese. IVb
308 Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. *Circulation* 2009; **119**: 3028–3035. VI
309 Mazzaglia G, Ambrosioni E, Alacqua M, Filippi A, Sessa E, Immordino V, Borghi C, Brignoli O, Caputi AP, Cricelli C, Mantovani LG. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. *Circulation* 2009; **120**: 1598–15605. IVa
310 Grassi G, Seravalle G, Mancia G. Cardiovascular consequences of poor compliance to antihypertensive therapy. *Blood Press* 2011; **20**: 196–203. VI
311 Roumie CL, Elasy TA, Greevy R, Griffin MR, Liu X, Stone WJ, Wallston KA, Dittus RS, Alvarez V, Cobb J, Speroff T. Improving blood pressure control through provider education, provider alerts, and patient education: a cluster randomized trial. *Ann Intern Med* 2006; **145**: 165–175. II
312 Lee JK, Grace KA, Taylor AJ. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. *JAMA* 2006; **296**: 2563–2571. II
313 Hill MN, Miller NH, Degeest S, Materson BJ, Black HR, Izzo JL Jr, Oparil SWeber MA, American Society of Hypertension Writing Group. Adherence and persistence with taking medication to control high blood pressure. *J Am Soc Hypertens* 2011; **5**: 56–63. VI
314 Marshall IJ, Wolfe CD, McKevitt C. Lay perspectives on hypertension and drug adherence: systematic review of qualitative research. *BMJ* 2012; **345**: e3953. I
315 Burnier M. Medication adherence and persistence as the cornerstone of effective antihypertensive therapy. *Am J Hypertens* 2006; **19**: 1190–1196. VI
316 Schroeder K, Fahey T, Ebrahim S. How can we improve adherence to blood pressure-lowering medication in ambulatory care? Systematic review of randomized controlled trials. *Arch Intern Med* 2004; **164**: 722–732. E-Ia
317 Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. *Am J Med* 2007; **120**: 713–719. I
318 Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. *BMJ* 2002; **324**: 71–86. I
319 Hart RG, Tonarelli SB, Pearce LA. Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas. *Stroke* 2005; **36**: 1588–1593. VI
320 Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, Leys D, Matias-Guiu J, Rupprecht HJ, MATCH investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. *Lancet* 2004; **364**: 331–337. II
321 Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Brennan DM, Fabry-Ribaudo L, Booth J, Topol EJ, CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. *New Engl J Med* 2006; **354**: 1706–1717. II
322 Dentali F, Douketis JD, Lim W, Crowther M. Combined aspirin-oral anticoagulant therapy compared with oral anticoagulant therapy alone among patients at risk for cardiovascular disease: a meta-analysis of randomized trials. *Arch Intern Med* 2007; **167**: 117–124. I
323 Toyoda K, Yasaka M, Iwade K, Nagata K, Koretsune Y, Sakamoto T, Uchiyama S, Gotoh J, Nagao T, Yamamoto M, Takahashi JC, Minematsu K, Bleeding with Antithrombotic Therapy (BAT) Study Group. Dual antithrombotic therapy increases severe bleeding events in patients with stroke and cardiovascular disease: a prospective, multicenter, observational study. *Stroke* 2008; **39**: 1740–1745. E-Ib
324 Arima H, Anderson C, Omae T, Woodward M, MacMahon S, Mancia G, Bousser MG, Tzourio C, Rodgers A, Neal B, Chalmers J, Perindopril Protection Against Recurrent Stroke Study (PROGRESS) Collaborative Group. Effects of blood pressure lowering on intracranial and extracranial bleeding in patients on antithrombotic therapy: the PROGRESS trial. *Stroke* 2012; **43**: 1675–1677. III
325 Toyoda K, Yasaka M, Uchiyama S, Nagao T, Gotoh J, Nagata K, Koretsune Y, Sakamoto T, Iwade K, Yamamoto M, Takahashi JC, Minematsu K, Bleeding with Antithrombotic Therapy (BAT) Study Group. Blood pressure levels and bleeding events during antithrombotic therapy: the Bleeding with Antithrombotic Therapy (BAT) Study. *Stroke* 2010; **41**: 1440–1444. V
326 Ikeda S. Cost-effectiveness of hypertension (examination/treatment). *Hypertension Therapeutics*. Edited by Imaizumi T, Osaka, Nagai Shoten, 2010, pp. 327–332. Japanese. VI
327 Okubo I. Basis of clinical economics (10). *Jpn J Publ Health* 2008; **55**: 254–255. VI
328 Shiroiwa T, Sung YK, Fukuda T, Lang HC, Bae SC, Tsutani K. International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? *Health Econ* 2010; **19**: 422–437. IVb
329 Fukunaga H, Ohkubo T, Kobayashi M, Tamaki Y, Kikuya M, Obara T, Nakagawa M, Hara A, Asayama K, Metoki H, Inoue R, Hashimoto J, Totsune K, Imai Y. Cost-effectiveness of the introduction of home blood pressure measurement in patients with office hypertension. *J Hypertens* 2008; **26**: 685–690. IVb
330 Lovibond K, Jowett S, Barton P, Caulfield M, Heneghan C, Hobbs FD, Hodgkinson J, Mant J, Martin U, Williams B, Wonderling D, McManus RJ. Cost-effectiveness of options for the diagnosis of high blood pressure in primary care: a modelling study. *Lancet* 2011; **378**: 1219–1230. IVb
331 Jönsson B, Carides GW, Burke TA, Dasbach EJ, Lindholm LH, Dahlöf B, LIFE Study Group. Cost effectiveness of losartan in patients with hypertension and LVH: an economic evaluation for Sweden of the LIFE trial. *J Hypertens* 2005; **23**: 1425–1431. III
332 Lindgren P, Buxton M, Kahan T, Poulter NR, Dahlöf B, Sever PS, Wedel H, Jönsson B, ASCOT trial investigators. Economic evaluation of ASCOT-BPLA:antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen. *Heart* 2008; **94**: e4. III
333 Heidenreich PA, Davis BR, Cutler JA, Furberg CD, Lairson DR, Shlipak MG, Pressel SL, Nwachuku C, Goldman L. Cost-effectiveness of chlorthalidone, amlodipine, and lisinopril as first-step treatment for patients with hypertension: an analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *J Gen Intern Med* 2008; **23**: 509–5016. III
334 Saito I, Kobayashi M, Saruta T. Economic analysis of antihypertensive agents in treating patients with essential hypertension. *J Clin Ther Med* 2003; **19**: 777–788. Japanese. VI
335 Saito I, Kobayashi M, Matsushita Y, Saruta T. Pharmacoeconomical evaluation of combination therapy for lifetime hypertension treatment in Japan. *Jpn Med Assoc J* 2006; **48**: 574–585. VI
336 Saito I, Kobayashi M, Matsushita Y, Mori A, Kawasugi K, Saruta T. Cost-utility analysis of antihypertensive combination therapy in Japan by a Monte Carlo simulation model. *Hypertens Res* 2008; **31**: 1373–1383. IVb
337 Saito I, Kobayashi M, Saruta T. Hypertension Treatment in Japan from the perspective of medical economics. *Prog Med* 2009; **29**: 376–385. Japanese. IVb
338 Taylor AA, Shoheiber O. Adherence to antihypertensive therapy with fixed-dose amlodipine besylate/benazepril HCl versus comparable component-based therapy. *Congest Heart Fail* 2003; **9**: 324–332. IVb
339 Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, Obarzanek E, Conlin PR, Miller ER 3rd, Simons-Morton DG, Karanja N, Lin PH, DASH-Sodium Collaborative Research Group. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. *New Engl J Med* 2001; **344**: 3–10. II
340 Ando K, Kawarazaki H, Miura K, Matsuura H, Watanabe Y, Yoshita K, Kawamura M, Kusaka M, Kai H, Tsuchihashi T, Kawano Y. [Scientific Statement] Report of the Salt Reduction Committee of the Japanese Society of Hypertension(1) Role of salt in hypertension and cardiovascular diseases. *Hypertens Res* 2013; **36**: 1009-19. GL
341 He FJ, MacGregor GA. Effect of modest salt reduction on blood pressure: a meta-analysis of randomized trials. Implications for public health. *J Hum Hypertens* 2002; **16**: 761–770. I
342 Dickinson HO, Mason JM, Nicolson DJ, Campbell F, Beyer FR, Cook JV, Williams B, Ford GA. Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials. *J Hypertens* 2006; **24**: 215–233. I
343 Espeland MA, Whelton PK, Kostis JB, Bahnson JL, Ettinger WH, Cutler JA, Appel LJ, Kumanyika S, Farmer D, Elam J, Wilson AC, Applegate WB, TONE Cooperative Research Group. Predictors and mediators of successful long-term withdrawal from antihypertensive medications. *Arch Fam Med* 1999; **8**: 228–236. IVb
344 Miura K, Ando K, Tsuchihashi T, Yoshita K, Watanabe Y, Kawarazaki H, Matsuura H, Kusaka M, Kai H, Kawamura M, Kawano Y. Scientific Statement Report of the Salt Reduction Committee of the Japanese Society of Hypertension (2) Goal and strategies of dietary salt reduction in the management of hypertension. *Hypertens Res* 2013; **36**: 1020-5. GL
345 WHO. Guideline: Sodium intake for adults and children. World Health Organization: Geneva, 2012. GL
346 Matsuura H, Nakahigashi N. Report of the Working Group for Dietary Salt Reduction of the Japanese Society of Hypertension. Recipes of low-salt diet for hypertensive patients. The Japanese Society of Hypertension: Tokyo, 2012. Japanese. VI
347 Strazzullo P, D'Elia L, Kandala NB, Cappuccio FP. Salt intake, stroke, and cardiovascular disease: meta-analysis of prospective studies. *BMJ* 2009; **339**: b4567. IVa

348 He FJ, MacGregor GA. Salt reduction lowers cardiovascular risk: meta-analysis of outcome trials. *Lancet* 2011; **378**: 380–382. I
349 Cook NR, Cutler JA, Obarzanek E, Buring JE, Rexrode KM, Kumanyika SK, Appel LJ, Whelton PK. Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP). *BMJ* 2007; **334**: 885–888. III
350 General Information from the Salt Restriction Committee of The Japanese Society of Hypertension: Importance of salt restriction and the Salt Restriction Committee's activities (in Japanese). The Japanese Society of Hypertension. http://www.jpnsh.jp/general_salt.html. Accessed 24 December 2013. VI
351 Tsuchihashi T, Kai H, Kusaka M, Kawamura M, Matsuura H, Miura K, Ando K, Maruyama S, Hayabuchi H, Takagi Y, Nakahigashi N, Sato T, Kawano Y. Scientific Statement Report of the Salt Reduction Committee of the Japanese Society of Hypertension (3) Assessment and application of salt intake in the management of hypertension. *Hypertens Res* 2013; **36**: 1026-31. GL
352 Anderson CA, Appel LJ, Okuda N, Brown IJ, Chan Q, Zhao L, Ueshima H, Kesteloot H, Miura K, Curb JD, Yoshita K, Elliott P, Yamamoto ME, Stamler J. Dietary sources of sodium in China, Japan, the United Kingdom, and the United States, women and men aged 40 to 59 years: the INTERMAP study. *J Am Diet Assoc* 2010; **110**: 736–745. IVb
353 Geleijnse JM, Hofman A, Witteman JC, Hazebroek AA, Valkenburg HA, Grobbee DE. Long-term effects of neonatal sodium restriction on blood pressure. *Hypertension* 1997; **29**: 913–917. E-Ib
354 Morinaga Y, Tsuchihashi T, Ohta Y, Matsumura K. Salt intake in 3-year-old Japanese children. *Hypertens Res* 2011; **34**: 836–839. IVb
355 Appel LJ, Brands MW, Daniels SR, Karanja N, Elmer PJ, Sacks FM, American Heart Association. Dietary approaches to prevent and treat hypertension: a scientific statement from the American Heart Association. *Hypertension* 2006; **47**: 296–308. GL
356 Fujita T, Ando K. Hemodynamic and endocrine changes associated with potassium supplementation in sodium-loaded hypertensives. *Hypertension* 1984; **6**: 184–192. IVa
357 Kawano Y, Minami J, Takishita S, Omae T. Effects of potassium supplementation on office, home, and 24-h blood pressure in patients with essential hypertension. *Am J Hypertens* 1998; **11**: 1141–1146. II
358 Yang Q, Liu T, Kuklina EV, Flanders WD, Hong Y, Gillespie C, Chang MH, Gwinn M, Dowling N, Khoury MJ, Hu FB. Sodium and potassium intake and mortality among US adults: prospective data from the Third National Health and Nutrition Examination Survey. *Arch Intern Med* 2011; **171**: 1183–1191. IVa
359 WHO. *Guideline: Potassium Intake for Adults and Children*. World Health Organization: Geneva, 2012. GL
360 The Ministry of Health, Labour and Welfare and Ministry of Agriculture, Forestry and Fisheries: *Dietary Balance Guide—Food Guide (tentative name) Review Board's report* (in Japanese). Daiichi Shuppan Co, Ltd: Tokyo, 2005. (As the 'Reference Dietary Intake in the Japanese' was revised in 2010, the Dietary Balance Guide was also modified. Concerning the details, see http://www.maff.go.jp/j/balance_guide/henkou. Accessed 20 December 2012. VI)
361 Akita S, Sacks FM, Svetkey LP, Conlin PR, Kimura G, DASH-Sodium Trial Collaborative Research Group. Effects of the Dietary Approaches to Stop Hypertension (DASH) diet on the pressure-natriuresis relationship. *Hypertension* 2003; **42**: 8–13. III
362 Azadbakht L, Mirmiran P, Esmaillzadeh A, Azizi T, Azizi F. Beneficial effects of a Dietary Approaches to Stop Hypertension eating plan on features of the metabolic syndrome. *Diabetes Care* 2005; **28**: 2823–2831.II
363 He K, Liu K, Daviglus ML, Morris SJ, Loria CM, Van Horn L, Jacobs DR Jr, Savage PJ. Magnesium intake and incidence of metabolic syndrome among young adults. *Circulation* 2006; **113**: 1675–1682. IVa
364 Ueshima H, Stamler J, Elliott P, Chan Q, Brown IJ, Carnethon MR, Daviglus ML, He K, Moag-Stahlberg A, Rodriguez BL, Steffen LM, Van Horn L, Yarnell J, Zhou B, INTERMAP Research Group. Food omega-3 fatty acid intake of individuals (total, linolenic acid, long-chain) and their blood pressure: INTERMAP study. *Hypertension* 2007; **50**: 313–319. IVb
365 Geleijnse JM, Giltay EJ, Grobbee DE, Donders AR, Kok FJ. Blood pressure response to fish oil supplementation: metaregression analysis of randomized trials. *J Hypertens* 2002; **20**: 1493–1499. I
366 Iso H, Kobayashi M, Ishihara J, Sasaki S, Okada K, Kita Y, Kokubo Y, Tsugane S, JPHC Study Group. Intake of fish and n3 fatty acids and risk of coronary heart disease among Japanese: the Japan Public Health Center-Based (JPHC) Study Cohort I. *Circulation* 2006; **113**: 195–202. IVa
367 Roncaglioni MC, Tombesi M, Avanzini F, Barlera S, Caimi V, Longoni P, Marzona I, Milani V, Silletta MG, Tognoni G, Marchioli R, Risk and Prevention Study Collaborative Group. n-3 fatty acids in patients with multiple cardiovascular risk factors. *New Engl J Med* 2013; **368**: 1800–1808. II
368 Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K, Japan EPA lipid intervention study (JELIS) Investigators. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. *Lancet* 2007; **369**: 1090–1098. II
369 Appel LJ, Sacks FM, Carey VJ, Obarzanek E, Swain JF, Miller ER 3rd, Conlin PR, Erlinger TP, Rosner BA, Laranjo NM, Charleston J, McCarron P, Bishop LM, OmniHeart Collaborative Research Group. Effects of protein, monounsaturated fat, and carbohydrate intake on blood pressure and serum lipids: results of the OmniHeart randomized trial. *JAMA* 2005; **294**: 2455–1464. II
370 Whelton SP, Hyre AD, Pedersen B, Yi Y, Whelton PK, He J. Effect of dietary fiber intake on blood pressure: a meta-analysis of randomized, controlled clinical trials. *J Hypertens* 2005; **23**: 475–481. I
371 Obesity Criteria-Reviewing Committee, Japan Society for the Study of Obesity. Diagnostic criteria for obesity in 2011. *J Jpn Soc Stu Obes* 2011; 17 (special volume) (in Japanese). GL
372 Kambham N, Markowitz GS, Valeri AM, Lin J, D'Agati VD. Obesity-related glomerulopathy: an emerging epidemic. *Kidney Int* 2001; **59**: 1498–1509. E-II
373 Fox CS, Massaro JM, Hoffmann U, Pou KM, Maurovich-Horvat P, Liu CY, Vasan RS, Murabito JM, Meigs JB, Cupples LA, D'Agostino RB Sr, O'Donnell CJ. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. *Circulation* 2007; **116**: 39–48. E-II
374 Siebenhofer A, Jeitler K, Berghold A, Waltering A, Hemkens LG, Semlitsch T, Pachler C, Strametz R, Horvath K. Long-term effects of weight-reducing diets in hypertensive patients. *Cochrane Database Syst Rev* 2011; CD008274. I
375 Hsieh SD, Yoshinaga H, Muto T, Sakurai Y. Regular physical activity and coronary risk factors in Japanese men. *Circulation* 1998; **97**: 661–665. E-II
376 Haskell WL, Lee IM, Pate RR, Powell KE, Blair SN, Franklin BA, Macera CA, Heath GW, Thompson PD, Bauman A, American College of Sports Medicine, American Heart Association. Physical activity and public health: updated recommendation for adults from the American College of Sports Medicine and the American Heart Association. *Circulation* 2007; **116**: 1081–1093. GL
377 Tashiro E, Miura S, Koga M, Sasaguri M, Ideishi M, Ikeda M, Tanaka H, Shindo M, Arakawa K. Crossover comparison between the depressor effects of low and high work-rate exercise in mild hypertension. *Clin Exp Pharmacol Physiol* 1993; **20**: 689–696. II
378 Shaper AG, Wannamethee G, Walker M. Physical activity, hypertension and risk of heart attack in men without evidence of ischaemic heart disease. *J Hum Hypertens* 1994; **8**: 3–10. IVa
379 Brook RD, Appel LJ, Rubenfire M, Ogedegbe G, Bisognano JD, Elliott WJ, Fuchs FD, Hughes JW, Lackland DT, Staffileno BA, Townsend RR, Rajagopalan S, American Heart Association Professional Education Committee of the Council for High Blood Pressure Research, Council on Cardiovascular and Stroke Nursing, Council on Epidemiology and Prevention, and Council on Nutrition, Physical Activity. Beyond medications and diet: alternative approaches to lowering blood pressure: a scientific statement from the american heart association. *Hypertension* 2013; **61**: 1360–1383. GL
380 Cornelissen VA, Fagard RH, Coeckelberghs E, Vanhees L. Impact of resistance training on blood pressure and other cardiovascular risk factors: a meta-analysis of randomized, controlled trials. *Hypertension* 2011; **58**: 950–958. I
381 Review Board to Establish Exercise Requirement/Guidelines. *Exercise and Physical Activity Guide for Health Promotion 2013* (in Japanese), Ministry of Health, Labour and Welfare: Tokyo, 2013. Available from: http://www.mhlw.go.jp/stf/houdou/2r9852000002xple-att/2r9852000002xpqt.pdf. Accessed 21 December 2013. GL
382 Nakamura K, Okamura T, Hayakawa T, Hozawa A, Kadowaki T, Murakami Y, Kita Y, Okayama A, Ueshima H, NIPPON DATA90 Research Group. The proportion of individuals with alcohol-induced hypertension among total hypertensives in a general Japanese population: NIPPON DATA90. *Hypertens Res* 2007; **30**: 663–668. IVb
383 Xin X, He J, Frontini MG, Ogden LG, Motsamai OI, Whelton PK. Effects of alcohol reduction on blood pressure: a meta-analysis of randomized controlled trials. *Hypertension* 2001; **38**: 1112–1117. I
384 Higashiyama A, Okamura T, Watanabe M, Kokubo Y, Wakabayashi I, Okayama A, Miyamoto Y. Alcohol consumption and cardiovascular disease incidence in men with and without hypertension: the Suita study. *Hypertens Res* 2013; **36**: 58–64. IVa
385 Kawano Y, Abe H, Kojima S, Ashida T, Yoshida K, Imanishi M, Yoshimi H, Kimura G, Kuramochi M, Omae T. Acute depressor effect of alcohol in patients with essential hypertension. *Hypertension* 1992; **20**: 219–226. II
386 Puddey IB, Beilin LJ, Vandongen R. Regular alcohol use raises blood pressure in treated hypertensive subjects. A randomised controlled trial. *Lancet* 1987; **1**: 647–651. II
387 Ueshima H, Mikawa K, Baba S, Sasaki S, Ozawa H, Tsushima M, Kawaguchi A, Omae T, Katayama Y, Kayamori Y, Ito K. Effect of reduced alcohol consumption on blood pressure in untreated hypertensive men. *Hypertension* 1993; **21**: 248–252. II
388 Halperin RO, Gaziano JM, Sesso HD. Smoking and the risk of incident hypertension in middle-aged and older men. *Am J Hypertens* 2008; **21**: 148–152. IVa
389 Groppelli A, Giorgi DM, Omboni S, Parati G, Mancia G. Persistent blood pressure increase induced by heavy smoking. *J Hypertens* 1992; **10**: 495–499. IVb
390 Minami J, Ishimitsu T, Matsuoka H. Effects of smoking cessation on blood pressure and heart rate variability in habitual smokers. *Hypertension* 1999; **33**: 586–590. II
391 Minami J, Ishimitsu T, Ohrui M, Matsuoka H. Association of smoking with aortic wave reflection and central systolic pressure and metabolic syndrome in normotensive Japanese men. *Am J Hypertens* 2009; **22**: 617–623. IVb
392 Takami T, Saito Y. Effects of smoking cessation on central blood pressure and arterial stiffness. *Vasc Health Risk Manag* 2011; **7**: 633–638. IVb
393 Krijnen P, van Jaarsveld BC, Steyerberg EW, Man in 't Veld AJ, Schalekamp MA, Habbema JD. A clinical prediction rule for renal artery stenosis. *Ann Intern Med* 1998; **129**: 705–711. IVb
394 Tamura U, Tanaka T, Okamura T, Kadowaki T, Yamato H, Tanaka H, Nakamura M, Okayama A, Ueshima H, Yamagata Z, HIPOP-OHP research group. Changes in Weight, cardiovascular risk factors and estimated risk of coronary heart disease

following smoking cessation in Japanese male workers: HIPOP-OHP study. *J Atheroscler Thromb* 2010; **17**: 12–20. IVa

395 Makris TK, Thomopoulos C, Papadopoulos DP, Bratsas A, Papazachou O, Massias S, Michalopoulou E, Tsioufis C, Stefanadis C. Association of passive smoking with masked hypertension in clinically normotensive nonsmokers. *Am J Hypertens* 2009; **22**: 853–859. IVb

396 Japanese Society for Oral Health, Japanese Society of Oral and Maxillofacial Surgeons, Japanese Society of Public Health, Japanese Respiratory Society, Japan Society of Obstetrics and Gynecology, Japanese Circulation Society, Japan Pediatric Society, Japanese College of Cardiology, Japan Lung Cancer Society. 2009 Cooperative Study Group. Guidelines for diagnosis and treatment of cardiovascular diseases (2009 Cooperative Study Group report): Guidelines for Smoking Cessation (JCS 2010): Revised on July 14, 2011 (in Japanese). Available from: http://www.j-circ.or.jp/guideline/pdf/JCS2010murohara.h.pdf. Accessed 22 December 2012. GL

397 Japanese Circulation Society, Japan Lung Cancer Society, Japanese Cancer Association, Japanese Respiratory Society. Standard Operating Procedures for Smoking Cessation version 5 (in Japanese). Available from: http://www.j-circ.or.jp/kinen/anti_smoke_std/pdf/anti_smoke_std_rev5.pdf. Accessed 22 December 2012. GL

398 The Eurowinter Group. Cold exposure and winter mortality from ischaemic heart disease, cerebrovascular disease, respiratory disease, and all causes in warm and cold regions of Europe. *Lancet* 1997; **349**: 1341–1346. IVb

399 Bansil P, Kuklina EV, Merritt RK, Yoon PW. Associations between sleep disorders, sleep duration, quality of sleep, and hypertension: results from the National Health and Nutrition Examination Survey, 2005 to 2008. *J Clin Hypertens (Greenwich)* 2011; **13**: 739–743. IVb

400 Fernandez-Mendoza J, Vgontzas AN, Liao D, Shaffer ML, Vela-Bueno A, Basta M, Bixler EO. Insomnia with objective short sleep duration and incident hypertension: the Penn State Cohort. *Hypertension* 2012; **60**: 929–935. IVa

401 Nakazaki C, Noda A, Koike Y, Yamada S, Murohara T, Ozaki N. Association of insomnia and short sleep duration with atherosclerosis risk in the elderly. *Am J Hypertens* 2012; **25**: 1149–1155. IVb

402 Turnbull F, Neal B, Pfeffer M, Kostis J, Algert C, Woodward M, Chalmers J, Zanchetti AMacMahon S, Blood Pressure Lowering Treatment Trialists' Collaboration. Blood pressure-dependent and independent effects of agents that inhibit the renin–angiotensin system. *J Hypertens* 2007; **25**: 951–958. I

403 Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. *Lancet* 2007; **369**: 201–207. I

404 Mancia G, Grassi G, Zanchetti A. New-onset diabetes and antihypertensive drugs. *J Hypertens* 2006; **24**: 3–10. VI

405 Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. *Am J Med* 2003; **115**:41–46. I

406 Lindholm LH, Carlberg B, Samuelsson O. Should β blockers remain first choice in the treatment of primary hypertension? A meta-analysis. *Lancet* 2005; **366**: 1545–1553. I

407 Opie LH. Beta-blockade should not be among several choices for initial therapy of hypertension. *J Hypertens* 2008; **26**: 161–163. VI

408 Messerli FH, Bangalore S, Julius S. Risk/benefit assessment of β-blockers and diuretics precludes their use for first-line therapy in hypertension. *Circulation* 2008; **117**: 2706–2715; discussion 2715. VI

409 Hypertension: management of hypertension in adults in primary care NICE/BHS; June 2006. www.nice.org.uk/CG034. GL

410 Blackburn DF, Lamb DA, Eurich DT, Johnson JA, Wilson TW, Dobson RT, Blackburn JL. Atenolol as initial antihypertensive therapy: an observational study comparing first-line agents. *J Hypertens* 2007; **25**: 1499–1505. IVa

411 Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA, Raskin P, Wright JT Jr, Oakes R, Lukas MA, Anderson KM, Bell DS, GEMINI Investigators. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. *JAMA* 2004; **292**: 2227–2236. II

412 Uzu T, Kimura G. Diuretics shift circadian rhythm of blood pressure from nondipper to dipper in essential hypertension. *Circulation* 1999; **100**: 1635–168. III

413 National Intervention Cooperative Study in Elderly Hypertensives Study Group. Randomized double-blind comparison of a calcium antagonist and a diuretic in elderly hypertensives. *Hypertension* 1999; **34**: 1129–1133. II

414 Kuwajima I, Kuramoto K, Ogihara T, Iimura O, Abe K, Saruta T, Ishii M, Hiwada K, Fujishima M, Fukiyama K, National Intervention Cooperative Study in Elderly Hypertensives (NICS-EH) Study Group. Tolerability and safety of a calcium channel blocker in comparison with a diuretic in the treatment of elderly patients with hypertension: secondary analysis of the NICS-EH. *Hypertens Res* 2001; **24**: 475–480. III

415 Matsuzaki M, Ogihara T, Umemoto S, Rakugi H, Matsuoka H, Shimada K, Abe K, Suzuki N, Eto T, Higaki J, Ito S, Kamiya A, Kikuchi K, Suzuki H, Tei C, Ohashi Y, Saruta T, Combination Therapy of Hypertension to Prevent Cardiovascular Events Trial Group. Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: a randomized controlled trial. *J Hypertens* 2011; **29**: 1649–1659. II

416 Ohkubo T, Obara T, Funahashi J, Kikuya M, Asayama K, Metoki H, Oikawa T, Takahashi H, Hashimoto J, Totsune K, Imai Y, J-HOME Study Group. Control of blood pressure as measured at home and office, and comparison with physicians' assessment of control among treated hypertensive patients in Japan: First Report of the Japan Home versus Office Blood Pressure Measurement Evaluation (J-HOME) study. *Hypertens Res* 2004; **27**: 755–763. IVb

417 Morgan TO, Anderson AI, MacInnis RJ. ACE inhibitors, beta-blockers, calcium blockers, and diuretics for the control of systolic hypertension. *Am J Hypertens* 2001; **14**: 241–247. II

418 Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. *Am J Med* 2009; **122**: 290–300. I

419 Mahmud A, Feely J. Low-dose quadruple antihypertensive combination: more efficacious than individual agents–a preliminary report. *Hypertension* 2007; **49**: 272–275. II

420 Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. *BMJ* 2003; **326**: 1427. I

421 Hermida RC, Ayala DE, Calvo C, López JE, Mojón A, Fontao MJ, Soler R, Fernández JR. Effects of time of day of treatment on ambulatory blood pressure pattern of patients with resistant hypertension. *Hypertension* 2005; **46**: 1053–1059. II

422 Kario K, Hoshide S, Shimizu M, Yano Y, Eguchi K, Ishikawa J, Ishikawa S, Shimada K. Effect of dosing time of angiotensin II receptor blockade titrated by self-measured blood pressure recordings on cardiorenal protection in hypertensives: the Japan Morning Surge-Target Organ Protection (J-TOP) study. *J Hypertens* 2010; **28**: 1574–1583. IVb

423 Hermida RC, Ayala DE, Mojón A, Fernández JR. Influence of time of day of blood pressure-lowering treatment on cardiovascular risk in hypertensive patients with type 2 diabetes. *Diabetes Care* 2011; **34**: 1270–1276. II

424 Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A, VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. *Lancet* 2004; **363**: 2022–2031. II

425 Elliott WJ. Drug interactions and drugs that affect blood pressure. *J Clin Hypertens (Greenwich)* 2006; **8**: 731–737. VI

426 Sugiyama T, Kiraku J, Ashida T, Fujii J. Remission of hypertension: retrospective observations over a period of 20 years. *Hypertens Res* 1998; **21**: 103–108. IVb

427 Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J, ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. *Lancet* 2005; **366**: 895–906. II

428 Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. *Lancet* 2002; **359**: 995–1003. II

429 Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. *New Engl J Med* 2001; **345**: 861–869. II

430 Fujita T, Ando K, Nishimura H, Ideura T, Yasuda G, Isshiki M, Takahashi K, Cilnidipine versus Amlodipine Randomised Trial for Evaluation in Renal Desease (CARTER) Study Investigators. Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin–angiotensin inhibition in hypertensive patients with chronic renal disease. *Kidney Int* 2007; **72**: 1543–1549. II

431 Hasebe N, Kikuchi K, NICE Combi Study Group. Controlled-release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension: the NICE Combi (Nifedipine and Candesartan Combination) Study. *J Hypertens* 2005; **23**: 445–453. II

432 Saito I, Saruta T, ADVANCE-Combi Study Group. Controlled release nifedipine and valsartan combination therapy in patients with essential hypertension: the adalat CR and valsartan cost–effectiveness combination (ADVANCE-combi) study. *Hypertens Res* 2006; **29**: 789–796. II

433 Ogawa H, Kim-Mitsuyama S, Matsui K, Jinnouchi T, Jinnouchi H, Arakawa K, OlmeSartan and Calcium Antagonists Randomized (OSCAR) Study Group. Angiotensin II receptor blocker-based therapy in Japanese elderly, high-risk, hypertensive patients. *Am J Med* 2012; **125**: 981–990. II

434 Yamaguchi J, Hagiwara N, Ogawa H, Koyanagi R, Kasanuki H, Takagi A, Mori F, Nagashima M, Yagi M, HIJ-CREATE Investigators. Effect of amlodipine+candesartan on cardiovascular events in hypertensive patients with coronary artery disease (from The Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease[HIJ-CREATE]Study). *Am J Cardiol* 2010; **106**: 819–824. III

435 Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, Harrap S, Poulter N, Marre M, Cooper M, Glasziou P, Grobbee DE, Hamet P, Heller S, Liu LS, Mancia G, Mogensen CE, Pan CY, Rodgers AWilliams B, ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. *Lancet* 2007; **370**: 829–840. II

436 Bakris GL, Toto RD, McCullough PA, Rocha R, Purkayastha D, Davis P, GUARD (Gauging Albuminuria Reduction With Lotrel in Diabetic Patients With Hypertension) Study Investigators. Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study. *Kidney Int* 2008; **73**: 1303–1309. II

437 Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, Velazquez EJ, ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. *New Engl J Med* 2008; **359**: 2417–2428. II
438 Bakris GL, Sarafidis PA, Weir MR, Dahlöf B, Pitt B, Jamerson K, Velazquez EJ, Staikos-Byrne L, Kelly RY, Shi V, Chiang YT, Weber MA, ACCOMPLISH Trial investigators. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. *Lancet* 2010; **375**: 1173–1181. III
439 Japanese Society of Nephrology. *Clinical Practice Guidebook for Diagnosis and Treatment of Chronic Kidney Disease 2012* (in Japanese). Japanese Society of Nephrology: Tokyo, 2012. GL
440 Weber MA, Jamerson K, Bakris GL, Weir MR, Zappe D, Zhang Y, Dahlof B, Velazquez EJ, Pitt B. Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial. *Lancet* 2013; **381**: 537–545. III
441 Zanchetti A, Bond MG, Hennig M, Neiss A, Mancia G, Dal Palù C, Hansson L, Magnani B, Rahn KH, Reid JL, Rodicio J, Safar M, Eckes L, Rizzini P, European Lacidipine Study on Atherosclerosis investigators. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. *Circulation* 2002; **106**: 2422–2427. II
442 Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, Mancia G, Cangiano JL, Garcia-Barreto D, Keltai M, Erdine S, Bristol HA, Kolb HR, Bakris GL, Cohen JD, Parmley WW, INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil–Trandolapril Study (INVEST): a randomized controlled trial. *JAMA* 2003; **290**: 2805–2816. II
443 Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. *Ann Intern Med* 2008; **148**: 30–48. I
444 Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C, ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. *New Engl J Med* 2008; **358**: 1547–1559. II
445 Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Metsärinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S, ONTARGET investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. *Lancet* 2008; **372**: 547–553. III
446 Lubsen J, Wagener G, Kirwan BA, de Brouwer S, Poole-Wilson PA, ACTION (A Coronary disease Trial Investigating Outcome with Nifedipine GITS) investigators. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trial. *J Hypertens* 2005; **23**: 641–648. III
447 The Japanese Circulation Society. *Guideline for Treatment of Chronic Heart Failure (JCS 2010)* (in Japanese). The Japanese Circulation Society: Tokyo, 2010. GL
448 Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. *Circulation* 2013; **128**: e240-319. GL
449 Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL, American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol* 2013; **62**: e147-239. GL
450 Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. *Hypertension* 2010; **55**: 399–407. IVa
451 Iimura O, Kikuchi K, Shimamoto K, Nozawa A, Hasegawa R, Homma C, Komura H, Kobayakawa H. Effects of nisoldipine on sympathetic activity, the renin–angiotensin-aldosterone system, and water-sodium-calcium metabolism in patients with essential hypertension. *Arzneimittelforschung* 1989; **39**: 710–714. III
452 Abe M, Okada K, Maruyama N, Matsumoto S, Maruyama T, Fujita T, Matsumoto K, Soma M. Benidipine reduces albuminuria and plasma aldosterone in mild-to-moderate stage chronic kidney disease with albuminuria. *Hypertens Res* 2011; **34**: 268–273. II
453 Terpstra WF, May JF, Smit AJ, Graeff PA, Meyboom-de Jong B, Crijns HJ. Effects of amlodipine and lisinopril on intima-media thickness in previously untreated, elderly hypertensive patients (the ELVERA trial). *J Hypertens* 2004; **22**: 1309–1316. III
454 Sipahi I, Tuzcu EM, Schoenhagen P, Wolski KE, Nicholls SJ, Balog C, Crowe TD, Nissen SE. Effects of normal, pre-hypertensive, and hypertensive blood pressure levels on progression of coronary atherosclerosis. *J Am Coll Cardiol* 2006; **48**: 833–838. IVa
455 Ishimitsu T, Kameda T, Akashiba A, Takahashi T, Ohta S, Yoshii M, Minami J, Ono H, Numabe A, Matsuoka H. Efonidipine reduces proteinuria and plasma aldosterone in patients with chronic glomerulonephritis. *Hypertens Res* 2007; **30**: 621–626. II
456 Nakamura T, Sugaya T, Kawagoe Y, Suzuki T, Ueda Y, Koide H, Inoue T, Node K. Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease. *Am J Med Sci* 2007; **333**: 321–326. II
457 Ohishi M, Takagi T, Ito N, Terai M, Tatara Y, Hayashi N, Shiota A, Katsuya T, Rakugi H, Ogihara T. Renal-protective effect of T- and L-type calcium channel blockers in hypertensive patients: an Amlodipine-to-Benidipine Changeover (ABC) study. *Hypertens Res* 2007; **30**: 797–806. III
458 Matsui Y, Eguchi K, O'Rourke MF, Ishikawa J, Miyashita H, Shimada K, Kario K. Differential effects between a calcium channel blocker and a diuretic when used in combination with angiotensin II receptor blocker on central aortic pressure in hypertensive patients. *Hypertension* 2009; **54**: 716–723. II
459 Manisty CH, Zambanini A, Parker KH, Davies JE, Francis DP, Mayet J, McG Thom SA, Hughes AD, Anglo-Scandinavian Cardiac Outcome Trial Investigators. Differences in the magnitude of wave reflection account for differential effects of amlodipine- versus atenolol-based regimens on central blood pressure: an Anglo-Scandinavian Cardiac Outcome Trial substudy. *Hypertension* 2009; **54**: 724–730. III
460 Rothwell PM, Howard SC, Dolan E, O'Brien E, Dobson JE, Dahlöf B, Poulter NR, Sever PS, ASCOT-BPLA and MRC Trial Investigators. Effects of β blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. *Lancet Neurol* 2010; **9**: 469–480. I
461 Webb AJ, Fischer U, Mehta Z, Rothwell PM. Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis. *Lancet* 2010; **375**: 906–915. I
462 Wu L, Iwai M, Nakagami H, Li Z, Chen R, Suzuki J, Akishita M, de Gasparo M, Horiuchi M. Roles of angiotensin II type 2 receptor stimulation associated with selective angiotensin II type 1 receptor blockade with valsartan in the improvement of inflammation-induced vascular injury. *Circulation* 2001; **104**: 2716–2721.
463 Makino H, Haneda M, Babazono T, Moriya T, Ito S, Iwamoto Y, Kawamori R, Takeuchi M, Katayama S, INNOVATION Study Group. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. *Diabetes Care* 2007; **30**: 1577–1578. II
464 Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. *New Engl J Med* 2001; **345**: 851–860. II
465 Lindholm LH, Ibsen H, Dahlöf B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristiansson K, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman J, Snapinn S, LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. *Lancet* 2002; **359**: 1004–1010. II
466 Ogihara T, Nakao K, Fukui T, Fukiyama K, Ueshima K, Oba K, Sato T, Saruta T, Candesartan Antihypertensive Survival Evaluation in Japan Trial Group. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial. *Hypertension* 2008; **51**: 393–398. II
467 McMurray JJ, Holman RR, Haffner SM, Bethel MA, Holzhauer B, Hua TA, Belenkov Y, Boolell M, Buse JB, Buckley BM, Chacra AR, Chiang FT, Charbonnel B, Chow CC, Davies MJ, Deedwania P, Diem P, Einhorn D, Fonseca V, Fulcher GR, Gaciong Z, Gaztambide S, Giles T, Horton E, Ilkova H, Jenssen T, Kahn SE, Krum H, Laakso M, Leiter LA, Levitt NS, Mareev V, Martinez F, Masson C, Mazzone T, Meaney E, Nesto R, Pan C, Prager R, Raptis SA, Rutten GE, Sandstroem H, Schaper F, Scheen A, Schmitz O, Sinay I, Soska V, Stender S, Tamás G, Tognoni G, Tuomilehto J, Villamil AS, Vozár JCaliff RM, NAVIGATOR Study Group. Effect of valsartan on the incidence of diabetes and cardiovascular events. *New Engl J Med* 2010; **362**: 1477–1490. II
468 Disertori M, Latini R, Barlera S, Franzosi MG, Staszewsky L, Maggioni AP, Lucci D, Di Pasquale GTognoni G, GISSI-AF Investigators. Valsartan for prevention of recurrent atrial fibrillation. *New Engl J Med* 2009; **360**: 1606–1617. II
469 Yusuf S, Healey JS, Pogue J, Chrolavicius S, Flather M, Hart RG, Hohnloser SH, Joyner CD, Pfeffer MAConnolly SJ, ACTIVE I Investigators. Irbesartan in patients with atrial fibrillation. *New Engl J Med* 2011; **364**: 928–938. II
470 Yamashita T, Inoue H, Okumura K, Kodama I, Aizawa Y, Atarashi H, Ohe T, Ohtsu H, Kato T, Kamakura S, Kumagai K, Kurachi Y, Koretsune Y, Saikawa T, Sakurai M, Sato T, Sugi K, Nakaya H, Hirai M, Hirayama A, Fukatani M, Mitamura H, Yamazaki T, Watanabe E, Ogawa S, J-RHYTHM II Investigators. Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study). *Europace* 2011; **13**: 473–479. II
471 Iwanaga T, Sato M, Maeda T, Ogihara T, Tamai I. Concentration-dependent mode of interaction of angiotensin II receptor blockers with uric acid transporter. *J Pharmacol Exp Ther* 2007; **320**: 211–217.
472 Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA, Kurtz TW. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. *Hypertension* 2004; **43**: 993–1002.
473 Høieggen A, Alderman MH, Kjeldsen SE, Julius S, Devereux RB, De Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen

MS, Omvik P, Oparil S, Wedel H, Chen C, Dahlöf B, LIFE Study Group. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. *Kidney Int* 2004; **65**: 1041–1049. E-Ib
474 Naritomi H, Fujita T, Ito S, Ogihara T, Shimada K, Shimamoto K, Tanaka H, Yoshiike N. Efficacy and safety of long-term losartan therapy demonstrated by a prospective observational study in Japanese patients with hypertension: The Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J-HEALTH) study. *Hypertens Res* 2008; **31**: 295–304. IVa
475 Miao Y, Ottenbros SA, Laverman GD, Brenner BM, Cooper ME, Parving HH, Grobbee DE, Shahinfar S, de Zeeuw D, Lambers Heerspink HJ. Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial. *Hypertension* 2011; **58**: 2–7. III
476 Choi HK, Soriano LC, Zhang Y, Rodríguez LA. Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study. *BMJ* 2012; **344**: d8190. IVa
477 Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, Pillinger MH, Merill J, Lee S, Prakash S, Kaldas M, Gogia M, Perez-Ruiz F, Taylor W, Lioté F, Choi H, Singh JA, Dalbeth N, Kaplan S, Niyyar V, Jones D, Yarows SA, Roessler B, Kerr G, King C, Levy G, Furst DE, Edwards NL, Mandell B, Schumacher HR, Robbins M, Wenger N, Terkeltaub R, American College of Rheumatology. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. *Arthritis Care Res (Hoboken)* 2012; **64**: 1431–146. GL
478 Derosa G, Cicero AF, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Ferrari I, Gravina A, Fogari R. Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-alpha. *Hypertens Res* 2006; **29**: 849–856. II
479 Shimabukuro M, Tanaka H, Shimabukuro T. Effects of telmisartan on fat distribution in individuals with the metabolic syndrome. *J Hypertens* 2007; **25**: 841–848. II
480 Makita S, Abiko A, Naganuma Y, Moriai Y, Nakamura M. Effects of telmisartan on adiponectin levels and body weight in hypertensive patients with glucose intolerance. *Metabolism* 2008; **57**: 1473–1478. II
481 Bähr IN, Tretter P, Krüger J, Stark RG, Schimkus J, Unger T, Kappert K, Scholze J, Parhofer KG, Kintscher U. High-dose treatment with telmisartan induces monocytic peroxisome proliferator-activated receptor-ã target genes in patients with the metabolic syndrome. *Hypertension* 2011; **58**: 725–732. II
482 Fogari R, Zoppi A, Salvadeo SA, Mugellini A, Lazzari P, Santoro T, Derosa G. Fibrinolysis and insulin sensitivity in imidapril and candesartan (FISIC study) recipients with hypertension. *Hypertens Res* 2011; **34**: 509–515. II
483 Guidelines for Secondary Prevention of Myocardial Infarction (JCS 2011). The Japanese Circulation Society. 2011. GL
484 McDowell SE, Coleman JJ, Ferner RE. Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine. *BMJ* 2006; **332**: 1177–1181. I
485 Caldeira D, Alarcão J, Vaz-Carneiro A, Costa J. Risk of pneumonia associated with use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers: systematic review and meta-analysis. *BMJ* 2012; **345**: e4260. I
486 Brown NJ, Byiers S, Carr D, Maldonado M, Warner BA. Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema. *Hypertension* 2009; **54**: 516–523. I
487 Kushiro T, Itakura H, Abo Y, Gotou H, Terao S, Keefe DL. Aliskiren, a novel oral renin inhibitor, provides dose-dependent efficacy and placebo-like tolerability in Japanese patients with hypertension. *Hypertens Res* 2006; **29**: 997–1005. II
488 Kushiro T, Itakura H, Abo Y, Gotou H, Terao S, Keefe DL. Long-term safety, tolerability, and antihypertensive efficacy of aliskiren, an oral direct renin inhibitor, in Japanese patients with hypertension. *Hypertens Res* 2009; **32**: 169–175. IVb
489 Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK, AVOID Study Investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. *New Engl J Med* 2008; **358**: 2433–2446. II]
490 Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Desai AS, Nicolaides M, Richard A, Xiang Z, Brunel P, Pfeffer MA, ALTITUDE Investigators. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. *New Engl J Med* 2012; **367**: 2204–2213. II
491 Sciarretta S, Palano F, Tocci G, Baldini R, Volpe M. Antihypertensive treatment and development of heart failure in hypertension: a Bayesian network meta-analysis of studies in patients with hypertension and high cardiovascular risk. *Arch Intern Med* 2011; **171**: 384–394. I
492 Messerli FH, Grossman E, Goldbourt U. Are β-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. *JAMA* 1998; **279**: 1903–1907. I
493 Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. *New Engl J Med* 2000; **342**: 905–912. IVa
494 Manrique C, Johnson M, Sowers JR. Thiazide diuretics alone or with β-blockers impair glucose metabolism in hypertensive patients with abdominal obesity. *Hypertension* 2010; **55**: 15–17. VI
495 Torp-Pedersen C, Metra M, Charlesworth A, Spark P, Lukas MA, Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Remme WJ, Scherhag A, COMET investigators. Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET). *Heart* 2007; **93**: 968–973. III
496 Karachalios GN, Charalabopoulos A, Papalimneou V, Kiortsis D, Dimicco P, Kostoula OK, Charalabopoulos K. Withdrawal syndrome following cessation of antihypertensive drug therapy. *Int J Clin Pract* 2005; **59**: 562–570. VI
497 Kario K, Matsui Y, Shibasaki S, Eguchi K, Ishikawa J, Hoshide S, Ishikawa S, Kabutoya T, Schwartz JE, Pickering TG, Shimada K, Japan Morning Surge-1 (JMS-1) Study Group. An alpha-adrenergic blocker titrated by self-measured blood pressure recordings lowered blood pressure and microalbuminuria in patients with morning hypertension: the Japan Morning Surge-1 Study. *J Hypertens* 2008; **26**: 1257–1265. II
498 Colussi G, Catena C, Sechi LA. Spironolactone, eplerenone and the new aldosterone blockers in endocrine and primary hypertension. *J Hypertens* 2013; **31**: 3–15. VI
499 Ezekowitz JA, McAlister FA. Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials. *Eur Heart J* 2009; **30**: 469–477. I
500 Hu LJ, Chen YQ, Deng SB, Du JL, She Q. Additional use of an aldosterone antagonist in patients with mild to moderate chronic heart failure: a systematic review and meta-analysis. *Br J Clin Pharmacol* 2013; **75**: 1202–1212. I
501 Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B, EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. *New Engl J Med* 2011; **364**: 11–21. II
502 Bomback AS, Kshirsagar AV, Amamoo MA, Klemmer PJ. Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review. *Am J Kidney Dis* 2008; **51**: 199–211. I
503 Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF. Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. *Clin J Am Soc Nephrol* 2009; **4**: 542–551. I
504 Shavit L, Lifschitz MD, Epstein M. Aldosterone blockade and the mineralocorticoid receptor in the management of chronic kidney disease: current concepts and emerging treatment paradigms. *Kidney Int* 2012; **81**: 955–968. VI
505 Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. *Hypertension* 2008; **51**: 1403–1419. GL
506 Moser M, Setaro JF. Clinical practice. Resistant or difficult-to-control hypertension. *New Engl J Med* 2006; **355**: 385–392. VI
507 Cuspidi C, Macca G, Sampieri L, Michev I, Salerno M, Fusi V, Severgnini B, Meani S, Magrini F, Zanchetti A. High prevalence of cardiac and extracardiac target organ damage in refractory hypertension. *J Hypertens* 2001; **19**: 2063–2070. IVb
508 Kaplan NM, *et al*. Treatment of hypertension: drug therapy. In: *Kaplan's Clinical Hypertension*, 10th edition. Philadelphia, Lippincott Williams & Wilkins, 2010, pp 192–273. 5. VI
509 Persell SD. Prevalence of resistant hypertension in the United States, 2003–2008. *Hypertension* 2011; **57**: 1076–1080. IVb
510 Black HR, Elliott WJ, Grandits G, Grambsch P, Lucente T, White WB, Neaton JD, Grimm RH Jr, Hansson L, Lacourciere Y, Muller J, Sleight P, Weber MA, Williams G, Wittes J, Zanchetti A, Anders RJ, CONVINCE Research Group. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. *JAMA* 2003; **289**: 2073–2082. II
511 Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, Ruilope LM. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). *Lancet* 2000; **356**: 366–372. II
512 Ogihara T, Nakao K, Fukui T, Fukiyama K, Fujimoto A, Ueshima K, Oba K, Shimamoto K, Matsuoka H, Saruta T, CASE-J Trial Group. The optimal target blood pressure for antihypertensive treatment in Japanese elderly patients with high-risk hypertension: a subanalysis of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial. *Hypertens Res* 2008; **31**: 1595–1601. E-Ib
513 Obara T, Ohkubo T, Funahashi J, Kikuya M, Asayama K, Metoki H, Oikawa T, Hashimoto J, Totsune K, Imai Y. Isolated uncontrolled hypertension at home and in the office among treated hypertensive patients from the J-HOME study. *J Hypertens* 2005; **23**: 1653–1660. IVb
514 Mori H, Ukai H, Yamamoto H, Saitou S, Hirao K, Yamauchi M, Umemura S. Current status of antihypertensive prescription and associated blood pressure control in Japan. *Hypertens Res* 2006; **29**: 143–151. IVb
515 de la Sierra A, Segura J, Banegas JR, Gorostidi M, de la Cruz JJ, Armario P, Oliveras A, Ruilope LM. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. *Hypertension* 2011; **57**: 898–902. IVb
516 Bunker J, Callister W, Chang CL, Sever PS. How common is true resistant hypertension? *J Hum Hypertens* 2011; **25**: 137–140. IVb
517 Pedrosa RP, Drager LF, Gonzaga CC, Sousa MG, de Paula LK, Amaro AC, Amodeo C, Bortolotto LA, Krieger EM, Bradley TD, Lorenzi-Filho G. Obstructive sleep apnea: the most common secondary cause of hypertension associated with resistant hypertension. *Hypertension* 2011; **58**: 811–817. IVb
518 Ono A, Fujita T. Factors relating to inadequate control of blood pressure in hypertensive outpatients. *Hypertens Res* 2003; **26**: 219–224. IVb
519 Salles GF, Cardoso CR, Muxfeldt ES. Prognostic influence of office and ambulatory blood pressures in resistant hypertension. *Arch Intern Med* 2008; **168**: 2340–2346. IVa
520 Ohta Y, Tsuchihashi T, Fujii K, Matsumura K, Ohya Y, Uezono K, Abe I, Iida M. Improvement of blood pressure control in a hypertension clinic: a 10-year follow-up study. *J Hum Hypertens* 2004; **18**: 273–278. IVa

521 Pimenta E, Gaddam KK, Oparil S, Aban I, Husain S, Dell'Italia LJ, Calhoun DA. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. *Hypertension* 2009; **54**: 475–481. II
522 Oparil S, Melino M, Lee J, Fernandez V, Heyrman R. Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: The TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study. *Clin Ther* 2010; **32**: 1252–1269. II
523 Hermida RC, Ayala DE, Mojón A, Fernández JR. Effects of time of antihypertensive treatment on ambulatory blood pressure and clinical characteristics of subjects with resistant hypertension. *Am J Hypertens* 2010; **23**: 432–439. IVb
524 Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. *Am J Hypertens* 2003; **16**: 925–930. III
525 Chapman N, Dobson J, Wilson S, Dahlöf B, Sever PS, Wedel H, Poulter NR, Anglo-Scandinavian Cardiac Outcomes Trial Investigators. Effect of spironolactone on blood pressure in subjects with resistant hypertension. *Hypertension* 2007; **49**: 839–845. III
526 Krum H, Sobotka P, Mahfoud F, Böhm M, Esler M, Schlaich M. Device-based antihypertensive therapy: therapeutic modulation of the autonomic nervous system. *Circulation* 2011; **123**: 209–215. VI
527 Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, Kapelak B, Walton A, Sievert H, Thambar S, Abraham WT, Esler M. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. *Lancet* 2009; **373**: 1275–1281. IVa
528 Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. *Hypertension* 2011; **57**: 911–917. IVa
529 Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Böhm M, Symplicity HTN-2 Investigators. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. *Lancet* 2010; **376**: 1903–1909. II
530 Peet MM. Hypertension and its surgical treatment by bilateral supradiaphragmatic splanchnicectomy. *Am J Surg* 1948; **75**: 48–68. VI
531 Smithwick RH, Thompson JE. Splanchnicectomy for essential hypertension; results in 1,266 cases. *J Am Med Assoc* 1953; **152**: 1501–1504. E-III
532 Persu A, Renkin J, Thijs L, Staessen JA. Renal denervation: ultima ratio or standard in treatment-resistant hypertension. *Hypertension* 2012; **60**: 596–606. VI
533 Schmieder RE, Redon J, Grassi G, Kjeldsen SE, Mancia G, Narkiewicz K, Parati G, Ruilope L, van de Borne P, Tsioufis C. ESH position paper: renal denervation: an interventional therapy of resistant hypertension. *J Hypertens* 2012; **30**: 837–841. VI
534 Pathak A, Girerd X, Azizi M, Benamer H, Halimi JM, Lantelme P, Lefevre T, Sapoval M, Société Française d'Hypertension Artérielle, Société Française de Cardiologie, Groupe Athérome Coronaire et Interventionnel, Société Française de Radiologie. Expert consensus: Renal denervation for the treatment of hypertension. *Diagn Interv Imaging* 2012; **93**: 386–394. VI
535 Katholi RE, Rocha-Singh KJ, Goswami NJ, Sobotka PA. Renal nerves in the maintenance of hypertension: a potential therapeutic target. *Curr Hypertens Rep* 2010; **12**: 196–204. VI
536 Jauch EC, Saver JL, Adams HP Jr, Bruno A, Connors JJ, Demaerschalk BM, Khatri P, McMullan PW Jr, Qureshi AI, Rosenfield K, Scott PA, Summers DR, Wang DZ, Wintermark M, Yonas H, American Heart Association Stroke Council, Council on Cardiovascular Nursing, Council on Peripheral Vascular Disease, Council on Clinical Cardiology. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke* 2013; **44**: 870–947. GL
537 Morgenstern LB, Hemphill JC 3rd, Anderson C, Becker K, Broderick JP, Connolly ES Jr, Greenberg SM, Huang JN, MacDonald RL, Messé SR, Mitchell PH, Selim M, Tamargo RJ, American Heart Association Stroke Council and Council on Cardiovascular Nursing. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke* 2010; **41**: 2108–2129. GL
538 Kuriyama Y. [CBF (cerebral blood flow) autoregulation and antihypertensive treatment]. In: Saruta T (ed). ACE inhibitors; innovative clinical applications (in Japanese). Medical Tribune: Tokyo, 1990, pp. 89–96. VI
539 Bath P, Chalmers J, Powers W, Beilin L, Davis S, Lenfant C, Mancia G, Neal B, Whitworth J, Zanchetti A, International Society of Hypertension Writing Group. International Society of Hypertension (ISH): statement on the management of blood pressure in acute stroke. *J Hypertens* 2003; **21**: 665–672. GL
540 Osaki Y, Matsubayashi K, Yamasaki M, Okumiya K, Yoshimura K, Yoshimura K, Hamashige N, Doi Y. Post-stroke hypertension correlates with neurologic recovery in patients with acute ischemic stroke. *Hypertens Res* 1998; **21**: 169–173. E-II
541 Schrader J, Lüders S, Kulschewski A, Berger J, Zidek W, Treib J, Einhäupl K, Diener HC, Dominiak P, Acute Candesartan Cilexetil Therapy in Stroke Survivors Study Group. The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. *Stroke* 2003; **34**: 1699–1703. II
542 Sandset EC, Bath PM, Boysen G, Jatuzis D, Kõrv J, Lüders S, Murray GD, Richter PS, Roine RO, Terént A, Thijs V, Berge E, SCAST Study Group. The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial. *Lancet* 2011; **377**: 741–750. II
543 Anderson CS, Huang Y, Wang JG, Arima H, Neal B, Peng B, Heeley E, Skulina C, Parsons MW, Kim JS, Tao QL, Li YC, Jiang JD, Tai LW, Zhang JL, Xu E, Cheng Y, Heritier S, Morgenstern LB, Chalmers J, INTERACT Investigators. Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trial. *Lancet Neurol*. 2008; **7**: 391–399. II
544 Anderson CS, Heeley E, Huang Y, Wang J, Stapf C, Delcourt C, Lindley R, Robinson T, Lavados P, Neal B, Hata J, Arima H, Parsons M, Li Y, Wang J, Heritier S, Li Q, Woodward M, Simes RJ, Davis SM, Chalmers J, INTERACT2 Investigators. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. *New Engl J Med* 2013; **368**: 2355–2365. II
545 Koga M, Toyoda K, Naganuma M, Kario K, Nakagawara J, Furui E, Shiokawa Y, Hasegawa Y, Okuda S, Yamagami H, Kimura K, Okada Y, Minematsu K, Stroke Acute Management with Urgent Risk-factor Assessment and Improvement (SAMURAI) Study Investigators. Nationwide survey of antihypertensive treatment for acute intracerebral hemorrhage in Japan. *Hypertens Res* 2009; **32**: 759–764. E-II
546 Koga M, Toyoda K, Yamagami H, Okuda S, Okada Y, Kimura K, Shiokawa Y, Nakagawara J, Furui E, Hasegawa Y, Kario K, Osaki M, Miyagi T, Endo K, Nagatsuka K, Minematsu K, Stroke Acute Management with Urgent Risk-factor Assessment and Improvement Study Investigators. Systolic blood pressure lowering to 160 mmHg or less using nicardipine in acute intracerebral hemorrhage: a prospective, multicenter, observational study (the Stroke Acute Management with Urgent Risk-factor Assessment and Improvement-Intracerebral Hemorrhage study). *J Hypertens* 2012; **30**: 2357–2364. V
547 Sakamoto Y, Koga M, Yamagami H, Okuda S, Okada Y, Kimura K, Shiokawa Y, Nakagawara J, Furui E, Hasegawa Y, Kario K, Arihiro S, Sato S, Kobayashi J, Tanaka E, Nagatsuka K, Minematsu K, Toyoda K, SAMURAI Study Investigators. Systolic blood pressure after intravenous antihypertensive treatment and clinical outcomes in hyperacute intracerebral hemorrhage: the stroke acute management with urgent risk-factor assessment and improvement-intracerebral hemorrhage study. *Stroke* 2013; **44**: 1846–1851. E-II
548 Connolly ES Jr, Rabinstein AA, Carhuapoma JR, Derdeyn CP, Dion J, Higashida RT, Hoh BL, Kirkness CJ, Naidech AM, Ogilvy CS, Patel AB, Thompson BG, Vespa P, American Heart Association Stroke Council, Council on Cardiovascular Radiology and Intervention, Council on Cardiovascular Nursing, Council on Cardiovascular Surgery and Anesthesia, Council on Clinical Cardiology. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke* 2012; **43**: 1711–1737. GL
549 Yusuf S, Diener HC, Sacco RL, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, Bornstein N, Chan BP, Chen ST, Cunha L, Dahlöf B, De Keyser J, Donnan GA, Estol C, Gorelick P, Gu V, Hermansson K, Hilbrich L, Kaste M, Lu C, Machnig T, Pais P, Roberts R, Skvortsova V, Teal P, Toni D, VanderMaelen C, Voigt T, Weber M, Yoon BW, PRoFESS Study Group. Telmisartan to prevent recurrent stroke and cardiovascular events. *New Engl J Med* 2008; **359**: 1225–1237. II
550 Ovbiagele B, Diener HC, Yusuf S, Martin RH, Cotton D, Vinisko R, Donnan GA, Bath PM, PROFESS Investigators. Level of systolic blood pressure within the normal range and risk of recurrent stroke. *JAMA* 2011; **306**: 2137–2144. III
551 Irie K, Yamaguchi T, Minematsu K, Omae T. The J-curve phenomenon in stroke recurrence. *Stroke* 1993; **24**: 1844–1849. V
552 The Dutch TIA Trial Study Group. Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling ischemic stroke. *Stroke* 1993; **24**: 543–548. II
553 PATS Collaborating Group. Post-stroke antihypertensive treatment study. A preliminary result. *Chin Med J (Engl)* 1995; **108**: 710–717. II
554 Eriksson S, Olofsson B, Wester P. Atenolol in secondary prevention after stroke. *Cerebrovasc Dis* 1995; **5**: 21–25. II
555 Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G, The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. *New Engl J Med* 2000; **342**: 145–153. II
556 Schrader J, Lüders S, Kulschewski A, Hammersen F, Plate K, Berger J, Zidek W, Dominiak P, Diener HC, MOSES Study Group. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). *Stroke* 2005; **36**: 1218–1226. II
557 Benavente OR, Coffey CS, Conwit R, Hart RG, McClure LA, Pearce LA, Pergola PE, Szychowski JM, SPS3 Study Group. Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. *Lancet* 2013; **382**: 507–515. II
558 Rashid P, Leonardi-Bee J, Bath P. Blood pressure reduction and secondary prevention of stroke and other vascular events: a systematic review. *Stroke* 2003; **34**: 2741–2748. I
559 Arima H, Chalmers J. PROGRESS: Prevention of Recurrent Stroke. *J Clin Hypertens(Greenwich)* 2011; **13**: 693–702. VI
560 Turan TN, Cotsonis G, Lynn MJ, Chaturvedi S, Chimowitz M, Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) Trial Investigators. Relationship between blood pressure and stroke recurrence in patients with intracranial arterial stenosis. *Circulation* 2007; **115**: 2969–2975. III
561 Yamauchi H, Higashi T, Kagawa S, Kishibe Y, Takahashi M. Impaired perfusion modifies the relationship between blood pressure and stroke risk in major cerebral artery disease. *J Neurol Neurosurg Psychiatry* 2013; **84**: 1226–1232. V
562 Furie KL, Kasner SE, Adams RJ, Albers GW, Bush RL, Fagan SC, Halperin JL, Johnston SC, Katzan I, Kernan WN, Mitchell PH, Ovbiagele B, Palesch YY, Sacco RL, Schwamm LH, Wassertheil-Smoller S, Turan TN, Wentworth D, American Heart Association Stroke Council, Council on Cardiovascular Nursing, Council on Clinical Cardiology, and Interdisciplinary Council on Quality of Care and Outcomes Research. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association. *Stroke* 2011; **42**: 227–276. GL
563 Ebihara S, Suzuki N. Cerebral circulation/metabolism in patients with cerebral circulatory disorder. In: Goto Y, Gotoh F, Tazaki Y, Hasegawa T (eds) *Cerebrovascular disease* (in Japanese). Life Science Co, Ltd: Tokyo, 1980, pp 116–125. VI

564 Arakawa S, Saku Y, Ibayashi S, Nagao T, Fujishima M. Blood pressure control and recurrence of hypertensive brain hemorrhage. *Stroke* 1998; **29**: 1806–1809. V
565 Committee to Prepare New Guidelines for 'Brain Dock'. Guidelines for Brain Dock in 2003 (in Japanese). The Japan Brain Dock Society, 2003. http://www.snh.or.jp/jsbd/pdf/guideline2003.pdf. Accessed 13 June 2008. GL
566 Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM. Silent brain infarcts and the risk of dementia and cognitive decline. *New Engl J Med* 2003; **348**: 1215–1222. IVa
567 Kinoshita T, Okudera T, Tamura H, Ogawa T, Hatazawa J. Assessment of lacunar hemorrhage associated with hypertensive stroke by echo-planar gradient-echo T2*-weighted MRI. *Stroke* 2000; **31**: 1646–1650. V
568 Kato H, Izumiyama M, Izumiyama K, Takahashi A, Itoyama Y. Silent cerebral microbleeds on T2*-weighted MRI: correlation with stroke subtype, stroke recurrence, and leukoaraiosis. *Stroke* 2002; **33**: 1536–1540. IVb
569 Leary MC, Saver JL. Annual incidence of first silent stroke in the United States: a preliminary estimate. *Cerebrovasc Dis* 2003; **16**: 280–285. IVb
570 Hasegawa Y, Yamaguchi T, Omae T, Woodward M, Chalmers J, PROGRESS CT Substudy Investigators. Effects of perindopril-based blood pressure lowering and of patient characteristics on the progression of silent brain infarct: the Perindopril Protection against Recurrent Stroke Study (PROGRESS) CT Substudy in Japan. *Hypertens Res* 2004; **27**: 147–156. III
571 Yamamoto Y, Akiguchi I, Oiwa K, Hayashi M, Kimura J. Adverse effect of nighttime blood pressure on the outcome of lacunar infarct patients. *Stroke* 1998; **29**: 570–576. IVa
572 Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. *Am J Med* 1995; **98**: 476–484. E-1b
573 Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. *Am J Med* 2002; **113**: 359–364. E-1b
574 Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. *Am J Cardiol* 1998; **82**: 2N-9N. VI
575 Conen D, Tedrow UB, Koplan BA, Glynn RJ, Buring JE, Albert CM. Influence of systolic and diastolic blood pressure on the risk of incident atrial fibrillation in women. *Circulation* 2009; **119**: 2146–2152. E-1b
576 Okin PM, Wachtell K, Devereux RB, Harris KE, Jern S, Kjeldsen SE, Julius S, Lindholm LH, Nieminen MS, Edelman JM, Hille DA, Dahlöf B. Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. *JAMA* 2006; **296**: 1242–1248. E-Ib
577 Rienstra M, Van Veldhuisen DJ, Crijns HJ, Van Gelder IC, RACE Investigators. Enhanced cardiovascular morbidity and mortality during rhythm control treatment in persistent atrial fibrillation in hypertensives: data of the RACE study. *Eur Heart J* 2007; **28**: 741–751. III
578 Lip GY, Frison L, Grind M, SPORTIF Invetigators. Effect of hypertension on anticoagulated patients with atrial fibrillation. *Eur Heart J* 2007; **28**: 752–759. E-Ib
579 Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. *Lancet* 2001; **358**: 1305–1315. I
580 Moser M, Hebert P, Hennekens CH. An overview of the meta-analyses of the hypertension treatment trials. *Arch Intern Med* 1991; **151**: 1277–1279. VI
581 Fox KM, EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). *Lancet* 2003; **362**: 782–788. II
582 Pitt B, Byington RP, Furberg CD, Hunninghake DB, Mancini GB, Miller ME, Riley W, PREVENT Investigators. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. *Circulation* 2000; **102**: 1503–1510. II
583 Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D, Berman L, Shi H, Buebendorf E, Topol EJ, CAMELOT Investigators. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. *JAMA* 2004; **292**: 2217–2225. II
584 Kondo J, Sone T, Tsuboi H, Mukawa H, Morishima I, Uesugi M, Kono T, Kosaka T, Yoshida T, Numaguchi Y, Matsui H, Murohara T, Okumura K. Effects of low-dose angiotensin II receptor blocker candesartan on cardiovascular events in patients with coronary artery disease. *Am Heart J* 2003; **146**: E20. II
585 Yui Y, Sumiyoshi T, Kodama K, Hirayama A, Nonogi H, Kanmatsuse K, Origasa H, Iimura O, Ishii M, Saruta T, Arakawa K, Hosoda S, Kawai C, Japan Multicenter Investigation for Cardiovascular Diseases-B Study Group. Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial. *Hypertens Res* 2004; **27**: 181–191. II
586 Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E, Cholesterol and Recurrent Events Trial investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. *New Engl J Med* 1996; **335**: 1001–1009. II
587 Smith SC Jr, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA, Gibbons RJ, Grundy SM, Hiratzka LF, Jones DW, Lloyd-Jones DM, Minissian M, Mosca L, Peterson ED, Sacco RL, Spertus J, Stein JH, Taubert KA, World Heart Federation and the Preventive Cardiovascular Nurses Association. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. *Circulation* 2011; **124**: 2458–2473. GL
588 Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, Caso P, Dudek D, Gielen S, Huber K, Ohman M, Petrie MC, Sonntag F, Uva MS, Storey RF, Wijns W, Zahger D, ESC Committee for Practice Guidelines. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). *Eur Heart J* 2011; **32**: 2999–3054. GL
589 Thune JJ, Signorovitch J, Kober L, Velazquez EJ, McMurray JJ, Califf RM, Maggioni AP, Rouleau JL, Howlett J, Zelenkofske S, Pfeffer MA, Solomon SD. Effect of antecedent hypertension and follow-up blood pressure on outcomes after high-risk myocardial infarction. *Hypertension* 2008; **51**: 48–54. E-Ib
590 Bangalore S, Messerli FH, Wun CC, Zuckerman AL, DeMicco D, Kostis JB, LaRosa JC, Treating to New Targets Steering Committee and Investigators. J-curve revisited: An analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial. *Eur Heart J* 2010; **31**: 2897–2908. III
591 Bangalore S, Qin J, Sloan S, Murphy SA, Cannon CP, PROVE IT-TIMI 22 Trial Investigators. What is the optimal blood pressure in patients after acute coronary syndromes?: Relationship of blood pressure and cardiovascular events in the PRavastatin OR atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction (PROVE IT-TIMI) 22 trial. *Circulation* 2010; **122**: 2142–2151. III
592 Kai H, Ueno T, Kimura T, Adachi H, Furukawa Y, Kita T, Imaizumi T, CREDO-Kyoto Investigators. Low DBP may not be an independent risk for cardiovascular death in revascularized coronary artery disease patients. *J Hypertens* 2011; **29**: 1889–1896. IVa
593 Bangalore S, Kumar S, Volodarskiy A, Messerli FH. Blood pressure targets in patients with coronary artery disease: observations from traditional and Bayesian random effects meta-analysis of randomised trials. *Heart* 2013; **99**: 601–613. I
594 Ginsburg R, Lamb IH, Schroeder JS, Hu M, Harrison DC. Randomized double-blind comparison of nifedipine and isosorbide dinitrate therapy in variant angina pectoris due to coronary artery spasm. *Am Heart J* 1982; **103**: 44–49. II
595 Chahine RA, Feldman RL, Giles TD, Nicod P, Raizner AE, Weiss RJ, Vanov SK, Amlodipine Study 160 Group. Randomized placebo-controlled trial of amlodipine in vasospastic angina. *J Am Coll Cardiol* 1993; **21**: 1365–1370. II
596 Nishigaki K, Inoue Y, Yamanouchi Y, Fukumoto Y, Yasuda S, Sueda S, Urata H, Shimokawa H, Minatoguchi S. Prognostic effects of calcium channel blockers in patients with vasospastic angina–a meta-analysis. *Circ J* 2010; **74**: 1943–1950. IVa
597 van de Ven LL, Vermeulen A, Tans JG, Tans AC, Liem KL, Lageweg NC, Lie KI. Which drug to choose for stable angina pectoris: a comparative study between bisoprolol and nitrates. *Int J Cardiol* 1995; **47**: 217–223. II
598 Heidenreich PA, McDonald KM, Hastie T, Fadel B, Hagan V, Lee BK, Hlatky MA. Meta-analysis of trials comparing β-blockers, calcium antagonists, and nitrates for stable angina. *JAMA* 1999; **281**: 1927–1936. I
599 Boberg J, Larsen FF, Pehrsson SK, Visacor Study Group. The effects of beta blockade with (epanolol) and without (atenolol) intrinsic sympathomimetic activity in stable angina pectoris. *Clin Cardiol* 1992; **15**: 591–595. II
600 Bradley HA, Wiysonge CS, Volmink JA, Mayosi BM, Opie LH. How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis. *J Hypertens* 2006; **24**: 2131–2141. I
601 Bangalore S, Messerli FH, Kostis JB, Pepine CJ. Cardiovascular protection using beta-blockers: a critical review of the evidence. *J Am Coll Cardiol* 2007; **50**: 563–572. VI
602 Pedersen TR. Six-year follow-up of the Norwegian Multicenter Study on Timolol after Acute Myocardial Infarction. *New Engl J Med* 1985; **313**: 1055–1058. II
603 Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. *Lancet* 2001; **357**: 1385–1390. II
604 The Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. *New Engl J Med* 1988; **319**: 385–392. II
605 Japanese beta-Blockers and Calcium Antagonists Myocardial Infarction (JBCMI) Investigators. Comparison of the effects of beta blockers and calcium antagonists on cardiovascular events after acute myocardial infarction in Japanese subjects. *Am J Cardiol* 2004; **93**: 969–973. II
606 Yui Y, Shinoda E, Kodama K, Hirayama A, Nonogi H, Haze K, Sumiyoshi T, Hosoda S, Kawai C, Japan Multicenter Investigation for Cardiovascular Diseases B (JMIC-B) Study Group. Nifedipine retard prevents hospitalization for angina pectoris better than angiotensin-converting enzyme inhibitors in hypertensive Japanese patients with previous myocardial infarction (JMIC-B substudy). *J Hypertens* 2007; **25**: 2019–2026. III
607 Nakagomi A, Kodani E, Takano H, Uchida T, Sato N, Ibuki C, Kusama Y, Seino Y, Munakata K, Mizuno K, Takano T. Secondary preventive effects of a calcium antagonist for ischemic heart attack: randomized parallel comparison with β-blockers. *Circ J* 2011; **75**: 1696–1705. II
608 Ishikawa K, Nakai S, Takenaka T, Kanamasa K, Hama J, Ogawa I, Yamamoto T, Oyaizu M, Kimura A, Yamamoto K, Yabushita H, Katori R, Secondary Prevention Group. Short-acting nifedipine and diltiazem do not reduce the incidence of

cardiac events in patients with healed myocardial infarction. *Circulation* 1997; **95**: 2368–2373. III
609 Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford J, Wertheimer JH, Hawkins CM, The SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. *New Engl J Med* 1992; **327**: 669–677. II
610 Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Køber L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM, Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. *New Engl J Med* 2003; **349**: 1893–1906. II
611 The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. *Lancet* 1993; **342**: 821–828. II
612 Køber L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, Videbaek J, Cole DS, Auclert L, Pauly NC, Trandolapril Cardiac Evaluation (TRACE) Study Group. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. *New Engl J Med* 1995; **333**: 1670–1676. II
613 Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M, Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. *New Engl J Med* 2003; **348**: 1309–1321. II
614 Tsutsui H, Tsuchihashi-Makaya M, Kinugawa S, Goto D, Takeshita A, JCARE-GENERAL Investigators. Characteristics and outcomes of patients with heart failure in general practices and hospitals. *Circ J* 2007; **71**: 449–454. E-1b
615 Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114mm Hg. *JAMA* 1970; **213**: 1143–1152. II
616 Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J, Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. *New Engl J Med* 1999; **341**: 709–717. II
617 The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. *New Engl J Med* 1991; **325**: 293–302. II
618 The SOLVD Investigattors. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. *New Engl J Med* 1992; **327**: 685–691. II
619 Cohn JN, Tognoni G, Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. *New Engl J Med* 2001; **345**: 1667–1675. II
620 Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Yusuf S, Pocock S, CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. *Lancet* 2003; **362**: 759–766. II
621 Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, Ostergren J, Pfeffer MA, Swedberg K, CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. *Lancet* 2003; **362**: 772–776. II
622 Dickstein K, Kjekshus J, OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. *Lancet* 2002; **360**: 752–760. II
623 Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH, U. S. Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. *New Engl J Med* 1996; **334**: 1349–1355. II
624 Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J, Wikstrand J, El Allaf D, Vítovec J, Aldershvile J, Halinen M, Dietz R, Neuhaus KL, Jánosi A, Thorgeirsson G, Dunselman PH, Gullestad L, Kuch J, Herlitz J, Rickenbacher P, Ball S, Gottlieb S, Deedwania P, MERIT-HF Study Group. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). *JAMA* 2000; **283**: 1295–1302. II
625 The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. *Lancet* 1999; **353**: 9–13. II
626 Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL, Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. *New Engl J Med* 2001; **344**: 1651–1658. II
627 Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldman AM, Francis GS, Ganiats TG, Goldstein S, Gregoratos G, Jessup ML, Noble RJ, Packer M, Silver MA, Stevenson LW, Gibbons RJ, Antman EM, Alpert JS, Faxon DP, Fuster V, Gregoratos G, Jacobs AK, Hiratzka LF, Russell RO, Smith SC Jr, American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure), International Society for Heart and Lung Transplantation, Heart Failure Society of America. ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): Developed in Collaboration With the International Society for Heart and Lung Transplantation; Endorsed by the Heart Failure Society of America. *Circulation* 2001; **104**: 2996–3007. GL
628 Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG, Konstam MA, Mancini DM, Rahko PS, Silver MA, Stevenson LW, Yancy CW. 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. *Circulation* 2009; **119**: 1977–2016. GL
629 McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Køber L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Rønnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A, ESC Committee for Practice Guidelines. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. *Eur Heart J* 2012; **33**: 1787–1847. GL
630 Packer M, O'Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN, Miller AB, Neuberg GW, Frid D, Wertheimer JH, Cropp AB, DeMets DL, Prospective Randomized Amlodipine Survival Evaluation Study Group. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. *New Engl J Med* 1996; **335**: 1107–1114. II
631 Verdecchia P, Angeli F, Cavallini C, Gattobigio R, Gentile G, Staessen JA, Reboldi G. Blood pressure reduction and renin–angiotensin system inhibition for prevention of congestive heart failure: a meta-analysis. *Eur Heart J* 2009; **30**: 679–688. I
632 Lee DS, Gona P, Vasan RS, Larson MG, Benjamin EJ, Wang TJ, Tu JV, Levy D. Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the framingham heart study of the national heart, lung, and blood institute. *Circulation* 2009; **119**: 3070–3077. IVb
633 Solomon SD, Verma A, Desai A, Hassanein A, Izzo J, Oparil S, Lacourciere Y, Lee J, Seifu Y, Hilkert RJ, Rocha R, Pitt B, Exforge Intensive Control of Hypertension to Evaluate Efficacy in Diastolic Dysfunction Investigators. Effect of intensive versus standard blood pressure lowering on diastolic function in patients with uncontrolled hypertension and diastolic dysfunction. *Hypertension* 2010; **55**: 241–248. II
634 Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. *Lancet* 2003; **362**: 777–781. II
635 Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J, PEP-CHF Investigators. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. *Eur Heart J* 2006; **27**: 2338–2345. II
636 Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A, I-PRESERVE Investigators. Irbesartan in patients with heart failure and preserved ejection fraction. *New Engl J Med* 2008; **359**: 2456–2467. II
637 Lund LH, Benson L, Dahlström U, Edner M. Association between use of renin–angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction. *JAMA* 2012; **308**: 2108–2117. E-1b
638 Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. *New Engl J Med* 1990; **322**: 1561–1566. E-1b
639 Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I, Reboldi G, Porcellati C. Prognostic significance of serial changes in left ventricular mass in essential hypertension. *Circulation* 1998; **97**: 48–54. E-1b
640 Wachtell K, Okin PM, Olsen MH, Dahlöf B, Devereux RB, Ibsen H, Kjeldsen SE, Lindholm LH, Nieminen MS, Thygesen K. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study. *Circulation* 2007; **116**: 700–705. E-Ib
641 Ogihara T, Saruta T, Rakugi H, Fujimoto A, Ueshima K, Yasuno S, Oba K, Takeda K, Higaki J, Nakao K, CASE-J trial Group. Relationship between the achieved blood pressure and the incidence of cardiovascular events in Japanese hypertensive patients with complications: a sub-analysis of the CASE-J trial. *Hypertens Res* 2009; **32**: 248–254. E-Ib
642 Sato A, Hayashi M, Saruta T. Relative long-term effects of spironolactone in conjunction with an angiotensin-converting enzyme inhibitor on left ventricular mass and diastolic function in patients with essential hypertension. *Hypertens Res* 2002; **25**: 837–842. II
643 Taniguchi I, Kawai M, Date T, Yoshida S, Seki S, Taniguchi M, Shimizu M, Mochizuki S. Effects of spironolactone during an angiotensin II receptor blocker treatment on the left ventricular mass reduction in hypertensive patients with concentric left ventricular hypertrophy. *Circ J* 2006; **70**: 995–1000. II
644 Gottdiener JS, Reda DJ, Massie BM, Materson BJ, Williams DW, Anderson RJ, The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents. *Circulation* 1997; **95**: 2007–2014. II

645 Miller AB, Reichek N, St John Sutton M, Iyengar M, Henderson LS, Tarka EA, Bakris GL. Importance of blood pressure control in left ventricular mass regression. *J Am Soc Hypertens* 2010; **4**: 302–310. II
646 Iseki K, Tohyama K, Matsumoto T, Nakamura H. High Prevalence of chronic kidney disease among patients with sleep related breathing disorder (SRBD). *Hypertens Res* 2008; **31**: 249–255. IVa
647 Sakaguchi Y, Shoji T, Kawabata H, Niihata K, Suzuki A, Kaneko T, Okada N, Isaka Y, Rakugi H, Tsubakihara Y. High prevalence of obstructive sleep apnea and its association with renal function among nondialysis chronic kidney disease patients in Japan: a cross-sectional study. *Clin J Am Soc Nephrol* 2011; **6**: 995–1000. E-II
648 Imai E, Horio M, Yamagata K, Iseki K, Hara S, Ura N, Kiyohara Y, Makino H, Hishida A, Matsuo S. Slower decline of glomerular filtration rate in the Japanese general population: a longitudinal 10-year follow-up study. *Hypertens Res* 2008; **31**: 433–441. E-Ib
649 Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, Tuttle K, Douglas J, Hsueh W, Sowers J, National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Preserving renal function in adults with hypertension and diabetes: a consensus approach. *Am J Kidney Dis* 2000; **36**: 646–661. GL
650 Nakai S, Iseki K, Itami N, Ogata S, Kazama JJ, Kimata N, Shigematsu T, Shinoda T, Shoji T, Suzuki K, Taniguchi M, Tsuchida K, Nakamoto H, Nishi H, Hashimoto S, Hasegawa T, Hanafusa N, Hamano T, Fujii N, Masakane I, Marubayashi S, Morita O, Yamagata K, Wakai K, Wada A, Watanabe Y, Tsubakihara Y. An overview of regular dialysis treatment in Japan (as of 31 December 2010). *Ther Apher Dial* 2012; **16**: 483–521. E-II
651 Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, Shulman NB, Stamler J. Blood pressure and end-stage renal disease in men. *New Engl J Med* 1996; **334**: 13–18. E-Ib
652 Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW, American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. *Circulation* 2003; **108**: 2154–2169. GL
653 The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. *Lancet* 1997; **349**: 1857–1863. II
654 de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. *Kidney Int* 2004; **65**: 2309–2320. IVa
655 Keane WF, Brenner BM, de Zeeuw D, Grunfeld JP, McGill J, Mitch WE, Ribeiro AB, Shahinfar S, Simpson RL, Snapinn SM, Toto R, RENAAL Study Investigators. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. *Kidney Int* 2003; **63**: 1499–1507. IVa
656 Nakamura K, Okamura T, Hayakawa T, Kadowaki T, Kita Y, Ohnishi H, Saitoh S, Sakata K, Okayama A, Ueshima H, NIPPON DATA90 Research Group. Chronic kidney disease is a risk factor for cardiovascular death in a community-based population in Japan: NIPPON DATA90. *Circ J* 2006; **70**: 954–959. IVa
657 Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. *Arch Intern Med* 2004; **164**: 659–663. E-Ib
658 Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. *New Engl J Med* 2004; **351**: 1296–12305. E-Ib
659 Nagata M, Ninomiya T, Kiyohara Y, Murakami Y, Irie F, Sairenchi T, Miura K, Okamura T, Ueshima H, EPOCH-JAPAN Research Group. Prediction of cardiovascular disease mortality by proteinuria and reduced kidney function: pooled analysis of 39,000 individuals from 7 cohort studies in Japan. *Am J Epidemiol* 2013; **178**: 1–11. E-Ia
660 National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. *Am J Kidney Dis* 2002; **39**: S1–266. GL
661 Japanese Society of Nephrology. Evidence-based Clinical Practice Guideline for CKD 2013 (in Japanese). Tokyo Igakusha: Tokyo. 2013. GL
662 Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J, Gansevoort RT, Chronic Kidney Disease Prognosis Consortium. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. *Lancet* 2010; **375**: 2073–2081. E-Ia
663 Stevens PE, Levin A, Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. *Ann Intern Med* 2013; **158**: 825–830. GL
664 Nakayama M, Sato T, Miyazaki M, Matsushima M, Sato H, Taguma Y, Ito S. Increased risk of cardiovascular events and mortality among non-diabetic chronic kidney disease patients with hypertensive nephropathy: the Gonryo study. *Hypertens Res* 2011; **34**: 1106–1110. E-Ib
665 Ito S. Cardiorenal syndrome: an evolutionary point of view. *Hypertension* 2012; **60**: 589–595. VI
666 Umemura T, Kawamura T, Sakakibara T, Mashita S, Hotta N, Sobue G. Microalbuminuria is independently associated with deep or infratentorial brain microbleeds in hypertensive adults. *Am J Hypertens* 2012; **25**: 430–436. E-II
667 Imai E, Horio M, Watanabe T, Iseki K, Yamagata K, Hara S, Ura N, Kiyohara Y, Moriyama T, Ando Y, Fujimoto S, Konta T, Yokoyama H, Makino H, Hishida A, Matsuo S. Prevalence of chronic kidney disease in the Japanese general population. *Clin Exp Nephrol* 2009; **13**: 621–630. E-II
668 Yokoyama H, Kawai K, Kobayashi M, Japan Diabetes Clinical Data Management Study Group. Microalbuminuria is common in Japanese type 2 diabetic patients: a nationwide survey from the Japan Diabetes Clinical Data Management Study Group (JDDM 10). *Diabetes Care* 2007; **30**: 989–992. E-II
669 Middleton RJ, Foley RN, Hegarty J, Cheung CM, McElduff P, Gibson JM, Kalra PA, O'Donoghue DJ, New JP. The unrecognized prevalence of chronic kidney disease in diabetes. *Nephrol Dial Transplant* 2006; **21**: 88–92. E-II
670 Araki S, Haneda M, Koya D, Hidaka H, Sugimoto T, Isono M, Isshiki K, Chin-Kanasaki M, Uzu T, Kashiwagi A. Reduction in microalbuminuria as an integrated indicator for renal and cardiovascular risk reduction in patients with type 2 diabetes. *Diabetes* 2007; **56**: 1727–1730. IVa
671 Ogawa S, Takeuchi K, Mori T, Nako K, Tsubono Y, Ito S. Effects of monotherapy of temocapril or candesartan with dose increments or combination therapy with both drugs on the suppression of diabetic nephropathy. *Hypertens Res* 2007; **30**: 325–334. II
672 Slagman MC, Waanders F, Hemmelder MH, Woittiez AJ, Janssen WM, Lambers Heerspink HJ, Navis G, Laverman GD, HOlland NEphrology STudy Group. Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial. *BMJ* 2011; **343**: d4366. II
673 Lambers Heerspink HJ, de Borst MH, Bakker SJ, Navis GJ. Improving the efficacy of RAAS blockade in patients with chronic kidney disease. *Nat Rev Nephrol* 2013; **9**: 112–121. VI
674 Vegter S, Perna A, Postma MJ, Navis G, Remuzzi G, Ruggenenti P. Sodium intake, ACE inhibition, and progression to ESRD. *J Am Soc Nephrol* 2012; **23**: 165–173. E-Ib
675 Iseki K, Ikemiya Y, Kinjo K, Inoue T, Iseki C, Takishita S. Body mass index and the risk of development of end-stage renal disease in a screened cohort. *Kidney Int* 2004; **65**: 1870–1876. E-Ib
676 Tozawa M, Iseki K, Iseki C, Oshiro S, Ikemiya Y, Takishita S. Influence of smoking and obesity on the development of proteinuria. *Kidney Int* 2002; **62**: 956–962. E-Ib
677 Bello AK, de Zeeuw D, El Nahas M, Brantsma AH, Bakker SJ, de Jong PE, Gansevoort RT. Impact of weight change on albuminuria in the general population. *Nephrol Dial Transplant* 2007; **22**: 1619–1627. IVa
678 Afshinnia F, Wilt TJ, Duval S, Esmaeili A, Ibrahim HN. Weight loss and proteinuria: systematic review of clinical trials and comparative cohorts. *Nephrol Dial Transplant* 2010; **25**: 1173–1183. IVa
679 Navaneethan SD, Yehnert H, Moustarah F, Schreiber MJ, Schauer PR, Beddhu S. Weight loss interventions in chronic kidney disease: a systematic review and meta-analysis. *Clin J Am Soc Nephrol* 2009; **4**: 1565–1574. IVa
680 Kramer H, Shoham D, McClure LA, Durazo-Arvizu R, Howard G, Judd S, Muntner P, Safford M, Warnock DG, McClellan W. Association of waist circumference and body mass index with all-cause mortality in CKD: The REGARDS (Reasons for Geographic and Racial Differences in Stroke) Study. *Am J Kidney Dis* 2011; **58**: 177–185. IVa
681 Elsayed EF, Tighiouart H, Weiner DE, Griffith J, Salem D, Levey AS, Sarnak MJ. Waist-to-hip ratio and body mass index as risk factors for cardiovascular events in CKD. *Am J Kidney Dis* 2008; **52**: 49–57. IVa
682 Orth SR. Smoking and the kidney. *J Am Soc Nephrol* 2002; **13**: 1663–1672. VI
683 Parving HH, Lewis JB, Ravid M, Remuzzi G, Hunsicker LG, DEMAND investigators. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. *Kidney Int* 2006; **69**: 2057–2063. E-II
684 Pedrini MT, Levey AS, Lau J, Chalmers TC, Wang PH. The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: a meta-analysis. *Ann Intern Med* 1996; **124**: 627–632. I
685 Pan Y, Guo LL, Jin HM. Low-protein diet for diabetic nephropathy: a meta-analysis of randomized controlled trials. *Am J Clin Nutr* 2008; **88**: 660–666. I
686 Robertson L, Waugh N, Robertson A. Protein restriction for diabetic renal disease. *Cochrane Database Syst Rev* 2007; CD002181. I
687 Koya D, Haneda M, Inomata S, Suzuki Y, Suzuki D, Makino H, Shikata K, Murakami Y, Tomino Y, Yamada K, Araki SI, Kashiwagi A, Kikkawa R, Low-Protein Diet Study Group. Long-term effect of modification of dietary protein intake on the progression of diabetic nephropathy: a randomised controlled trial. *Diabetologia* 2009; **52**: 2037–2045. II
688 Japanese Society of Nephrology. Guidelines for Life Style and Dietary Therapy for CKD patients. *Jpn J Nephrol* 1997; **39**: 1–37. Japanese. GL
689 Smart NA, Williams AD, Levinger I, Selig S, Howden E, Coombes JS, Fassett RG. Exercise & Sports Science Australia (ESSA) position statement on exercise and chronic kidney disease. *J Sci Med Sport* 2013; **16**: 406–411. GL
690 Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, Cifkova R, Clément D, Coca A, Dominiczak A, Erdine S, Fagard R, Farsang C, Grassi G, Haller H, Heagerty A, Kjeldsen SE, Kiowski W, Mallion JM, Manolis A, Narkiewicz K, Nilsson P, Olsen MH, Rahn KH, Redon J, Rodicio J, Ruilope L, Schmieder RE, Struijker-Boudier HA, van Zwieten PA, Viigimaa M, Zanchetti A, European Society of Hypertension. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. *J Hypertens* 2009; **27**: 2121–2158. GL

691 de Galan BE, Perkovic V, Ninomiya T, Pillai A, Patel A, Cass A, Neal B, Poulter N, Harrap S, Mogensen CE, Cooper M, Marre M, Williams B, Hamet P, Mancia G, Woodward M, Glasziou P, Grobbee DE, MacMahon S, Chalmers J, ADVANCE Collaborative Group. Lowering blood pressure reduces renal events in type 2 diabetes. *J Am Soc Nephrol* 2009; **20**: 883–892. II
692 Uzu T, Kida Y, Yamauchi A, Kume S, Isshiki K, Araki S, Koya D, Haneda M, Kashiwagi A, Maegawa H, Kikkawa R. The effects of blood pressure control levels on the renoprotection of type 2 diabetic patients without overt proteinuria. *J Am Soc Hypertens* 2012; **6**: 124–131. E-Ib
693 Pohl MA, Blumenthal S, Cordonnier DJ, De Alvaro F, Deferrari G, Eisner G, Esmatjes E, Gilbert RE, Hunsicker LG, de Faria JB, Mangili R, Moore J Jr, Reisin E, Ritz E, Schernthaner G, Spitalewitz S, Tindall H, Rodby RA, Lewis EJ. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations. *J Am Soc Nephrol* 2005; **16**: 3027–3037. IVa
694 Kawamori R, Fujita T, Matsuoka H, Umemura S, Saito Y. Relation between cardiovascular complications and blood pressure/blood glucose control in diabetic patients with hypertension receiving long-term candesartan cilexetil therapy: Challenge-DM study. *Diabetes Res Clin Pract* 2009; **83**: 241–248. IVb
695 Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG, African American Study of Kidney Disease and Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. *JAMA* 2002; **288**: 2421–2431. II
696 Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, Striker G, Modification of Diet in Renal Disease Study Group. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. *New Engl J Med* 1994; **330**: 877–884. II
697 Ruggenenti P, Perna A, Loriga G, Ganeva M, Ene-Iordache B, Turturro M, Lesti M, Perticucci E, Chakarski IN, Leonardis D, Garini G, Sessa A, Basile C, Alpa M, Scanziani R, Sorba G, Zoccali C, Remuzzi G, REIN-2 Study Group. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. *Lancet* 2005; **365**: 939–946. II
698 Peralta CA, Norris KC, Li S, Chang TI, Tamura MK, Jolly SE, Bakris G, McCullough PA, Shlipak M, KEEP Investigators. Blood pressure components and end-stage renal disease in persons with chronic kidney disease: the Kidney Early Evaluation Program (KEEP). *Arch Intern Med* 2012; **172**: 41–47. IVa
699 Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, King AJ, Klahr S, Massry SG, Seifter JL. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. *Ann Intern Med* 1995; **123**: 754–762. II
700 Appel LJ, Wright JT Jr, Greene T, Agodoa LY, Astor BC, Bakris GL, Cleveland WH, Charleston J, Contreras G, Faulkner ML, Gabbai FB, Gassman JJ, Hebert LA, Jamerson KA, Kopple JD, Kusek JW, Lash JP, Lea JP, Lewis JB, Lipkowitz MS, Massry SG, Miller ER, Norris K, Phillips RA, Pogue VA, Randall OS, Rostand SG, Smogorzewski MJ, Toto RD, Wang X, AASK Collaborative Research Group. Intensive blood-pressure control in hypertensive chronic kidney disease. *New Engl J Med* 2010; **363**: 918–929. IVa
701 Upadhyay A, Earley A, Haynes SM, Uhlig K. Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier. *Ann Intern Med* 2011; **154**: 541–548. IVa
702 Sarnak MJ, Greene T, Wang X, Beck G, Kusek JW, Collins AJ, Levey AS. The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study. *Ann Intern Med* 2005; **142**: 342–351. II
703 Lv J, Ehteshami P, Sarnak MJ, Tighiouart H, Jun M, Ninomiya T, Foote C, Rodgers A, Zhang H, Wang H, Strippoli GF, Perkovic V. Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis. *CMAJ* 2013; **185**: 949–957. I
704 Weiner DE, Tighiouart H, Levey AS, Elsayed E, Griffith JL, Salem DN, Sarnak MJ. Lowest systolic blood pressure is associated with stroke in stages 3 to 4 chronic kidney disease. *J Am Soc Nephrol* 2007; **18**: 960–966. E-Ib
705 Ninomiya T, Perkovic V, Gallagher M, Jardine M, Cass A, Arima H, Anderson C, Neal B, Woodward M, Omae T, MacMahon S, Chalmers J, PROGRESS Collaborative Group. Lower blood pressure and risk of recurrent stroke in patients with chronic kidney disease: PROGRESS trial. *Kidney Int* 2008; **73**: 963–970. III
706 Ninomiya T, Perkovic V, Verdon C, Barzi F, Cass A, Gallagher M, Jardine M, Anderson C, Chalmers J, Craig JC, Huxley R. Proteinuria and stroke: a meta-analysis of cohort studies. *Am J Kidney Dis* 2009; **53**: 417–425. E-Ia
707 Sarafidis PA, Khosla N, Bakris GL. Antihypertensive therapy in the presence of proteinuria. *Am J Kidney Dis* 2007; **49**: 12–26. VI
708 Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE, de Zeeuw D, Shahinfar S, Toto R, Levey AS, AIPRD Study Group. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. *Ann Intern Med* 2003; **139**: 244–252. E-Ia
709 Saruta T, Hayashi K, Ogihara T, Nakao K, Fukui T, Fukiyama K, CASE-J Study Group. Effects of candesartan and amlodipine on cardiovascular events in hypertensive patients with chronic kidney disease: subanalysis of the CASE-J Study. *Hypertens Res* 2009; **32**: 505–512. III
710 Keane WF, Eknoyan G. Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation. *Am J Kidney Dis* 1999; **33**: 1004–1010. GL
711 Kim-Mitsuyama S, Ogawa H, Matsui K, Jinnouchi T, Jinnouchi H, Arakawa K. An angiotensin II receptor blocker-calcium channel blocker combination prevents cardiovascular events in elderly high-risk hypertensive patients with chronic kidney disease better than high-dose angiotensin II receptor blockade alone. *Kidney Int* 2013; **83**: 167–176. III
712 Baba S, J-MIND Study Group. Nifedipine and enalapril equally reduce the progression of nephropathy in hypertensive type 2 diabetics. *Diabetes Res Clin Pract* 2001; **54**: 191–201. II
713 Hayashi K, Kumagai H, Saruta T. Effect of efonidipine and ACE inhibitors on proteinuria in human hypertension with renal impairment. *Am J Hypertens* 2003; **16**: 116–122. II
714 Katayama K, Nomura S, Ishikawa H, Murata T, Koyabu S, Nakano T. Comparison between valsartan and valsartan plus cilnidipine in type II diabetics with normo- and microalbuminuria. *Kidney Int* 2006; **70**: 151–156. II
715 Ogawa S, Mori T, Nako K, Ito S. Combination therapy with renin–angiotensin system inhibitors and the calcium channel blocker azelnidipine decreases plasma inflammatory markers and urinary oxidative stress markers in patients with diabetic nephropathy. *Hypertens Res* 2008; **31**: 1147–1155. II
716 Sato A, Hayashi K, Naruse M, Saruta T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. *Hypertension* 2003; **41**: 64–68. V
717 Bianchi S, Bigazzi R, Campese VM. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. *Kidney Int* 2006; **70**: 2116–2123. II
718 Zager PG, Nikolic J, Brown RH, Campbell MA, Hunt WC, Peterson D, Van Stone J, Levey A, Meyer KB, Klag MJ, Johnson HK, Clark E, Sadler JH, Teredesai P.'U'curve association of blood pressure and mortality in hemodialysis patients. Medical Directors of Dialysis Clinic, Inc. *Kidney Int* 1998; **54**: 561–569. IVa
719 Mazzuchi N, Carbonell E, Fernández-Cean J. Importance of blood pressure control in hemodialysis patient survival. *Kidney Int* 2000; **58**: 2147–2154. IVa
720 Iseki K, Miyasato F, Tokuyama K, Nishime K, Uehara H, Shiohira Y, Sunagawa H, Yoshihara K, Yoshi S, Toma S, Kowatari T, Wake T, Oura T, Fukiyama K. Low diastolic blood pressure, hypoalbuminemia, and risk of death in a cohort of chronic hemodialysis patients. *Kidney Int* 1997; **51**: 1212–1217. IVa
721 Robinson BM, Tong L, Zhang J, Wolfe RA, Goodkin DA, Greenwood RN, Kerr PG, Morgenstern H, Li Y, Pisoni RL, Saran R, Tentori F, Akizawa T, Fukuhara S, Port FK. Blood pressure levels and mortality risk among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. *Kidney Int* 2012; **82**: 570–580. E-II
722 Iseki K, Nakai S, Shinzato T, Morita O, Shinoda T, Kikuchi K, Wada A, Kimata N, Akiba T. Prevalence and determinants of hypertension in chronic hemodialysis patients in Japan. *Ther Apher Dial* 2007; **11**: 183–188. E-II
723 Shoji T, Tsubakihara Y, Fujii M, Imai E. Hemodialysis-associated hypotension as an independent risk factor for two-year mortality in hemodialysis patients. *Kidney Int* 2004; **66**: 1212–1220. IVa
724 Agarwal R, Alborzi P, Satyan S, Light RP. Dry-weight reduction in hypertensive hemodialysis patients (DRIP): a randomized, controlled trial. *Hypertension* 2009; **53**: 500–507. II
725 Moriya H, Ohtake T, Kobayashi S. Aortic stiffness, left ventricular hypertrophy and weekly averaged blood pressure (WAB) in patients on haemodialysis. *Nephrol Dial Transplant* 2007; **22**: 1198–1204. V
726 The Japanese Society for Dialysis Therapy. Clinical Guidelines for the Evaluation and the Treatment of Cardiovascular Complications in Hemodialysis Patients. *J Jpn Soc Dia Ther* 2011; **44**: 358–362. Japanese. GL
727 The Japanese Circulation Society. Guidelines for Diagnosis and Treatment of Aortic Aneurysm and Aortic Dissection (JCS 2011). The Japanese Circulation Society. Japanese. 2011. GL
728 Genoni M, Paul M, Jenni R, Graves K, Seifert B, Turina M. Chronic ß-blocker therapy improves outcome and reduces treatment costs in chronic type B aortic dissection. *Eur J Cardiothorac Surg* 2001; **19**: 606–610. IVa
729 Leach SD, Toole AL, Stern H, DeNatale RW, Tilson MD. Effect of β-adrenergic blockade on the growth rate of abdominal aortic aneurysms. *Arch Surg* 1988; **123**: 606–609. IVb
730 Hackam DG, Thiruchelvam D, Redelmeier DA. Angiotensin-converting enzyme inhibitors and aortic rupture: a population-based case-control study. *Lancet* 2006; **368**: 659–665. IVb
731 Isselbacher ME. Disease of the Aorta In: Douglas P, Libby P Bonow RO (eds), Braunwald' Heart Disease, a text book of cardiovascular medicine. 7th edn. Philadelphia, 2005, 1428. VI
732 Ashton HA, Buxton MJ, Day NE, Kim LG, Marteau TM, Scott RA, Thompson SG, Walker NM, Multicentre Aneurysm Screening Study Group. The Multicentre Aneurysm Screening Study (MASS) into the effect of abdominal aortic aneurysm screening on mortality in men: a randomised controlled trial. *Lancet* 2002; **360**: 1531–1539. II
733 Shores J, Berger KR, Murphy EA, Pyeritz RE. Progression of aortic dilatation and the benefit of long-term β-adrenergic blockade in Marfan's syndrome. *New Engl J Med* 1994; **330**: 1335–1341. II
734 Brooke BS, Habashi JP, Judge DP, Patel N, Loeys B, Dietz HC 3rd. Angiotensin II blockade and aortic-root dilation in Marfan's syndrome. *New Engl J Med* 2008; **358**: 2787–2795. V
735 MacSweeney ST, Ellis M, Worrell PC, Greenhalgh RM, Powell JT. Smoking and growth rate of small abdominal aortic aneurysms. *Lancet* 1994; **344**: 651–652. IVa

736 Brewster DC, Cronenwett JL, Hallett JW Jr, Johnston KW, Krupski WC, Matsumura JS, Joint Council of the American Association for Vascular Surgery and Society for Vascular Surgery. Guidelines for the treatment of abdominal aortic aneurysms. Report of a subcommittee of the Joint Council of the American Association for Vascular Surgery and Society for Vascular Surgery. *J Vasc Surg* 2003; **37**: 1106–1117. GL

737 Stewart KJ, Hiatt WR, Regensteiner JG, Hirsch AT. Exercise training for claudication. *New Engl J Med* 2002; **347**: 1941–1951. VI

738 Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG, TASC II Working Group. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). *J Vasc Surg* 2007; **45**(Suppl S): S5–S67. GL

739 Radack K, Deck C. β-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials. *Arch Intern Med* 1991; **151**: 1769–1776. I

740 Espinola-Klein C, Weisser G, Jagodzinski A, Savvidis S, Warnholtz A, Ostad MA, Gori T, Munzel T. β-Blockers in patients with intermittent claudication and arterial hypertension: results from the nebivolol or metoprolol in arterial occlusive disease trial. *Hypertension* 2011; **58**: 148–154. II

741 Iimura O. Insulin resistance and hypertension in Japanese. *Hypertens Res* 1996; **19**(Suppl 1): S1–S8. VI

742 American Diabetes Association. Role of cardiovascular risk factors in prevention and treatment of macrovascular disease in diabetes. *Diabetes Care* 1989; **12**: 573–579. GL

743 Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. *Ann Intern Med* 1993; **118**: 577–581. II

744 Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. *Diabetes Care* 2003; **26**(Suppl 1): S5–S20. GL

745 American Diabetes Association. Standards of medical care in diabetes–2013. *Diabetes Care* 2013; **36**(Suppl 1): S11–S66. GL

746 Doi Y, Ninomiya T, Hata J, Fukuhara M, Yonemoto K, Iwase M, Iida M, Kiyohara Y. Impact of glucose tolerance status on development of ischemic stroke and coronary heart disease in a general Japanese population: the Hisayama study. *Stroke* 2010; **41**: 203–209. E-Ib

747 Watanabe M, Kokubo Y, Higashiyama A, Ono Y, Okayama A, Okumura T, New disgnosis criteria for diabetes with hemoglobin A1c and risks of macro-vascular complications in an urban Japanese cohort: the Suita study. *Diabetes Res Clin Pract* 2010; **88**: e20–e203. E-Ib

748 Sone H, Tanaka S, Tanaka S, Iimuro S, Oida K, Yamasaki Y, Oikawa S, Ishibashi S, Katayama S, Ohashi Y, Akanuma Y, Yamada N, Japan Diabetes Complications Study Group. Serum level of triglycerides is a potent risk factor comparable to LDL cholesterol for coronary heart disease in Japanese patients with type 2 diabetes: subanalysis of the Japan Diabetes Complications Study (JDCS). *J Clin Endocrinol Metab* 2011; **96**: 3448–3456. E-Ib

749 Reboldi G, Gentile G, Angeli F, Ambrosio G, Mancia G, Verdecchia P. Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta-analysis in 73,913 patients. *J Hypertens* 2011; **29**: 1253–1269. I

750 Onishi H, Saito S, Shimamoto K. Tanno–Sobetsu Study Review in 2007. *Ther Res* 2007; **28**: 513–525. Japanese. VI

751 Eguchi K, Hoshide S, Ishikawa S, Shimada K, Kario K. Aggressive blood pressure-lowering therapy guided by home blood pressure monitoring improves target organ damage in hypertensive patients with type 2 diabetes/prediabetes. *J Clin Hypertens(Greenwich)* 2012; **14**: 422–428. III

752 Bavry AA, Anderson RD, Gong Y, Denardo SJ, Cooper-Dehoff RM, Handberg EM, Pepine CJ. Outcomes Among hypertensive patients with concomitant peripheral and coronary artery disease: findings from the INternational VErapamil-SR/Trandolapril STudy. *Hypertension* 2010; **55**: 48–53. IVa

753 Iimura O, Shimamoto K, Matsuda K, Masuda A, Takizawa H, Higashiura K, Miyazaki Y, Hirata A, Ura N, Nakagawa M. Effects of angiotensin receptor antagonist and angiotensin converting enzyme inhibitor on insulin sensitivity in fructose-fed hypertensive rats and essential hypertensives. *Am J Hypertens* 1995; **8**: 353–357. III

754 The EUCLID Study Group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. *Lancet* 1997; **349**: 1787–1792. II

755 Kazumi T, Yoshino G, Kikkawa R, Baba S. Comparison of the long-term effects of Ca channel blockers and ACE inhibitors on the onset/progression of diabetic nephropathy. *J Jpn Diabetes Soc* 1999; **42**: S225. Japanese. II

756 UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. *BMJ* 1998; **317**: 713–720. II

757 Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, Drury PL, Esmatjes E, Hricik D, Parikh CR, Raz I, Vanhille P, Wiegmann TB, Wolfe BM, Locatelli F, Goldhaber SZ, Lewis EJ, Irbesartan Diabetic Nephropathy Trial. Collaborative Study Group. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. *Ann Intern Med* 2003; **138**: 542–549. III

758 Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P, Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. *New Engl J Med* 2001; **345**: 870–878. II

759 Viberti G, Wheeldon NM, MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. *Circulation* 2002; **106**: 672–678. II

760 Haller H, Ito S, Izzo JL Jr, Januszewicz A, Katayama S, Menne J, Mimran A, Rabelink TJ, Ritz E, Ruilope LM, Rump LC, Viberti G, ROADMAP Trial Investigators. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. *New Engl J Med* 2011; **364**: 907–917. II

761 Niskanen L, Hedner T, Hansson L, Lanke J, Niklason A, CAPPP Study Group. Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/β-blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project. *Diabetes Care* 2001; **24**: 2091–2096. III

762 Tuomilehto J, Rastenyte D, Birkenhäger WH, Thijs L, Antikainen R, Bulpitt CJ, Fletcher AE, Forette F, Goldhaber A, Palatini P, Sarti C, Fagard R, Systolic Hypertension in Europe Trial Investigators. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. *New Engl J Med* 1999; **340**: 677–684. III

763 Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. *New Engl J Med* 1998; **338**: 645–652. II

764 Tatti P, Pahor M, Byington RP, Di Mauro P, Guarisco R, Strollo G, Strollo F. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. *Diabetes Care* 1998; **21**: 597–603. II

765 Leenen FH, Nwachuku CE, Black HR, Cushman WC, Davis BR, Simpson LM, Alderman MH, Atlas SA, Basile JN, Cuyjet AB, Dart R, Felicetta JV, Grimm RH, Haywood LJ, Jafri SZ, Proschan MA, Thadani U, Whelton PK, Wright JT, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group. Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. *Hypertension* 2006; **48**: 374–384. III

766 Weber MA, Bakris GL, Jamerson K, Weir M, Kjeldsen SE, Devereux RB, Velazquez EJ, Dahlöf B, Kelly RY, Hua TA, Hester A, Pitt B, ACCOMPLISH Investigators. Cardiovascular events during differing hypertension therapies in patients with diabetes. *J Am Coll Cardiol* 2010; **56**: 77–85. III

767 Matsuzaki M, Kita T, Mabuchi H, Matsuzawa Y, Nakaya N, Oikawa S, Saito Y, Sasaki J, Shimamoto K, Itakura H, J-LIT Study Group. Japan Lipid Intervention Trial. Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia. *Circ J* 2002; **66**: 1087–1095. E-Ib

768 Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J, ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. *Lancet* 2003; **361**: 1149–1158. II

769 Kushiro T, Mizuno K, Nakaya N, Ohashi Y, Teramoto T, Yokoyama S, Kakinoki S, Nakamura H, MEGA Study Group. Blood pressure control status and effects of pravastatin on cardiovascular events occurrence in patients with dyslipidaemia. *J Hum Hypertens* 2012; **26**: 388–395. E-Ib

770 Velasco M, Hurt E, Silva H, Urbina-Quintana A, Hernández-Pieretti O, Feldstein E, Camejo G. Effects of prazosin and propranolol on blood lipids and lipoproteins in hypertensive patients. *Am J Med* 1986; **80**: 109–113. II

771 The Ministry of Welfare, Japan. Report of the National Nutrition Survey in 1990. Daiichi-Shuppan: Tokyo, 1992, pp. 121. Japanese. E-III

772 Neter JE, Stam BE, Kok FJ, Grobbee DE, Geleijnse JM. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. *Hypertension* 2003; **42**: 878–884. I

773 Barzilay JI, Howard AG, Evans GW, Fleg JL, Cohen RM, Booth GL, Kimel AR, Pedley CF, Cushman WC. Intensive blood pressure treatment does not improve cardiovascular outcomes in centrally obese hypertensive individuals with diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Blood Pressure Trial. *Diabetes Care* 2012; **35**: 1401–1405. III

774 Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). *JAMA* 2001; **285**: 2486–2497. GL

775 Definition of metabolic syndrome and diagnostic criteria. *J Jpn Soc Intern Med* 2005, **94**: 794–809. Japanese. VI

776 Ohnishi H, Saito S, Takagi S, Katoh N, Chiba Y, Akasaka H, Nakamura Y Shimamoto K. Incidence of type 2 diabetes in individuals with central obesity and metabolic syndrome by routine medical check-up in a rural Japanese population: The Tanno and Sobetsu study. *J Jpn Diabetes Soc* 2006; **49**; s-50. Japanese. E-Ib

777 Somers VK, White DP, Amin R, Abraham WT, Costa F, Culebras A, Daniels S, Floras JS, Hunt CE, Olson LJ, Pickering TG, Russell R, Woo M, Young T, American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology; American Heart Association Stroke Council; American Heart Association Council on Cardiovascular Nursing; American College of Cardiology Foundation. Sleep apnea and cardiovascular disease: an American Heart Association/american College Of Cardiology Foundation Scientific

Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council On Cardiovascular Nursing. In collaboration with the National Heart, Lung, and Blood Institute National Center on Sleep Disorders Research (National Institutes of Health). *Circulation* 2008; **118**: 1080–1111. GL
778 Parati G, Lombardi C, Hedner J, Bonsignore MR, Grote L, Tkacova R, Levy P, Riha R, Bassetti C, Narkiewicz K, Mancia G, McNicholas WT, European Respiratory Society, EU COST ACTION B26 members. Position paper on the management of patients with obstructive sleep apnea and hypertension: joint recommendations by the European Society of Hypertension, by the European Respiratory Society and by the members of European COST (COoperation in Scientific and Technological research) ACTION B26 on obstructive sleep apnea. *J Hypertens* 2012; **30**: 633–646. GL
779 Eguchi K, Kario K, Hoshide S, Ishikawa J, Morinari M, Shimada K. Nocturnal hypoxia is associated with silent cerebrovascular disease in a high-risk Japanese community-dwelling population. *Am J Hypertens* 2005; **18**: 1489–1495. IVb
780 Kario K. Obstructive sleep apnea syndrome and hypertension: ambulatory blood pressure. *Hypertens Res* 2009; **32**: 428–432. VI
781 Kario K. Obstructive sleep apnea syndrome and hypertension: mechanism of the linkage and 24-h blood pressure control. *Hypertens Res* 2009; **32**: 537–541. VI
782 Sasanabe R, Banno K, Otake K, Hasegawa R, Usui K, Morita M, Shiomi T. Metabolic syndrome in Japanese patients with obstructive sleep apnea syndrome. *Hypertens Res* 2006; **29**: 315–322. IVb
783 Shiina K, Tomiyama H, Takata Y, Usui Y, Asano K, Hirayama Y, Nakamura T, Yamashina A. Concurrent presence of metabolic syndrome in obstructive sleep apnea syndrome exacerbates the cardiovascular risk: a sleep clinic cohort study. *Hypertens Res* 2006; **29**: 433–341. IVb
784 Endo S, Mataki S, Kurosaki N. Cephalometric evaluation of craniofacial and upper airway structures in Japanese patients with obstructive sleep apnea. *J Med Dent Sci* 2003; **50**: 109–120. IVb
785 Yumino D, Wang H, Floras JS, Newton GE, Mak S, Ruttanaumpawan P, Parker JD, Bradley TD. Prevalence and physiological predictors of sleep apnea in patients with heart failure and systolic dysfunction. *J Card Fail* 2009; **15**: 279–285. IVb
786 Sim JJ, Rasgon SA, Kujubu DA, Kumar VA, Liu IL, Shi JM, Pham TT, Derose SF. Sleep apnea in early and advanced chronic kidney disease: Kaiser Permanente Southern California cohort. *Chest* 2009; **135**: 710-6. IVb
787 Momomura S, Akashiba T, Asanoi H, Ando S, Kario K, Shiomi T, Seino Y, Tamura A, Chin K, Nakamoto T, Narui K, Hagiwara N, Yamashina A, Adachi H, Kuriyama T, Sasayama S, Yamaguchi T, Osada N, Kasai T, Sasanabe R, Sata M, Shinozaki T, Suga C, Serizawa N, Takata Y, Naito R, Maeno K, Minoguchi K, Yoshioka T, Tomoike H, Hori M. Guidelines for Diagnosis and Treatment of Sleep Disordered Breathing in Cardiovascular Disease (JCS 2010) (Chairman: Shinichi Momomura). *Circ J* 2010; **74**(Suppl II). Japanese. GL
788 Hla KM, Young T, Finn L, Peppard PE, Szklo-Coxe M, Stubbs M. Longitudinal association of sleep-disordered breathing and nondipping of nocturnal blood pressure in the Wisconsin Sleep Cohort Study. *Sleep* 2008; **31**: 795–800. IVa
789 Sekizuka H, Osada N, Kida K, Yoneyama K, Eguchi Y, Miyake F. Relationship between chronic kidney disease and sleep blood pressure in patients with sleep apnea syndrome. *Hypertens Res* 2010; **33**: 1278–1282. IVb
790 Giles TL, Lasserson TJ, Smith BH, White J, Wright J, Cates CJ. Continuous positive airways pressure for obstructive sleep apnoea in adults. *Cochrane Database Syst Rev* 2006; CD001106. I
791 Bazzano LA, Khan Z, Reynolds K, He J. Effect of nocturnal nasal continuous positive airway pressure on blood pressure in obstructive sleep apnea. *Hypertension* 2007; **50**: 417–423. I
792 Akashiba T, Minemura H, Yamamoto H, Kosaka N, Saito O, Horie T. Nasal continuous positive airway pressure changes blood pressure'non-dippers'to'dippers'in patients with obstructive sleep apnea. *Sleep* 1999; **22**: 849–853. III
793 Marin JM, Carrizo SJ, Vicente E, Agusti AG. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. *Lancet* 2005; **365**: 1046–1053. IVa
794 Marin JM, Agusti A, Villar I, Forner M, Nieto D, Carrizo SJ, Barbé F, Vicente E, Wei Y, Nieto FJ, Jelic S. Association between treated and untreated obstructive sleep apnea and risk of hypertension. *JAMA* 2012; **307**: 2169–2176. IVa
795 Barbé F, Mayoralas LR, Duran J, Masa JF, Maimó A, Montserrat JM, Monasterio C, Bosch M, Ladaria A, Rubio M, Rubio R, Medinas M, Hernandez L, Vidal S, Douglas NJ, Agustí AG. Treatment with continuous positive airway pressure is not effective in patients with sleep apnea but no daytime sleepiness. a randomized, controlled trial. *Ann Intern Med* 2001; **134**: 1015–1023. II
796 Robinson GV, Smith DM, Langford BA, Davies RJ, Stradling JR. Continuous positive airway pressure does not reduce blood pressure in nonsleepy hypertensive OSA patients. *Eur Respir J* 2006; **27**: 1229–1235. II
797 Barbé F, Durán-Cantolla J, Sánchez-de-la-Torre M, Martínez-Alonso M, Carmona C, Barceló A, Chiner E, Masa JF, Gonzalez M, Marín JM, Garcia-Rio F, Diaz de Atauri J, Terán J, Mayos M, de la Peña M, Monasterio C, del Campo F, Montserrat JM, Spanish Sleep And Breathing Network. Effect of continuous positive airway pressure on the incidence of hypertension and cardiovascular events in nonsleepy patients with obstructive sleep apnea: a randomized controlled trial. *JAMA* 2012; **307**: 2161–2168. II
798 Andrén A, Hedberg P, Walker-Engström ML, Wahlén P, Tegelberg A. Effects of treatment with oral appliance on 24-h blood pressure in patients with obstructive sleep apnea and hypertension: a randomized clinical trial. *Sleep Breath* 2013; **17**: 705–712. II
799 Kraiczi H, Hedner J, Peker Y, Grote L. Comparison of atenolol, amlodipine, enalapril, hydrochlorothiazide, and losartan for antihypertensive treatment in patients with obstructive sleep apnea. *Am J Respir Crit Care Med* 2000; **161**: 1423–1428. II
800 Pelttari LH, Hietanen EK, Salo TT, Kataja MJ, Kantola IM. Little effect of ordinary antihypertensive therapy on nocturnal high blood pressure in patients with sleep disordered breathing. *Am J Hypertens* 1998; **11**: 272–279. II
801 Bucca CB, Brussino L, Battisti A, Mutani R, Rolla G, Mangiardi L, Cicolin A. Diuretics in obstructive sleep apnea with diastolic heart failure. *Chest* 2007; **132**: 440–446. III
802 Gaddam K, Pimenta E, Thomas SJ, Cofield SS, Oparil S, Harding SM, Calhoun DA. Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report. *J Hum Hypertens* 2010; **24**: 532–537. III
803 Friedman O, Bradley TD, Chan CT, Parkes R, Logan AG. Relationship between overnight rostral fluid shift and obstructive sleep apnea in drug-resistant hypertension. *Hypertension* 2010; **56**: 1077–1082. IVb
804 Witkowski A, Prejbisz A, Florczak E, Kądziela J, Śliwiński P, Bieleń P, Michałowska I, Kabat M, Warchoł E, Januszewicz M, Narkiewicz K, Somers VK, Sobotka PA, Januszewicz A. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. *Hypertension* 2011; **58**: 559–565. V
805 Guideline-Revising Committee, Japanese Society of Gout and Nucleic Acid Metabolism (ed). *Guideline for the Management of Hyperuricemia and Gout*: 2nd edition. Supplement revision in 2012, Tokyo. Japanese. GL
806 Forman JP, Scheven L, de Jong PE, Bakker SJ, Curhan GC, Gansevoort RT. Association between sodium intake and change in uric acid, urine albumin excretion, and the risk of developing hypertension. *Circulation* 2012; **125**: 3108–3116. E-Ib
807 Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. *JAMA* 2008; **300**: 924–932. II
808 Higgins P, Dawson J, Lees KR, McArthur K, Quinn TJ, Walters MR. Xanthine oxidase inhibition for the treatment of cardiovascular disease: a systematic review and meta-analysis. *Cardiovasc Ther* 2012; **30**: 217–226. I
809 Noman A, Ang DS, Ogston S, Lang CC, Struthers AD. Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. *Lancet* 2010; **375**: 2161–2167. II
810 Rajendra NS, Ireland S, George J, Belch JJ, Lang CC, Struthers AD. Mechanistic insights into the therapeutic use of high-dose allopurinol in angina pectoris. *J Am Coll Cardiol* 2011; **58**: 820–828. II
811 Soletsky B, Feig DI. Uric acid reduction rectifies prehypertension in obese adolescents. *Hypertension* 2012; **60**: 1148–1156. II
812 Ogino K, Kato M, Furuse Y, Kinugasa Y, Ishida K, Osaki S, Kinugawa T, Igawa O, Hisatome I, Shigemasa C, Anker SD, Doehner W. Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study. *Circ Heart Fail* 2010; **3**: 73–81. II
813 Enomoto A, Kimura H, Chairoungdua A, Shigeta Y, Jutabha P, Cha SH, Hosoyamada M, Takeda M, Sekine T, Igarashi T, Matsuo H, Kikuchi Y, Oda T, Ichida K, Hosoya T, Shimokata K, Niwa T, Kanai Y, Endou H. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. *Nature* 2002; **417**: 447–452.
814 Ito S, Naritomi H, Ogihara T, Shimada K, Shimamoto K, Tanaka H, Yoshiike N. Impact of serum uric acid on renal function and cardiovascular events in hypertensive patients treated with losartan. *Hypertens Res* 2012; **35**: 867–873. E-Ib
815 Fabbri LM, Luppi F, Beghé B, Rabe KF. Complex chronic comorbidities of COPD. *Eur Respir J* 2008; **31**: 204–212. VI
816 Hirota SA, Janssen LJ. Sodium and asthma: something borrowed, something new? *Am J Physiol Lung Cell Mol Physiol* 2007; **293**: L1369–L1373. VI
817 Boulet LP, Milot J, Lampron N, Lacourcière Y. Pulmonary function and airway responsiveness during long-term therapy with captopril. *JAMA* 1989; **261**: 413–416. IVb
818 Covar RA, Macomber BA, Szefler SJ. Medications as asthma triggers. *Immunol Allergy Clin North Am* 2005; **25**: 169–190. VI
819 Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. *Cochrane Database Syst Rev* 2005; CD003566. I
820 Hawkins NM, MacDonald MR, Petrie MC, Chalmers GW, Carter R, Dunn FG, McMurray JJ. Bisoprolol in patients with heart failure and moderate to severe chronic obstructive pulmonary disease: a randomized controlled trial. *Eur J Heart Fail* 2009; **11**: 684–690. II
821 Rutten FH, Zuithoff NP, Hak E, Grobbee DE, Hoes AW. β-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. *Arch Intern Med* 2010; **170**: 880–887. IVa
822 Short PM, Lipworth SI, Elder DH, Schembri S, Lipworth BJ. Effect of β blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. *BMJ* 2011; **342**: d2549. IVa
823 Jabbour A, Macdonald PS, Keogh AM, Kotlyar E, Mellemkjaer S, Coleman CF, Elsik M, Krum H, Hayward CS. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. *J Am Coll Cardiol* 2010; **55**: 1780–1787. III
824 Cheng JW, Zhu L, Gu MJ, Song ZM. Meta analysis of propranolol effects on gastrointestinal hemorrhage in cirrhotic patients. *World J Gastroenterol* 2003; **9**: 1836–1839. I

825 Yokohama S, Yoneda M, Haneda M, Okamoto S, Okada M, Aso K, Hasegawa T, Tokusashi Y, Miyokawa N, Nakamura K. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. *Hepatology* 2004; **40**: 1222–1225. IVb
826 Counter of Government statistics: [List of statistical tables] (in Japanese). http://www.e-stat.go.jp/SG1/estat/GL08020103.do?_toGL08020103_&listID=000001108362&disp=Other&requestSender=dsearch. Accessed 18 May 2013. E-III
827 Aronow WS, Ahn C. Postprandial hypotension in 499 elderly persons in a long-term health care facility. *J Am Geriatr Soc* 1994; **42**: 930–932. E-II
828 Franklin SS, Wilkinson IB, McEniery CM. Unusual hypertensive phenotypes: what is their significance? *Hypertension* 2012; **59**: 173–178. VI
829 Insua JT, Sacks HS, Lau TS, Lau J, Reitman D, Pagano D, Chalmers TC. Drug treatment of hypertension in the elderly: a meta-analysis. *Ann Intern Med* 1994; **121**: 355–362. I
830 Peters R, Beckett N, Forette F, Tuomilehto J, Clarke R, Ritchie C, Waldman A, Walton I, Poulter R, Ma S, Comsa M, Burch L, Fletcher A, Bulpitt C, HYVET investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. *Lancet Neurol*. 2008; **7**: 683–689. II
831 Peters R, Beckett N, Burch L, de Vernejoul MC, Liu L, Duggan J, Swift C, Gil-Extremera B, Fletcher A, Bulpitt C. The effect of treatment based on a diuretic (indapamide) +/− ACE inhibitor (perindopril) on fractures in the Hypertension in the Very Elderly Trial (HYVET). *Age Ageing* 2010; **39**: 609–616. II
832 Liu L, Wang JG, Gong L, Liu G, Staessen JA, Systolic Hypertension in China (Syst-China) Collaborative Group. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. *J Hypertens* 1998; **16**: 1823–1829. III
833 Gong L, Zhang W, Zhu Y, Zhu J, Kong D, Pagé V, Ghadirian P, LeLorier J, Hamet P. Shanghai trial of nifedipine in the elderly (STONE). *J Hypertens* 1996; **14**: 1237–1245. III
834 Black HR, Elliott WJ, Weber MA, Frishman WH, Strom JA, Liebson PR, Hwang CT, Ruff DA, Montoro R, DeQuattro V, Zhang D, Schleman MM, Klibaner MI. One-year study of felodipine or placebo for stage 1 isolated systolic hypertension. *Hypertension* 2001; **38**: 1118–1123. II
835 SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). *JAMA* 1991; **265**: 3255–3264. II
836 Odden MC, Peralta CA, Haan MN, Covinsky KE. Rethinking the association of high blood pressure with mortality in elderly adults: the impact of frailty. *Arch Intern Med* 2012; **172**: 1162–1168. E-Ib
837 National Institute for Health and Clinical-Excellence. Hypertension: management of hypertension in adults in primary care. (2011). http://www.nice.org.uk/nicemedia/live/13561/56007/56007.pdf. Accessed on 20 May 2013. GL
838 Aronow WS, Fleg JL, Pepine CJ, Artinian NT, Bakris G, Brown AS, Ferdinand KC, Forciea MA, Frishman WH, Jaigobin C, Kostis JB, Mancia G, Oparil S, Ortiz E, Reisin E, Rich MW, Schocken DD, Weber MA, Wesley DJ, Harrington RA, ACCF Task Force. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. *Circulation* 2011; **123**: 2434–2506. VI
839 Zhang Y, Zhang X, Liu L, Zanchetti A, FEVER Study Group. Is a systolic blood pressure target <140mmHg indicated in all hypertensives? Subgroup analyses of findings from the randomized FEVER trial. *Eur Heart J* 2011; **32**: 1500–1508. III
840 Kjeldsen SE, Kolloch RE, Leonetti G, Mallion JM, Zanchetti A, Elmfeldt D, Warnold I, Hansson L. Influence of gender and age on preventing cardiovascular disease by antihypertensive treatment and acetylsalicylic acid. The HOT study. Hypertension Optimal Treatment. *J Hypertens* 2000; **18**: 629–642. E-Ib
841 JATOS Study Group. Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS). *Hypertens Res* 2008; **31**: 2115–2127. II
842 Ogihara T, Saruta T, Rakugi H, Matsuoka H, Shimamoto K, Shimada K, Imai Y, Kikuchi K, Ito S, Eto T, Kimura G, Imaizumi T, Takishita S, Ueshima H, Valsartan in Elderly Isolated Systolic Hypertension Study Group. Target blood pressure for treatment of isolated systolic hypertension in the elderly: valsartan in elderly isolated systolic hypertension study. *Hypertension* 2010; **56**: 196–202. II
843 Somes GW, Pahor M, Shorr RI, Cushman WC, Applegate WB. The role of diastolic blood pressure when treating isolated systolic hypertension. *Arch Intern Med* 1999; **159**: 2004–2009. E-Ib
844 Fagard RH, Staessen JA, Thijs L, Celis H, Bulpitt CJ, de Leeuw PW, Leonetti G, Tuomilehto J, Yodfat Y. On-treatment diastolic blood pressure and prognosis in systolic hypertension. *Arch Intern Med* 2007; **167**: 1884–1891. E-Ib
845 Ogihara T. Practitioner's Trial on the Efficacy of Antihypertensive Treatment in the Elderly Hypertension (The PATE-Hypertension Study) in Japan. *Am J Hypertens* 2000; **13**: 461–467. III
846 Ogihara T, Matsuoka H, Rakugi H. Practitioner's trial on the efficacy of antihypertensive treatment in elderly patients with hypertension II (PATE-hypertension II study) in Japan. *Geriatr Gerontol Int* 2011; **11**: 414–421. E-Ib
847 Denardo SJ, Gong Y, Nichols WW, Messerli FH, Bavry AA, Cooper-Dehoff RM, Handberg EM, Champion A, Pepine CJ. Blood pressure and outcomes in very old hypertensive coronary artery disease patients: an INVEST substudy. *Am J Med* 2010; **123**: 719–726. E-Ib
848 Denardo SJ, Messerli FH, Gaxiola E, Aranda JM Jr, Cooper-Dehoff RM, Handberg EM, Gong Y, Champion A, Zhou Q, Pepine CJ. Coronary revascularization strategy and outcomes according to blood pressure (from the International Verapamil SR-Trandolapril Study[INVEST]). *Am J Cardiol* 2010; **106**: 498–503. E-Ib
849 Bulpitt C, Fletcher A, Beckett N, Coope J, Gil-Extremera B, Forette F, Nachev C, Potter J, Sever P, Staessen J, Swift C, Tuomilehto J. Hypertension in the Very Elderly Trial (HYVET): protocol for the main trial. *Drugs Aging* 2001; **18**: 151–164. II
850 Masuo K, Mikami H, Ogihara T, Tuck ML. Changes in frequency of orthostatic hypotension in elderly hypertensive patients under medications. *Am J Hypertens* 1996; **9**: 263–268. III
851 Motoyama M, Sunami Y, Kinoshita F, Kiyonaga A, Tanaka H, Shindo M, Irie T, Urata H, Sasaki J, Arakawa K. Blood pressure lowering effect of low intensity aerobic training in elderly hypertensive patients. *Med Sci Sports Exerc* 1998; **30**: 818–823. III
852 Hansson L, Lindholm LH, Ekbom T, Dahlöf B, Lanke J, Scherstén B, Wester PO, Hedner T, de Faire U. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. *Lancet* 1999; **354**: 1751–1756. II
853 Kjeldsen SE, Dahlöf B, Devereux RB, Julius S, Aurup P, Edelman J, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Snapinn S, Wedel H, LIFE (Losartan Intervention for Endpoint Reduction) Study Group. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. *JAMA* 2002; **288**: 1491–1498. III
854 Wing LM, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GL, Johnston CI, McNeil JJ, Macdonald GJ, Marley JE, Morgan TO, West MJ, Second Australian National Blood Pressure Study Group. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. *New Engl J Med* 2003; **348**: 583–592. II
855 Ogihara T, Matsuzaki M, Umemoto S, Rakugi H, Matsuoka H, Shimada K, Higaki J, Ito S, Kamiya A, Suzuki H, Ohashi Y, Shimamoto K, Saruta T, Combination Therapy of Hypertension to Prevent Cardiovascular Events Trial Group. Combination therapy for hypertension in the elderly: a sub-analysis of the Combination Therapy of Hypertension to Prevent Cardiovascular Events (COPE) Trial. *Hypertens Res* 2012; **35**: 441–448. III
856 Arai T, Yasuda Y, Toshima S, Yoshimi N, Kashiki Y. ACE inhibitors and pneumonia in elderly people. *Lancet* 1998; **352**: 1937–1938. E-Ib
857 Okaishi K, Morimoto S, Fukuo K, Niinobu T, Hata S, Onishi T, Ogihara T. Reduction of risk of pneumonia associated with use of angiotensinI converting enzyme inhibitors in elderly inpatients. *Am J Hypertens* 1999; **12**: 778–783. E-II
858 Meisinger C, Heier M, Lang O, Döring A. β-blocker use and risk of fractures in men and women from the general population: the MONICA/KORA Augsburg cohort study. *Osteoporos Int* 2007; **18**: 1189–1195. E-Ib
859 Schlienger RG, Kraenzlin ME, Jick SS, Meier CR. Use of β-blockers and risk of fractures. *JAMA* 2004; **292**: 1326–1332. E-II
860 Solomon DH, Mogun H, Garneau K, Fischer MA. Risk of fractures in older adults using antihypertensive medications. *J Bone Miner Res* 2011; **26**: 1561–1567. E-Ib
861 The Japan Geriatrics Society. *Health and Long Life Treatment Handbook—Geriatric essence for practitioners* (in Japanese). Medical View Co, Ltd: Tokyo, 2011. GL
862 Butt DA, Mamdani M, Austin PC, Tu K, Gomes T, Glazier RH. The risk of hip fracture after initiating antihypertensive drugs in the elderly. *Arch Intern Med* 2012; **172**: 1739–1744. E-Ib
863 Amery A, Birkenhäger W, Brixko P, Bulpitt C, Clement D, Deruyttere M, De Schaepdryver A, Dollery C, Fagard R, Forette F, Hamdy R, Joossens JV, Lund-Johansen P, Petrie J, Tuomilehto J, Williams B. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. *Lancet* 1985; **1**: 1349–1354. II
864 Forette F, Seux ML, Staessen JA, Thijs L, Birkenhäger WH, Babarskiene MR, Babeanu S, Bossini A, Gil-Extremera B, Girerd X, Laks T, Lilov E, Moisseyev V, Tuomilehto J, Vanhanen H, Webster J, Yodfat Y, Fagard R. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. *Lancet* 1998; **352**: 1347–1351. II
865 MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. *BMJ* 1992; **304**: 405–412. II
866 Coope J, Warrender TS. Randomised trial of treatment of hypertension in elderly patients in primary care. *Br Med J (Clin Res Ed)* 1986; **293**: 1145–1151. II
867 Dahlöf B, Lindholm LH, Hansson L, Scherstén B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). *Lancet* 1991; **338**: 1281–1285. II
868 Kuzuya M, Endo H, Umegaki H, Nakao M, Niwa T, Kumagai T, Ushida Y, Nabeshima T, Shimokata H, Iguchi A. Factors influencing Noncompliance with Medication Regimens in the Elderly. *Nippon Ronen Igakkai Zasshi* 2000; **37**: 363–370. Japanese. E-II
869 Gorelick PB, Scuteri A, Black SE, Decarli C, Greenberg SM, Iadecola C, Launer LJ, Laurent S, Lopez OL, Nyenhuis D, Petersen RC, Schneider JA, Tzourio C, Arnett DK, Bennett DA, Chui HC, Higashida RT, Lindquist R, Nilsson PM, Roman GC, Sellke FW, Seshadri S, American Heart Association Stroke Council, Council on Epidemiology and Prevention, Council on Cardiovascular Nursing, Council on Cardiovascular Radiology and Intervention, and Council on Cardiovascular Surgery and Anesthesia. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association. *Stroke* 2011; **42**: 2672–2713. VI

870 Cooperative Committee for Preparing the 'Guidelines for the Treatment of Dementia'. *Guidelines for the Treatment of Dementia in 2010* (in Japanese). Igaku-Shoin Ltd: Tokyo, 2010. GL
871 Reitz C, Brayne C, Mayeux R. Epidemiology of Alzheimer disease. *Nat Rev Neurol* 2011; **7**: 137–152. VI
872 Novak V, Hajjar I. The relationship between blood pressure and cognitive function. *Nat Rev Cardiol* 2010; **7**: 686–698. E-Ia
873 Glynn RJ, Beckett LA, Hebert LE, Morris MC, Scherr PA, Evans DA. Current and remote blood pressure and cognitive decline. *JAMA* 1999; **281**: 438–445. E-Ib
874 Matsubayashi K, Okumiya K, Wada T, Osaki Y, Fujisawa M, Doi Y, Ozawa T. Postural dysregulation in systolic blood pressure is associated with worsened scoring on neurobehavioral function tests and leukoaraiosis in the older elderly living in a community. *Stroke* 1997; **28**: 2169–2173. E-II
875 Ohya Y, Ohtsubo T, Tsuchihashi T, Eto K, Sadanaga T, Nagao T, Abe I, Fujishima M. Altered diurnal variation of blood pressure in elderly subjects with decreased activity of daily living and impaired cognitive function. *Hypertens Res* 2001; **24**: 655–661. E-II
876 Forette F, Seux ML, Staessen JA, Thijs L, Babarskiene MR, Babeanu S, Bossini A, Fagard R, Gil-Extremera B, Laks T, Kobalava Z, Sarti C, Tuomilehto J, Vanhanen H, Webster J, Yodfat Y, Birkenhäger WH, Systolic Hypertension in Europe Investigators. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. *Arch Intern Med* 2002; **162**: 2046–2052. III
877 Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, Trenkwalder P, Zanchetti A, SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. *J Hypertens* 2003; **21**: 875–886. II
878 Diener HC, Sacco RL, Yusuf S, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, Bornstein N, Chan BP, Chen ST, Cunha L, Dahlöf B, De Keyser J, Donnan GA, Estol C, Gorelick P, Gu V, Hermansson K, Hilbrich L, Kaste M, Lu C, Machnig T, Pais P, Roberts R, Skvortsova V, Teal P, Toni D, VanderMaelen C, Voigt T, Weber M, Yoon BW, Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) study group. Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study. *Lancet Neurol* 2008; **7**: 875–884. III
879 Anderson C, Teo K, Gao P, Arima H, Dans A, Unger T, Commerford P, Dyal L, Schumacher H, Pogue J, Paolasso E, Holwerda N, Chazova I, Binbrek A, Young J, Yusuf S, ONTARGET and TRANSCEND Investigators. Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies. *Lancet Neurol* 2011; **10**: 43–53. III
880 Li NC, Lee A, Whitmer RA, Kivipelto M, Lawler E, Kazis LE, Wolozin B. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. *BMJ* 2010; **340**: b5465. IVa
881 Ohrui T, Matsui T, Yamaya M, Arai H, Ebihara S, Maruyama M, Sasaki H. Angiotensin-converting enzyme inhibitors and incidence of Alzheimer's disease in Japan. *J Am Geriatr Soc* 2004; **52**: 649–650. VI
882 Sink KM, Leng X, Williamson J, Kritchevsky SB, Yaffe K, Kuller L, Yasar S, Atkinson H, Robbins M, Psaty B, Goff DC Jr. Angiotensin-converting enzyme inhibitors and cognitive decline in older adults with hypertension: results from the Cardiovascular Health Study. *Arch Intern Med* 2009; **169**: 1195–1202. IVa
883 Sörös P, Whitehead S, Spence JD, Hachinski V. Antihypertensive treatment can prevent stroke and cognitive decline. *Nat Rev Neurol* 2013; **9**: 174–178. VI
884 Li J, Wang YJ, Zhang M, Xu ZQ, Gao CY, Fang CQ, Yan JC, Zhou HD, Chongqing Ageing Study Group. Vascular risk factors promote conversion from mild cognitive impairment to Alzheimer disease. *Neurology* 2011; **76**: 1485–1491. IVa
885 Kume K, Hanyu H, Sakurai H, Takada Y, Onuma T, Iwamoto T. Effects of telmisartan on cognition and regional cerebral blood flow in hypertensive patients with Alzheimer's disease. *Geriatr Gerontol Int* 2012; **12**: 207–214. II
886 Furiya Y, Ryo M, Kawahara M, Kiriyama T, Morikawa M, Ueno S. Renin-angiotensin system blockers affect cognitive decline and serum adipocytokines in Alzheimer's disease. *Alzheimers Dement* 2013; **9**: 512–518. IVb
887 Ohrui T, Tomita N, Sato-Nakagawa T, Matsui T, Maruyama M, Niwa K, Arai H, Sasaki H. Effects of brain-penetrating ACE inhibitors on Alzheimer disease progression. *Neurology* 2004; **63**: 1324–1325. II
888 Chapman AB, Abraham WT, Zamudio S, Coffin C, Merouani A, Young D, Johnson A, Osorio F, Goldberg C, Moore LG, Dahms T, Schrier RW. Temporal relationships between hormonal and hemodynamic changes in early human pregnancy. *Kidney Int* 1998; **54**: 2056-63. E-III
889 Karumanchi SA, Lindheimer MD. Preeclampsia pathogenesis: 'triple a rating'-autoantibodies and antiangiogenic factors. *Hypertension* 2008; **51**: 991–992. VI
890 Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, Epstein FH, Romero R, Thadhani R, Karumanchi SA, CPEP Study Group. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. *New Engl J Med* 2006; **355**: 992–1005. IVb
891 Barton JR, Sibai BM. Prediction and prevention of recurrent preeclampsia. *Obstet Gynecol* 2008; **112**: 359–372. VI
892 Metoki H, Ohkubo T, Obara T, Akutsu K, Yamamoto M, Ishikuro M, Sakurai K, Iwama N, Katagiri M, Sugawara J, Hirose T, Sato M, Kikuya M, Yagihashi K, Matsubara Y, Yaegashi N, Mori S, Suzuki M, Imai Y, BOSHI Study Group. Daily serial hemodynamic data during pregnancy and seasonal variation: the BOSHI study. *Clin Exp Hypertens* 2012; **34**: 290–296. VI
893 Pickering TG. Reflections in hypertension. How should blood pressure be measured during pregnancy? *J Clin Hypertens (Greenwich)* 2005; **7**: 46–49. VI
894 Verdecchia P, Schillaci G. Prognostic value of ambulatory blood pressure monitoring. In: White WB, Kaplan NM (eds) *Blood Pressure Monitoring in Cardiovascular Medicine and Therapeutics*, Humana Press: Totowa, New Jersey, pp 191–218, 2001. VI
895 Hermida RC, Ayala DE. Prognostic value of office and ambulatory blood pressure measurements in pregnancy. *Hypertension* 2002; **40**: 298–303. V
896 White WB, Weber MA, Davidai G, Neutel JM, Bakris GL, Giles T. Ambulatory blood pressure monitoring in the primary care setting: assessment of therapy on the circadian variation of blood pressure from the MICCAT-2 Trial. *Blood Press Monit* 2005; **10**: 157–163. III
897 Hermida RC, Ayala DE, Mojón A, Fernández JR. Ambulatory blood pressure control with bedtime aspirin administration in subjects with prehypertension. *Am J Hypertens* 2009; **22**: 896–903. II
898 Visser W, Wallenburg HC. Central hemodynamic observations in untreated preeclamptic patients. *Hypertension* 1991; **17**: 1072–1077. V
899 Abalos E, Duley L, Steyn DW, Henderson-Smart DJ. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. *Cochrane Database Syst Rev* 2007; CD002252. I
900 Ono Y, Takagi K, Seki H, Takai Y, Samejima K, Matsunaga S, Matsumura H. Neonatal outcome in infants of chronically hypertensive mothers. *J Obstet Gynaecol Res* 2013; **39**: 1142–1146. IVa
901 Jones DC, Hayslett JP. Outcome of pregnancy in women with moderate or severe renal insufficiency. *New Engl J Med* 1996; **335**: 226–232. IVa
902 Churchill D, Duley L. Interventionist versus expectant care for severe pre-eclampsia before term. *Cochrane Database Syst Rev* 2002; CD003106. IVa
903 Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, Sever PS, McG Thom S, British Hypertension Society. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHSIV. *J Hum Hypertens* 2004; **18**: 139–185. GL
904 Sibai BM. Chronic hypertension in pregnancy. *Obstet Gynecol* 2002; **100**: 369–377. VI
905 Podymow T, August P. Hypertension in pregnancy. *Adv Chronic Kidney Dis* 2007; **14**: 178–190. VI
906 Raheem IA, Saaid R, Omar SZ, Tan PC. Oral nifedipine versus intravenous labetalol for acute blood pressure control in hypertensive emergencies of pregnancy: a randomised trial. *BJOG* 2012; **119**: 78–85. II
907 Khan K, Zamora J, Lamont RF, Van Geijn Hp H, Svare J, Santos-Jorge C, Jacquemyn Y, Husslein P, Helmer HH, Dudenhausen J, Di Renzo GC, Roura LC, Beattie B. Safety concerns for the use of calcium channel blockers in pregnancy for the treatment of spontaneous preterm labour and hypertension: a systematic review and meta-regression analysis. *J Matern Fetal Neonatal Med* 2010; **23**: 1030–1038. I
908 Nij Bijvank SW, Duvekot JJ. Nicardipine for the treatment of severe hypertension in pregnancy: a review of the literature. *Obstet Gynecol Surv* 2010; **65**: 341–347. I
909 Manzur-Verástegui S, Mandeville PB, Gordillo-Moscoso A, Hernández-Sierra JF, Rodríguez-Martínez M. Efficacy of nitroglycerine infusion versus sublingual nifedipine in severe pre-eclampsia: a randomized, triple-blind, controlled trial. *Clin Exp Pharmacol Physiol* 2008; **35**: 580–585. II
910 Redman CW, Beilin LJ, Bonnar J. Treatment of hypertension in pregnancy with methyldopa: blood pressure control and side effects. *Br J Obstet Gynaeco*. 1977; **84**: 419–426. V
911 Cockburn J, Moar VA, Ounsted M, Redman CW. Final report of study on hypertension during pregnancy: the effects of specific treatment on the growth and development of the children. *Lancet* 1982; **1**: 647–649. IVa
912 Plouin PF, Breart G, Maillard F, Papiernik E, Relier JP. Comparison of antihypertensive efficacy and perinatal safety of labetalol and methyldopa in the treatment of hypertension in pregnancy: a randomized controlled trial. *Br J Obstet Gynaecol* 1988; **95**: 868–876. II
913 Magee LA, Cham C, Waterman EJ, Ohlsson A, von Dadelszen P. Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis. *BMJ* 2003; **327**: 955–960. I
914 Pickles CJ, Broughton Pipkin F, Symonds EM. A randomised placebo controlled trial of labetalol in the treatment of mild to moderate pregnancy induced hypertension. *Br J Obstet Gynaecol* 1992; **99**: 964–968. II
915 Pickles CJ, Symonds EM, Broughton Pipkin F. The fetal outcome in a randomized double-blind controlled trial of labetalol versus placebo in pregnancy-induced hypertension. *Br J Obstet Gynaecol* 1989; **96**: 38–43. II
916 Collins R, Yusuf S, Peto R. Overview of randomised trials of diuretics in pregnancy. *Br Med J (Clin Res Ed)* 1985; **290**: 17–23. VI
917 Freier DT, Thompson NW. Pheochromocytoma and pregnancy: the epitome of high risk. *Surgery* 1993; **114**: 1148–1152. V
918 Cooper WO, Hernandez-Diaz S, Arbogast PG, Dudley JA, Dyer S, Gideon PS, Hall K, Ray WA. Major congenital malformations after first-trimester exposure to ACE inhibitors. *New Engl J Med* 2006; **354**: 2443–2451. E-Ib
919 Khan NA, Hemmelgarn B, Padwal R, Larochelle P, Mahon JL, Lewanczuk RZ, McAlister FA, Rabkin SW, Hill MD, Feldman RD, Schiffrin EL, Campbell NR, Logan AG, Arnold M, Moe G, Campbell TS, Milot A, Stone JA, Jones C, Leiter LA, Ogilvie RI, Herman RJ, Hamet P, Fodor G, Carruthers G, Culleton B, Burns KD, Ruzicka M, deChamplain J, Pylypchuk G, Gledhill N, Petrella R, Boulanger JM, Trudeau L,

Hegele RA, Woo V, McFarlane P, Touyz RM, Tobe SW, Canadian Hypertension Education Program. The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2- therapy. *Can J Cardiol* 2007; **23**: 539–550. GL
920 Diav-Citrin O, Shechtman S, Halberstadt Y, Finkel-Pekarsky V, Wajnberg R, Arnon J, Di Gianantonio E, Clementi M, Ornoy A. Pregnancy outcome after in utero exposure to angiotensin converting enzyme inhibitors or angiotensin receptor blockers. *Reprod Toxicol* 2011; **31**: 540–545. E-Ib
921 Li DK, Yang C, Andrade S, Tavares V, Ferber JR. Maternal exposure to angiotensin converting enzyme inhibitors in the first trimester and risk of malformations in offspring: a retrospective cohort study. *BMJ* 2011; **343**: d5931. E-Ib
922 Duley L, Gülmezoglu AM, Henderson-Smart DJ. Magnesium sulphate and other anticonvulsants for women with pre-eclampsia. *Cochrane Database Syst Rev* 2003; CD000025. I
923 Speroff L, Barnhart KT, Gonzalez J. A signal for the future. In: Lobo RA (ed), *Treatment of Postmenoupausal Woman, Basic and Clinical Aspects*. Elsevier: Boston, MA, 2007.
924 Staessen J, Bulpitt CJ, Fagard R, Lijnen P, Amery A. The influence of menopause on blood pressure. *J Hum Hypertens* 1989; **3**: 427–433. E-II
925 Orshal JM, Khalil RA. Gender, sex hormones, and vascular tone. *Am J Physiol Regul Integr Comp Physiol* 2004; **286**: R233–R249. VI
926 Rossi R, Chiurlia E, Nuzzo A, Cioni E, Origliani G, Modena MG. Flow-mediated vasodilation and the risk of developing hypertension in healthy postmenopausal women. *J Am Coll Cardiol* 2004; **44**: 1636–1640. E-Ib
927 Taddei S, Virdis A, Ghiadoni L, Mattei P, Sudano I, Bernini G, Pinto S, Salvetti A. Menopause is associated with endothelial dysfunction in women. *Hypertension* 1996; **28**: 576–582. E-Ib
928 Zaydun G, Tomiyama H, Hashimoto H, Arai T, Koji Y, Yambe M, Motobe K, Hori S, Yamashina A. Menopause is an independent factor augmenting the age-related increase in arterial stiffness in the early postmenopausal phase. *Atherosclerosis* 2006; **184**: 137–142. E-II
929 Gragasin FS, Xu Y, Arenas IA, Kainth N, Davidge ST. Estrogen reduces angiotensin II-induced nitric oxide synthase and NAD(P)H oxidase expression in endothelial cells. *Arterioscler Thromb Vasc Biol* 2003; **23**: 38–44.
930 Herrick W, Tillman A. The mild toxemias of pregnancy: their relation ot cardiovascular and renal disease. *Am J Obstet Gynecol* 1936. **31**: 832–844. E-Ib
931 Sibai BM, Anderson GD. Pregnancy outcome of intensive therapy in severe hypertension in first trimester. *Obstet Gynecol* 1986; **67**: 517–522. E-III
932 Wikström AK, Haglund B, Olovsson M, Lindeberg SN. The risk of maternal ischaemic heart disease after gestational hypertensive disease. *BJOG* 2005; **112**: 1486–1491. E-II
933 Lino K, Ito M, Abe K, Tanaka K, Mizunuma H,Yamauchi Y, Misaki N, Higuchi T. Association between blood pressure on pregnancy and the onset of lifestyle-related diseases -Analysis of mother-and-baby notebooks. *Hypertens Pregnancy* 2012; **20**: 62–64. Japanese. E-Ib
934 Uchiyama M, Sakai K. Studies of blood pressures in school children in northern Japan. *Public Health* 1985; **99**: 18–22. IVb
935 Tochikubo O, Sasaki O, Umemura S, Kaneko Y. Management of hypertension in high school students by using new salt titrator tape. *Hypertension* 1986; **8**: 1164–1171. IVb
936 National Statistics Center. [Changes in the percentage of obese children with respect to age (1977 to 2012)] (in Japanese). http://www.e-stat.go.jp/SG1/estat/List.do?bid=000001014499&cycode=0. Accessed on 18 September 2013. E-III
937 Kikuchi T, Yamazaki H, Kameda K, Hiura M, Nishina M, Uchiyama M. The effects on the Blood Pressure Evaluation of School Children as Determined by the Frequency of Measurements. *J Child Health* 2002; **61**: 322–327. Japanese. IVb
938 National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. *Pediatrics* 2004; **114**: 555–576. GL
939 The Japanese Society of Hypertension Committee for Guidelines for the Management of Hypertension. Hypertension in children. In The Japanese Society of Hypertension (ed). *Guidelines for the Management of Hypertension in 2004* (in Japanese). The Japanese Society of Hypertension, Tokyo, 2004, pp 75–78. GL
940 Kikuchi T, Nagasaki K, Ogawa Y, Abe H, Hiura M, Tanaka Y, Sato H, Uchiyama M. Examination of reference blood pressure values with respect to gender and school age in Japanese children (Mitsuke Study) Tokyo. *Jpn J Pediatr Hypertens* 2011; **8**: 21–25. Japanese. IVb
941 Kikuchi T, Nagasaki K, Hiura M, Ogawa Y, Tanaka Y, Uchiyama M. Epidemiological approaches for childhood obesity. *J Jpn Soc Stu Obes* 2004; **10**: 12–17. Japanese. VI
942 Kotani K, Nishida M, Yamashita S, Funahashi T, Fujioka S, Tokunaga K, Ishikawa K, Tarui S, Matsuzawa Y. Two decades of annual medical examinations in Japanese obese children: do obese children grow into obese adults? *Int J Obes Relat Metab Disord* 1997; **21**: 912–921. IVa
943 Hashimoto N, Kawasaki T, Kikuchi T, Takahashi H, Uchiyama M. The relationship between the intrauterine environment and blood pressure in 3-year-old Japanese children. *Acta Paediatr* 1996; **85**: 132–138. IVa
944 Miura K, Nakagawa H, Tabata M, Morikawa Y, Nishijo M, Kagamimori S. Birth weight, childhood growth, and cardiovascular disease risk factors in Japanese aged 20 years. *Am J Epidemiol* 2001; **153**: 783–789. IVa
945 Abe Y, Kikuchi T, Nagasaki K, Hiura M, Tanaka Y, Ogawa Y, Uchiyama M. Lower birth weight associated with current overweight status is related with the metabolic syndrome in obese Japanese children. *Hypertens Res* 2007; **30**: 627–634. IVb
946 Lurbe E, Cifkova R, Cruickshank JK, Dillon MJ, Ferreira I, Invitti C, Kuznetsova T, Laurent S, Mancia G, Morales-Olivas F, Rascher W, Redon J, Schaefer F, Seeman T, Stergiou G, Wühl E, Zanchetti A, European Society of Hypertension. Management of high blood pressure in children and adolescents: recommendations of the European Society of Hypertension. *J Hypertens* 2009; **27**: 1719–1742. GL
947 Uchiyama M. Risk factors for the development of essential hypertension: long-term follow-up study in junior high school students in Niigata, Japan. *J Hum Hypertens* 1994; **8**: 323–325. V
948 Kawasaki T, Uezono K, Sanefuji M, Utsunomiya H, Fujino T, Kanaya S, Babazono A. A 17-year follow-up study of hypertensive and normotensive male university students in Japan. *Hypertens Res* 2003; **26**: 445–452. IVa
949 Bao W, Threefoot SA, Srinivasan SR, Berenson GS. Essential hypertension predicted by tracking of elevated blood pressure from childhood to adulthood: the Bogalusa Heart Study. *Am J Hypertens* 1995; **8**: 657–665. E-1b
950 Yang Q, Zhang Z, Kuklina EV, Fang J, Ayala C, Hong Y, Loustalot F, Dai S, Gunn JP, Tian N, Cogswell ME, Merritt R. Sodium intake and blood pressure among US children and adolescents. *Pediatrics* 2012; **130**: 611–619. IVb
951 Leary SD, Ness AR, Smith GD, Mattocks C, Deere K, Blair SN, Riddoch C. Physical activity and blood pressure in childhood: findings from a population-based study. *Hypertension* 2008; **51**: 92–98. E-II
952 Stergiou GS, Yiannes NG, Rarra VC, Panagiotakos DB. Home blood pressure normalcy in children and adolescents: the Arsakeion School study. *J Hypertens* 2007; **25**: 1375–1379. IVb
953 Holm JC, Gamborg M, Neland M, Ward L, Gammeltoft S, Heitmann BL, Sørensen TI, Ibsen KK. Longitudinal changes in blood pressure during weight loss and regain of weight in obese boys and girls. *J Hypertens* 2012; **30**: 368–374. IVa
954 Torrance B, McGuire KA, Lewanczuk R, McGavock J. Overweight, physical activity and high blood pressure in children: a review of the literature. *Vasc Health Risk Manag* 2007; **3**: 139–149. VI
955 Simonetti GD, Rizzi M, Donadini R, Bianchetti MG. Effects of antihypertensive drugs on blood pressure and proteinuria in childhood. *J Hypertens* 2007; **25**: 2370–2376. IVb
956 Wühl E, Trivelli A, Picca S, Litwin M, Peco-Antic A, Zurowska A, Testa S, Jankauskiene A, Emre S, Caldas-Afonso A, Anarat A, Niaudet P, Mir S, Bakkaloglu A, Enke B, Montini G, Wingen AM, Sallay P, Jeck N, Berg U, Caliskan S, Wygoda S, Hohbach-Hohenfellner K, Dusek J, Urasinski T, Arbeiter K, Neuhaus T, Gellermann J, Drozdz D, Fischbach M, Möller K, Wigger M, Peruzzi L, Mehls OSchaefer F, ESCAPE Trial Group. Strict blood-pressure control and progression of renal failure in children. *New Engl J Med* 2009; **361**: 1639–1650. II
957 Matteucci MC, Chinali M, Rinelli G, Wühl E, Zurowska A, Charbit M, Pongiglione G, Schaefer F, ESCAPE Trial Group. Change in cardiac geometry and function in CKD children during strict BP control: a randomized study. *Clin J Am Soc Nephrol* 2013; **8**: 203–210. III
958 Kaplan NM. Hypertensive crises. *Clinical Hypertension* (9th edn). Lippincott Williams & Wilkins: Baltimore, pp 311–324, 2006. VI
959 Rosei EA, Salvetti M, Farsang C. European Society of Hypertension Scientific Newsletter: treatment of hypertensive urgencies and emergencies. *J Hypertens* 2006; **24**: 2482–2485. VI
960 Deshmukh A, Kumar G, Kumar N, Nanchal R, Gobal F, Sakhuja A, Mehta JL. Effect of Joint National CommitteeVII report on hospitalizations for hypertensive emergencies in the United States. *Am J Cardiol* 2011; **108**: 1277–1282. E-II
961 Japan Society of Obstetrics and Gynecology (ed). Obstetric and Gynecological Treatment Guidelines-Obstetrics in 2014 (in Japanese). 2014. GL
962 Vaughan CJ, Delanty N. Hypertensive emergencies. *Lancet* 2000; **356**: 411–417. VI
963 Narotam PK, Puri V, Roberts JM, Taylon C, Vora Y, Nathoo N. Management of hypertensive emergencies in acute brain disease: evaluation of the treatment effects of intravenous nicardipine on cerebral oxygenation. *J Neurosurg* 2008; **109**: 1065–1074. E-II
964 Japanese Circulation Society. *JCS joint working group for guidelines for diagnosis and treatment of cardiovascular diseases (2010 JCS Joint Working Group Report): Guidelines for Treatment of Acute Heart Failure (JCS 2011)* (in Japanese). Japanese Circulation Society. 2011. GL
965 Nomura F, Kurobe N, Mori Y, Hikita A, Kawai M, Suwa M, Okutani Y. Multicenter prospective investigation on efficacy and safety of carperitide as a first-line drug for acute heart failure syndrome with preserved blood pressure: COMPASS: Carperitide Effects Observed Through Monitoring Dyspnea in Acute Decompensated Heart Failure Study. *Circ J* 2008; **72**: 1777–1786. E-III
966 Japanese Circulation Society. *JCS joint working group for guidelines for diagnosis and treatment of cardiovascular diseases (2006 JCS Joint Working Group Report): Guidelines for Management of Acute Coronary Syndrome without Persistent ST Segment Elevation (JCS 2007)* (in Japanese). Japanese Circulation Society. 2007. GL
967 Prejbisz A, Lenders JW, Eisenhofer G, Januszewicz A. Cardiovascular manifestations of phaeochromocytoma. *J Hypertens* 2011; **29**: 2049–2060. VI
968 Sesoko S, Akema N, Matsukawa T, Kaneko Y. Predisposing factors for the development of malignant essential hypertension. *Arch Intern Med* 1987; **147**: 1721–1724. E-II
969 Ohta Y, Tsuchihashi T, Ohya Y, Fujii K, Hirakata H, Abe I, Fujishima M. Trends in the pathophysiological characteristics of malignant hypertension. *Hypertens Res* 2001; **24**: 489–492. E-III
970 Kawazoe N, Eto T, Abe I, Takishita S, Ueno M, Kobayashi K, Uezono K, Muratani H, Kimura Y, Tsuchihashi T, Onoyama K, Kawasaki T, Fukiyama K, Fujishima M. Long-term prognosis of malignant hypertension; difference between underlying diseases

such as essential hypertension and chronic glomerulonephritis. *Clin Nephrol* 1988; **29**: 53–57. E-Ib
971 Lane DA, Lip GY, Beevers DG. Improving survival of malignant hypertension patients over 40 years. *Am J Hypertens* 2009; **22**: 1199–1204. V
972 Mann SJ. Severe paroxysmal hypertension (pseudopheochromocytoma). *Curr Hypertens Rep* 2008; **10**: 12–18. VI
973 Chen YH, Tsai SY, Lee HC, Lin HC. Increased risk of acute myocardial infarction for patients with panic disorder: a nationwide population-based study. *Psychosom Med* 2009; **71**: 798–804. IVa
974 Chen YH, Hu CJ, Lee HC, Lin HC. An increased risk of stroke among panic disorder patients: a 3-year follow-up study. *Can J Psychiatry* 2010; **55**: 43–49. IVa
975 Pickering TG, Clemow L. Paroxysmal hypertension: the role of stress and psychological factors. *J Clin Hypertens (Greenwich)* 2008; **10**: 575–581. VI
976 Fleisher LA, Beckman JA, Brown KA, Calkins H, Chaikof E, Fleischmann KE, Freeman WK, Froehlich JB, Kasper EK, Kersten JR, Riegel B, Robb JF, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Buller CE, Creager MA, Ettinger SM, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Hunt SA, Lytle BW, Nishimura R, Ornato JP, Page RL, Tarkington LG, Yancy CW, American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery); American Society of Echocardiography; American Society of Nuclear Cardiology; Heart Rhythm Society; Society of Cardiovascular Anesthesiologists; Society for Cardiovascular Angiography and Interventions; Society for Vascular Medicine and Biology; Society for Vascular Surgery. ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery): developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. *Circulation* 2007; **116**: e418–e499. GL
977 Bangalore S, Wetterslev J, Pranesh S, Sawhney S, Gluud C, Messerli FH. Perioperative β blockers in patients having non-cardiac surgery: a meta-analysis. *Lancet* 2008; **372**: 1962–1976. I
978 Ishikawa S, Griesdale DE, Lohser J. Acute kidney injury after lung resection surgery: incidence and perioperative risk factors. *Anesth Analg* 2012; **114**: 1256–1262. IVb
979 Herman WW, Konzelman JL Jr, Prisant LM, Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. New national guidelines on hypertension: a summary for dentistry. *J Am Dent Assoc* 2004; **135**: 576–584. GL
980 Tsuchihashi T, Takata Y, Kurokawa H, Miura K, Maruoka Y, Kajiyama M, Fujishima M. Blood pressure response during dental surgery. *Hypertens Res* 1996; **19**: 189–194. V
981 Whaley-Connell AT, Sowers JR, Stevens LA, McFarlane SI, Shlipak MG, Norris KC, Chen SC, Qiu Y, Wang C, Li S, Vassalotti JA, Collins AJ, Kidney Early Evaluation Program Investigators. CKD in the United States: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999–2004. *Am J Kidney Dis* 2008; **51**: S13–S20. IVb
982 Sinclair AM, Isles CG, Brown I, Cameron H, Murray GD, Robertson JW. Secondary hypertension in a blood pressure clinic. *Arch Intern Med* 1987; **147**: 1289–1293. IVb
983 Anderson GH Jr, Blakeman N, Streeten DH. The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients. *J Hypertens* 1994; **12**: 609–615. IVb
984 Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, Ganzaroli C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Mattarello MJ, Moretti A, Palumbo G, Parenti G, Porteri E, Semplicini A, Rizzoni D, Rossi E, Boscaro M, Pessina AC, Mantero F, PAPY Study Investigators. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. *J Am Coll Cardiol* 2006; **48**: 2293–2300. IVb
985 Omura M, Saito J, Yamaguchi K, Kakuta Y, Nishikawa T. Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan. *Hypertens Res* 2004; **27**: 193–202. IVb
986 Gifford RW. Evaluation of the hypertensive patients with emphasis on detecting curable causes. *Milbank Mem Fund Q* 1969; **47**: 170–186. V
987 Bech K, Hilden T. The frequency of secondary hypertension. *Acta Med Scand* 1975; **197**: 65–69. IVb
988 Ferguson RK. Cost and yield of the hypertensive evaluation. Experience of a community-based referral clinic. *Ann Intern Med* 1975; **82**: 761–765. V
989 Berglund G, Andersson O, Wilhelmsen L. Prevalence of primary and secondary hypertension: studies in a random population sample. *Br Med J* 1976; **2**: 554–556. E-II
990 Danielson M, Dammström B. The prevalence of secondary and curable hypertension. *Acta Med Scand* 1981; **209**: 451–455. E-II
991 Omae T. Pathogenesis and prognosis of hypertension. *J Jpn Soc Intern Med* 1985; **74**: 401–405. Japanese. VI
992 Japan Dialysis Medical Science Association Statistics Investigation Committee. An overview of regular dialysis treatment in Japan. *J Jpn Soc Dial Ther* 2013; **46**: 1–76. Japanese. E-II
993 Kimura G, Brenner BM. The renal basis for salt sensitivity in hypertension. In: Laragh JH, Brenner BM (eds), *Hypertension: Pathophysiology, Diagnosis and Management*, 2nd edn. pp 1569–1588, Raven Press: New York, 1995. VI
994 Kimura G. Glomerular function reserve and sodium sensitivity. *Clin Exp Nephrol* 2005; **9**: 102–113. VI
995 Kimura G. Clinical pathology and treatment of renin–angiotensin system 2. Chronic kidney disease and the renin–angiotensin system. *Intern Med* 2007; **46**: 1295–1298. VI
996 Usami T, Koyama K, Takeuchi O, Morozumi K, Kimura G. Regional variations in the incidence of end-stage renal failure in Japan. *JAMA* 2000; **284**: 2622–2624. E-III
997 Usami T, Sato R, Yoshida A, Kimura G. Regional variation in end-stage renal disease. *Curr Opin Nephrol Hypertens* 2002; **11**: 343–346. VI
998 Usami T, Nakao N, Fukuda M, Takeuchi O, Kamiya Y, Yoshida A, Kimura G. Maps of end-stage renal disease and amounts of angiotensin-converting enzyme inhibitors prescribed in Japan. *Kidney Int* 2003; **64**: 1445–1449. E-II
999 Usami T, Kimura G. Proposal for mapping renal failure in Japan and its application for strategy to arrest endstage renal disease. *Clin Exp Nephrol* 2006; **10**: 8–12. VI
1000 Wakamatsu-Yamanaka T, Fukuda M, Sato R, Naito T, Togawa H, Tomonari T, Kato Y, Miura T, Mizuno M, Ichikawa T, Miyagi S, Shirasawa Y, Ito A, Yoshida A, Kimura G. Geographic differences in the increasing ESRD rate have disappeared in Japan. *Clin Exp Nephrol* 2011; **15**: 708–713. E-III
1001 Blythe WB. Natural history of hypertension in renal parenchymal disease. *Am J Kidney Dis* 1985; **5**: A50–A56. VI
1002 Konishi Y, Imanishi M, Okamura M, Yoshioka K, Okumura M, Okada N, Tanaka S, Fujii S, Kimura G. Relationship of renal histological damage to glomerular hypertension in patients with immunoglobulin A nephropathy. *J Hypertens* 2000; **18**: 103–109. E-II
1003 Preston RA, Singer I, Epstein M. Renal Parenchymal Hypertension: current concepts of pathogenesis and management. *Arch Intern Med* 1996; **156**: 602–611. VI
1004 Progressive Kidney Damage Study Group (Chairman: Tomino Y, Director of the Multiple Cystic Kidney Working Group: Higashihara E), Research Business for Specific Disease Control, Ministry of Health, Labour and Welfare. Guidelines for the Treatment of Autosomal Dominant Multiple Cystic Kidney (2nd version)]. In: Higashihara E (ed), *Multiple cystic kidney*. Intermedica: Tokyo, 2006. pp 294–313. Japanese. GL
1005 Mizoguchi M, Tamura T, Yamaki A, Higashihara E, Shimizu Y. Genotypes of autosomal dominant polycystic kidney disease in Japanese. *J Hum Genet* 2002; **47**: 51–54. E-II
1006 Higashihara E, Nutahara K, Kojima M, Tamakoshi A, Yoshiyuki O, Sakai H, Kurokawa K. Prevalence and renal prognosis of diagnosed autosomal dominant polycystic kidney disease in Japan. *Nephron* 1998; **80**: 421–427. E-II
1007 Higashihara E, Aso Y, Shimazaki J, Ito H, Koiso K, Sakai O. Clinical aspects of polycystic kidney disease. *J Urol* 1992; **147**: 329–332. E-II
1008 Kelleher CL, McFann KK, Johnson AM, Schrier RW. Characteristics of hypertension in young adults with autosomal dominant polycystic kidney disease compared with the general U. S. population. *Am J Hypertens* 2004; **17**: 1029–1034. E-II
1009 Chapman AB, Johnson A, Gabow PA, Schrier RW. The renin–angiotensin-aldosterone system and autosomal dominant polycystic kidney disease. *New Engl J Med* 1990; **323**: 1091–1096. E-II
1010 Gansevoort RT, van der Heij B, Stegeman CA, de Charro FT, Nieuwenhuizen MG, de Zeeuw D, de Jong PE. Trends in the incidence of treated end-stage renal failure in The Netherlands: hope for the future? *Kidney Int Suppl* 2004; S7–S10.
1011 Sørensen VR, Hansen PM, Heaf J, Feldt-Rasmussen B. Stabilized incidence of diabetic patients referred for renal replacement therapy in Denmark. *Kidney Int* 2006; **70**: 187–191. E-II
1012 Safian RD, Textor SC. Renal-artery stenosis. *New Engl J Med* 2001; **344**: 431–442. VI
1013 de Mast Q, Beutler JJ. The prevalence of atherosclerotic renal artery stenosis in risk groups: a systematic literature review. *J Hypertens* 2009; **27**: 1333–1340. I
1014 Nakamura S, Iihara K, Matayoshi T, Yasuda H, Yoshihara F, Kamide K, Horio T, Miyamoto S, Kawano Y. The incidence and risk factors of renal artery stenosis in patients with severe carotid artery stenosis. *Hypertens Res* 2007; **30**: 839–844. IVb
1015 Preston RA, Epstein M. Ischemic renal disease: an emerging cause of chronic renal failure and end-stage renal disease. *J Hypertens* 1997; **15**: 1365–1377. VI
1016 Olin JW, Piedmonte MR, Young JR, DeAnna S, Grubb M, Childs MB. The utility of duplex ultrasound scanning of the renal arteries for diagnosing significant renal artery stenosis. *Ann Intern Med* 1995; **122**: 833–838. IVb
1017 Williams GJ, Macaskill P, Chan SF, Karplus TE, Yung W, Hodson EM, Craig JC. Comparative accuracy of renal duplex sonographic parameters in the diagnosis of renal artery stenosis: paired and unpaired analysis. *AJR Am J Roentgenol* 2007; **188**: 798–811. IVa
1018 Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, Hiratzka LF, Murphy WR, Olin JW, Puschett JB, Rosenfield KA, Sacks D, Stanley JC, Taylor LM Jr, White CJ, White J, White RA, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Hunt SA, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B, American Association for Vascular Surgery; Society for Vascular Surgery; Society for Cardiovascular Angiography and Interventions; Society for Vascular Medicine and Biology; Society of Interventional Radiology; ACC/AHA Task Force on Practice Guidelines Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease, American Association of Cardiovascular and Pulmonary Rehabilitation, National Heart, Lung, and Blood Institute, Society for Vascular Nursing, TransAtlantic Inter-Society Consensus, Vascular Disease Foundation. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for

Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. *Circulation* 2006; **113**: e463–e654. GL

1019 Postma CT, van Aalen J, de Boo T, Rosenbusch G, Thien T. Doppler ultrasound scanning in the detection of renal artery stenosis in hypertensive patients. *Br J Radiol* 1992; **65**: 857–860. IVb

1020 Vasbinder GB, Nelemans PJ, Kessels AG, Kroon AA, de Leeuw PW, van Engelshoven JM. Diagnostic tests for renal artery stenosis in patients suspected of having renovascular hypertension: a meta-analysis. *Ann Intern Med* 2001; **135**: 401–411. IVa

1021 Joint committee for NSF and use of gadolinium-based contrast agents (Japan Radiological Society/Japanese Society of Nephrology). Guidelines for Administering Gadolinium-Based Contrast Agents to Patients with Renal Dysfunction: Second edition (in Japanese). Tokyo Igakusha: Tokyo. 2009. GL

1022 Khoo MM, Deeab D, Gedroyc WM, Duncan N, Taube D, Dick EA. Renal artery stenosis: comparative assessment by unenhanced renal artery MRA versus contrast-enhanced MRA. *Eur Radiol* 2011; **21**: 1470–1476. IVb

1023 Japanese Society of Nephrology/Japan Radiological Society/The Japanese Circulation Society. *Guidelines for Iodinated Contrast in Patient with CKD 2012*. Tokyo Igakusha: Tokyo, 2012. Japanese. GL

1024 Wilcox CS. Use of angiotensin-converting-enzyme inhibitors for diagnosing renovascular hypertension. *Kidney Int* 1993; **44**: 1379–1390. IVb

1025 Rossi GP, Pavan E, Chiesura-Corona M, Bader M, Paganini G, Cesari M, De Toni R, Feltrin GP, Ganten D, Pessina AC. Renovascular hypertension with low-to-normal plasma renin: clinical and angiographic features. *Clin Sci (Lond)* 1997; **93**: 435–443. E-II

1026 Hackam DG, Spence JD, Garg AX, Textor SC. Role of renin–angiotensin system blockade in atherosclerotic renal artery stenosis and renovascular hypertension. *Hypertension* 2007; **50**: 998–1003. VI

1027 Losito A, Errico R, Santirosi P, Lupattelli T, Scalera GB, Lupattelli L. Long-term follow-up of atherosclerotic renovascular disease. Beneficial effect of ACE inhibition. *Nephrol Dial Transplant* 2005; **20**: 1604–1609. IVa

1028 Hackam DG, Duong-Hua ML, Mamdani M, Li P, Tobe SW, Spence JD, Garg AX. Angiotensin inhibition in renovascular disease: a population-based cohort study. *Am Heart J* 2008; **156**: 549–555. IVa

1029 van de Ven PJ, Beutler JJ, Kaatee R, Beek FJ, Mali WP, Koomans HA. Angiotensin converting enzyme inhibitor-induced renal dysfunction in atherosclerotic renovascular disease. *Kidney Int* 1998; **53**: 986–993. E-II

1030 Tegtmeyer CJ, Selby JB, Hartwell GD, Ayers C, Tegtmeyer V. Results and complications of angioplasty in fibromuscular disease. *Circulation* 1991; **83**: I155–I161. E-III

1031 Alhadad A, Mattiasson I, Ivancev K, Gottsäter A, Lindblad B. Revascularisation of renal artery stenosis caused by fibromuscular dysplasia: effects on blood pressure during 7-year follow-up are influenced by duration of hypertension and branch artery stenosis. *J Hum Hypertens* 2005; **19**: 761–767. E-III

1032 Bonelli FS, McKusick MA, Textor SC, Kos PB, Stanson AW, Johnson CM, Sheedy PF 2nd, Welch TJ, Schirger A. Renal artery angioplasty: technical results and clinical outcome in 320 patients. *Mayo Clin Proc* 1995; **70**: 1041–1052. III

1033 Zeller T, Frank U, Müller C, Bürgelin K, Sinn L, Bestehorn HP, Cook-Bruns N, Neumann FJ. Predictors of improved renal function after percutaneous stent-supported angioplasty of severe atherosclerotic ostial renal artery stenosis. *Circulation* 2003; **108**: 2244–2249. III

1034 Plouin PF, Chatellier G, Darné B, Raynaud A. Blood pressure outcome of angioplasty in atherosclerotic renal artery stenosis: a randomized trial. Essai Multicentrique Medicaments vs Angioplastie (EMMA) Study Group. *Hypertension* 1998; **31**: 823–829. II

1035 Webster J, Marshall F, Abdalla M, Dominiczak A, Edwards R, Isles CG, Loose H, Main J, Padfield P, Russell IT, Walker B, Watson M, Wilkinson R, Scottish and Newcastle Renal Artery Stenosis Collaborative Group. Randomised comparison of percutaneous angioplasty vs continued medical therapy for hypertensive patients with atheromatous renal artery stenosis. *J Hum Hypertens* 1998; **12**: 329–335. II

1036 van Jaarsveld BC, Krijnen P, Pieterman H, Derkx FH, Deinum J, Postma CT, Dees A, Woittiez AJ, Bartelink AK, Man in 't Veld AJ, Schalekamp MA, Dutch Renal Artery Stenosis Intervention Cooperative Study Group. The effect of balloon angioplasty on hypertension in atherosclerotic renal-artery stenosis. *New Engl J Med* 2000; **342**: 1007–1014. II

1037 Ives NJ, Wheatley K, Stowe RL, Krijnen P, Plouin PF, van Jaarsveld BC, Gray R. Continuing uncertainty about the value of percutaneous revascularization in atherosclerotic renovascular disease: a meta-analysis of randomized trials. *Nephrol Dial Transplant* 2003; **18**: 298–304. I

1038 Nordmann AJ, Woo K, Parkes R, Logan AG. Balloon angioplasty or medical therapy for hypertensive patients with atherosclerotic renal artery stenosis? A meta-analysis of randomized controlled trials. *Am J Med* 2003; **114**: 44–50. I

1039 Balk E, Raman G, Chung M, Ip S, Tatsioni A, Alonso A, Chew P, Gilbert SJ, Lau J. Effectiveness of management strategies for renal artery stenosis: a systematic review. *Ann Intern Med* 2006; **145**: 901–912. I

1040 Bax L, Woittiez AJ, Kouwenberg HJ, Mali WP, Buskens E, Beek FJ, Braam B, Huysmans FT, Schultze Kool LJ, Rutten MJ, Doorenbos CJ, Aarts JC, Rabelink TJ, Plouin PF, Raynaud A, van Montfrans GA, Reekers JA, van den Meiracker AH, Pattynama PM, van de Ven PJ, Vroegindeweij D, Kroon AA, de Haan MW, Postma CT, Beutler JJ. Stent placement in patients with atherosclerotic renal artery stenosis and impaired renal function: a randomized trial. *Ann Intern Med* 2009; **150**: 840–848, W150–1. II

1041 Wheatley K, Ives N, Gray R, Kalra PA, Moss JG, Baigent C, Carr S, Chalmers N, Eadington D, Hamilton G, Lipkin G, Nicholson AScoble J, ASTRAL Investigators. Revascularization versus medical therapy for renal-artery stenosis. *New Engl J Med* 2009; **361**: 1953–1962. II

1042 Cooper CJ, Murphy TP, Cutlip DE, Jamerson K, Henrich W, Reid DM, Cohen DJ, Matsumoto AH, Steffes M, Jaff MR, Prince MR, Lewis EF, Tuttle KR, Shapiro JI, Rundback JH, Massaro JM, D'Agostino RB Sr, Dworkin LD, CORAL Investigators. Stenting and medical therapy for atherosclerotic renal-artery stenosis. *New Engl J Med* 2014; **370**: 13-22. II

1043 Galaria II, Surowiec SM, Rhodes JM, Illig KA, Shortell CK, Sternbach Y, Green RM, Davies MG. Percutaneous and open renal revascularizations have equivalent long-term functional outcomes. *Ann Vasc Surg* 2005; **19**: 218–228. IVa

1044 Cherr GS, Hansen KJ, Craven TE, Edwards MS, Ligush J Jr, Levy PJ, Freedman BI, Dean RH. Surgical management of atherosclerotic renovascular disease. *J Vasc Surg* 2002; **35**: 236–245. III

1045 Modrall JG, Rosero EB, Smith ST, Arko FR 3rd, Valentine RJ, Clagett GP, Timaran CH. Operative mortality for renal artery bypass in the United States: Results from the National Inpatient Sample. *J Vasc Surg* 2008; **48**: 317–322. IVb

1046 Volpe C, Wahrenberg H, Hamberger B, Thorén M. Screening for primary aldosteronism in a primary care unit. *J Renin Angiotensin Aldosterone Syst* 2013; **14**: 212–219. IVa

1047 Quinkler M, Born-Frontsberg E, Fourkiotis VG. Comorbidities in primary aldosteronism. *Horm Metab Res* 2010; **42**: 429–434. VI

1048 Viera AJ, Hinderliter AL. Evaluation and management of the patient with difficult-to-control or resistant hypertension. *Am Fam Physician* 2009; **79**: 863–869. VI

1049 Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, Young WF Jr, Montori VM, Endocrine Society. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. *J Clin Endocrinol Metab* 2008; **93**: 3266–3281. GL

1050 Nishikawa T, Omura M, Satoh F, Shibata H, Takahashi K, Tamura N, Tanabe A, Task Force Committee on Primary Aldosteronism, The Japan Endocrine Society. Guidelines for the diagnosis and treatment of primary aldosteronism–the Japan Endocrine Society 2009. *Endocr J* 2011; **58**: 711–721. GL

1051 Gordon RD. Primary aldosteronism. *J Endocrinol Invest* 1995; **18**: 495–511. VI

1052 Hannemann A, Bidlingmaier M, Friedrich N, Manolopoulou J, Spyroglou A, Völzke H, Beuschlein F, Seissler J, Rettig R, Felix SB, Biffar R, Döring A, Meisinger C, Peters A, Wichmann HE, Nauck M, Wallaschofski H, Reincke M. Screening for primary aldosteronism in hypertensive subjects: results from two German epidemiological studies. *Eur J Endocrinol* 2012; **167**: 7–15. IVb

1053 Douma S, Petidis K, Doumas M, Papaefthimiou P, Triantafyllou A, Kartali N, Papadopoulos N, Vogiatzis K, Zamboulis C. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. *Lancet* 2008; **371**: 1921–1926. IVa

1054 Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P. Hyperaldosteronism among black and white subjects with resistant hypertension. *Hypertension* 2002; **40**: 892–896. IVa

1055 Vierhapper H. Determination of the aldosterone/renin ratio in 269 patients with adrenal incidentaloma. *Exp Clin Endocrinol Diabetes* 2007; **115**: 518–521. IVa

1056 Di Murro A, Petramala L, Cotesta D, Zinnamosca L, Crescenzi E, Marinelli C, Saponara M, Letizia C. Renin-angiotensin-aldosterone system in patients with sleep apnoea: prevalence of primary aldosteronism. *J Renin Angiotensin Aldosterone Syst* 2010; **11**: 165–172. IVa

1057 Suzuki S, Ito S. Aldosterone and Na metabolism on the renin stimulation test. *Jpn J Nephrol* 1978; **20**: 1–10. Japanese. VI

1058 Hiramatsu K, Yamada T, Yukimura Y, Komiya I, Ichikawa K, Ishihara M, Nagata H, Izumiyama T. A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients. *Arch Intern Med* 1981; **141**: 1589–1593. IVb

1059 Stowasser M, Taylor PJ, Pimenta E, Ahmed AH, Gordon RD. Laboratory investigation of primary aldosteronism. *Clin Biochem Rev* 2010; **31**: 39–56. VI]

1060 Stowasser M. Update in primary aldosteronism. *J Clin Endocrinol Metab* 2009; **94**: 3623–330. VI

1061 Fischer E, Beuschlein F, Bidlingmaier M, Reincke M. Commentary on the Endocrine Society Practice Guidelines: Consequences of adjustment of antihypertensive medication in screening of primary aldosteronism. *Rev Endocr Metab Disord* 2011; **12**: 43–48. IVb

1062 Tanabe A, Naruse M, Takagi S, Tsuchiya K, Imaki T, Takano K. Variability in the renin/aldosterone profile under random and standardized sampling conditions in primary aldosteronism. *J Clin Endocrinol Metab* 2003; **88**: 2489–2494. V

1063 Arlt W. A detour guide to the Endocrine Society Clinical Practice Guideline on case detection, diagnosis and treatment of patients with primary aldosteronism. *Eur J Endocrinol* 2010; **162**: 435–438. VI

1064 Nanba K, Tamanaha T, Nakao K, Kawashima ST, Usui T, Tagami T, Okuno H, Shimatsu A, Suzuki T, Naruse M. Confirmatory testing in primary aldosteronism. *J Clin Endocrinol Metab* 2012; **97**: 1688–1694. IVb

1065 Nishikawa T, Omura M. Clinical characteristics of primary aldosteronism: its prevalence and comparative studies on various causes of primary aldosteronism in Yokohama Rosai Hospital. *Biomed Pharmacother* 2000; **54**(Suppl 1): 83s-85s. IVb

1066 Ishidoya S, Kaiho Y, Ito A, Morimoto R, Satoh F, Ito S, Ishibashi T, Nakamura Y, Sasano H, Arai Y. Single-center outcome of laparoscopic unilateral adrenalectomy for patients with primary aldosteronism: lateralizing disease using results of adrenal venous sampling. *Urology* 2011; **78**: 68–73. V
1067 Mulatero P, Bertello C, Sukor N, Gordon R, Rossato D, Daunt N, Leggett D, Mengozzi G, Veglio F, Stowasser M. Impact of different diagnostic criteria during adrenal vein sampling on reproducibility of subtype diagnosis in patients with primary aldosteronism. *Hypertension* 2010; **55**: 667–673. IVb
1068 Rossi GP, Barisa M, Allolio B, Auchus RJ, Amar L, Cohen D, Degenhart C, Deinum J, Fischer E, Gordon R, Kickuth R, Kline G, Lacroix A, Magill S, Miotto D, Naruse M, Nishikawa T, Omura M, Pimenta E, Plouin PF, Quinkler M, Reincke M, Rossi E, Rump LC, Satoh F, Schultze Kool L, Seccia TM, Stowasser M, Tanabe A, Trerotola S, Vonend O, Widimsky J Jr, Wu KD, Wu VC, Pessina AC. The Adrenal Vein Sampling International Study (AVIS) for identifying the major subtypes of primary aldosteronism. *J Clin Endocrinol Metab* 2012; **97**: 1606–1614. IVb
1069 Stewart PM, Allolio B. Adrenal vein sampling for Primary Aldosteronism: time for a reality check. *Clin Endocrinol (Oxf)* 2010; **72**: 146–148. VI
1070 Vonend O, Ockenfels N, Gao X, Allolio B, Lang K, Mai K, Quack I, Saleh A, Degenhart C, Seufert J, Seiler L, Beuschlein F, Quinkler M, Podrabsky P, Bidlingmaier M, Lorenz R, Reincke M, Rump LC, German Conn's Registry. Adrenal venous sampling: evaluation of the German Conn's registry. *Hypertension* 2011; **57**: 990–995. IVb
1071 Morimoto S, Takeda R, Murakami M. Does prolonged pretreatment with large doses of spironolactone hasten a recovery from juxtaglomerular-adrenal suppression in primary aldosteronism? *J Clin Endocrinol Metab* 1970; **31**: 659–664. IVb
1072 Parthasarathy HK, Ménard J, White WB, Young WF Jr, Williams GH, Williams B, Ruilope LM, McInnes GT, Connell JM, MacDonald TM. A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. *J Hypertens* 2011; **29**: 980–990. II
1073 Mancini T, Kola B, Mantero F, Boscaro M, Arnaldi G. High cardiovascular risk in patients with Cushing's syndrome according to 1999 WHO/ISH guidelines. *Clin Endocrinol(Oxf)* 2004; **61**: 768–777. E-III
1074 Miyachi Y. [Study report in 2001 by the 'Study Group on Abnormalities in Adrenal Hormone Production', Research Business for Specific Disease Control by a scientific grant/subsidy from the Ministry of Health and Welfare]. Japanese. IVb
1075 Nawada H, Demura H, Suda T, Takayanagi R. [Adrenal preclinical Cushing's syndrome] (in Japanese). Study report in 1995 by the Working Group for Investigating 'Abnormalities in Adrenal Hormone Production', Specific Disease/Endocrine Disease Study Group, Ministry of Health and Welfare, 1999, pp 223–226. VI
1076 Tsuiki M, Tanabe A, Takagi S, Naruse M, Takano K. Cardiovascular risks and their long-term clinical outcome in patients with subclinical Cushing's syndrome. *Endocr J* 2008; **55**: 737–745. E-II
1077 Study Group on the Promotion of Pheochromocytoma Diagnosis and Treatment, Research Business for Refractory Disease Control, Ministry of Health, Labour and Welfare. Clinical Guide to the Management of Pheochromocytoma 2012 (In Japanese). 2012. GL
1078 Gimenez-Roqueplo AP, Dahia PL, Robledo M. An update on the genetics of paraganglioma, pheochromocytoma, and associated hereditary syndromes. *Horm Metab Res* 2012; **44**: 328–333. VI
1079 Kobayashi Y, Hashimoto H. [Guidelines for the diagnosis and treatment of aortitis syndrome (Takayasu's arteritis)] (in Japanese). Scientific grant/subsidy from the Ministry of Health and Welfare: Research Business for Specific Disease Control, Investigational study regarding refractory angiitis, Study report in 1999 to 2001, 2002, pp 41–63. VI
1080 Ishikawa K. [Takayasu's disease hypertension] (in Japanese). Syndrome series with respect to regions, 12 cardiovascular syndromes (special version of the Nihon Rinsho), 1996, pp 118–121. VI
1081 Hashimoto H. Study report in 2001 by the 'Working Group for Refractory Angiitis', Specific Disease/Immunological Disease Study Group, Ministry of Health and Welfare (in Japanese), 2002, pp. 21–25. VI
1082 Ohigashi H, Haraguchi G, Konishi M, Tezuka D, Kamiishi T, Ishihara T, Isobe M. Improved prognosis of Takayasu arteritis over the past decade: comprehensive analysis of 106 patients. *Circ J* 2012; **76**: 1004–1011. IVb
1083 Kobayashi K. *Epidemiological Study of Aortitis Syndrome: On the Number of New Crisis Patient and Complications*. Study report in 1994 by the Specific Disease/Refractory Angiitis Study Group, Ministry of Health and Welfare, 1994, pp. 7–10. VI
1084 Ogino H, Matsuda H, Minatoya K, Sasaki H, Tanaka H, Matsumura Y, Ishibashi-Ueda H, Kobayashi J, Yagihara T, Kitamura S. Overview of late outcome of medical and surgical treatment for Takayasu arteritis. *Circulation* 2008; **118**: 2738–2747. VI
1085 Machida M, Sakuma M, Aoki H, Yasuda Y. *Long-term Results of Cardiac Macro-Vascular Lesions Accompanying Takayasu's Arteritis* (in Japanese). Study report in 1993 by the Specific Disease/Immunological Disease Study Group, Ministry of Health and Welfare, 1993, pp 192–195. VI
1086 Miyata T, Sato O, Koyama H, Shigematsu H, Tada Y. Long-term survival after surgical treatment of patients with Takayasu's arteritis. *Circulation* 2003; **108**: 1474–1480. V
1087 Disease Control Section, Health and Medical Bureau, Ministry of Health and Welfare. [Nodular periarteritis]. *Guidelines for the Diagnosis and Treatment of Refractory Diseases* (in Japanese), Roppo Publishing Company: Aichi, 1997, pp 107–115. GL
1088 Blaustein DA, Kumbar L, Srivastava M, Avram MM. Polyarteritis nodosa presenting as isolated malignant hypertension. *Am J Hypertens* 2004; **17**: 380–381. V
1089 Kurosawa M, Inaba Y, Kobayashi S, Ozaki S, Nagai M. [Analysis of personal sheet-based electronic data on a clinical survey in 2004 regarding refractory angiitis (nodular periarteritis)] (in Japanese). Scientific grant/subsidy from the Ministry of Health, Labour and Welfare: Study report in 2005 by the 'Clinical Research Working Group for Intermediate/Micro Angiitis', Study Group on Refractory Angiitis, 2006, pp 137–150. VI
1090 Bussone G, Bérezné A, Pestre V, Guillevin L, Mouthon L. The scleroderma kidney: progress in risk factors, therapy, and prevention. *Curr Rheumatol Rep* 2011; **13**: 37–43. VI
1091 Murakami T, Ueno M, Takeda A, Yakuwa S. Pressure wave reflection after successful balloon dilatation of aortic coarctation. *Circ J* 2007; **71**: 1821–1822. V
1092 Trojnarska O, Szczepaniak-Chicheł L, Mizia-Stec K, Gabriel M, Bartczak A, Grajek S, Gąsior Z, Kramer L, Tykarski A. Vascular remodeling in adults after coarctation repair: impact of descending aorta stenosis and age at surgery. *Clin Res Cardiol* 2011; **100**: 447–455. IVb
1093 Ross RD, Clapp SK, Gunther S, Paridon SM, Humes RA, Farooki ZQ, Pinsky WW. Augmented norepinephrine and renin output in response to maximal exercise in hypertensive coarctectomy patients. *Am Heart J* 1992; **123**: 1293–1299. IVb
1094 Toro-Salazar OH, Steinberger J, Thomas W, Rocchini AP, Carpenter B, Moller JH. Long-term follow-up of patients after coarctation of the aorta repair. *Am J Cardiol* 2002; **89**: 541–547. V
1095 Canniffe C, Ou P, Walsh K, Bonnet D, Celermajer D. Hypertension after repair of aortic coarctation- A systematic review. *Int J Cardiol* 2013; **167**: 2456–2461. IVa
1096 Lee MG, Kowalski R, Galati JC, Cheung MM, Jones B, Koleff J, d'Udekem Y. Twenty-four-hour ambulatory blood pressure monitoring detects a high prevalence of hypertension late after coarctation repair in patients with hypoplastic arches. *J Thorac Cardiovasc Surg* 2012; **144**: 1110–1116. V
1097 Luijendijk P, Bouma BJ, Vriend JW, Vliegen HW, Groenink M, Mulder BJ. Usefulness of exercise-induced hypertension as predictor of chronic hypertension in adults after operative therapy for aortic isthmic coarctation in childhood. *Am J Cardiol* 2011; **108**: 435–439. IVa
1098 Jannetta PJ, Segal R, Wolfson SK Jr. Neurogenic hypertension: etiology and surgical treatment. I. Observations in 53 patients. *Ann Surg* 1985; **201**: 391–398. IVb
1099 Makino Y, Kawano Y, Okuda N, Horio T, Iwashima Y, Yamada N, Takamiya M, Takishita S. Autonomic function in hypertensive patients with neurovascular compression of the ventrolateral medulla oblongata. *J Hypertens* 1999; **17**: 1257–1263. IVb
1100 Schobel HP, Frank H, Naraghi R, Geiger H, Titz E, Heusser K. Hypertension in patients with neurovascular compression is associated with increased central sympathetic outflow. *J Am Soc Nephrol* 2002; **13**: 35–41. IVb
1101 Smith PA, Meaney JF, Graham LN, Stoker JB, Mackintosh AF, Mary DA, Ball SG. Relationship of neurovascular compression to central sympathetic discharge and essential hypertension. *J Am Coll Cardiol* 2004; **43**: 1453–1458. IVb
1102 Aoki S, Ohtsuki T, Hosomi N, Sueda Y, Kono T, Yamawaki T, Matsumoto M. Blood pressure variability and prognosis in acute ischemic stroke with vascular compression on the rostral ventrolateral medulla (RVLM). *Hypertens Res* 2011; **34**: 617–622. IVa
1103 Sasaki S, Tanda S, Hatta T, Morimoto S, Takeda K, Kizu O, Tamaki S, Saito M, Tamura Y, Kondo A. Neurovascular decompression of the rostral ventrolateral medulla decreases blood pressure and sympathetic nerve activity in patients with refractory hypertension. *J Clin Hypertens (Greenwich)* 2011; **13**: 818–820. V
1104 Sakuma T, Morimoto S, Aota Y, Takahashi N, Toyoda N, Kosaki A, Maehara M, Tanigawa N, Ikeda K, Sawada S, Iwasaka T. Efficacy of clonidine in patients with essential hypertension with neurovascular contact of the rostral ventrolateral medulla. *Hypertens Res* 2010; **33**: 633–637. IVa
1105 Aota Y, Morimoto S, Sakuma T, Morita T, Jo F, Takahashi N, Maehara M, Ikeda K, Sawada S, Iwasaka T. Efficacy of an L- and N-type calcium channel blocker in hypertensive patients with neurovascular compression of the rostral ventrolateral medulla. *Hypertens Res* 2009; **32**: 700–705. IVa
1106 Brown MJ. The causes of essential hypertension. *Br J Clin Pharmacol* 1996; **42**: 21–27. VI
1107 Kupper N, Willemsen G, Riese H, Posthuma D, Boomsma DI, de Geus EJ. Heritability of daytime ambulatory blood pressure in an extended twin design. *Hypertension* 2005; **45**: 80–85. IVb
1108 International Consortium for Blood Pressure Genome-Wide Association Studies. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. *Nature* 2011; **478**: 103–109. IVb
1109 Kato N. Ethnic differences in genetic predisposition to hypertension. *Hypertens Res* 2012; **35**: 574–581. VI
1110 Tabara Y, Kohara K, Kita Y, Hirawa N, Katsuya T, Ohkubo T, Hiura Y, Tajima A, Morisaki T, Miyata T, Nakayama T, Takashima N, Nakura J, Kawamoto R, Takahashi N, Hata A, Soma M, Imai Y, Kokubo Y, Okamura T, Tomoike H, Iwai N, Ogihara T, Inoue I, Tokunaga K, Johnson T, Caulfield M, Munroe P, Umemura S, Ueshima H, Miki T, Global Blood Pressure Genetics Consortium. Common variants in the ATP2B1 gene are associated with susceptibility to hypertension: the Japanese Millennium Genome Project. *Hypertension* 2010; **56**: 973–980. IVb
1111 Kato N, Takeuchi F, Tabara Y, Kelly TN, Go MJ, Sim X, Tay WT, Chen CH, Zhang Y, Yamamoto K, Katsuya T, Yokota M, Kim YJ, Ong RT, Nabika T, Gu D, Chang LC, Kokubo Y, Huang W, Ohnaka K, Yamori Y, Nakashima E, Jaquish CE, Lee JY, Seielstad M, Isono M, Hixson JE, Chen YT, Miki T, Zhou X, Sugiyama T, Jeon JP, Liu JJ, Takayanagi R, Kim SS, Aung T, Sung YJ, Zhang X, Wong TY, Han BG, Kobayashi S, Ogihara T, Zhu D, Iwai N, Wu JY, Teo YY, Tai ES, Cho YS, He J. Meta-analysis of genome-wide association studies identifies common variants associated with blood pressure variation in east Asians. *Nat Genet* 2011; **43**: 531–538. IVb

1112 Katsuya T, Ishikawa K, Sugimoto K, Rakugi H, Ogihara T. Salt sensitivity of Japanese from the viewpoint of gene polymorphism. *Hypertens Res* 2003; **26**: 521–525. VI
1113 Hunt SC, Cook NR, Oberman A, Cutler JA, Hennekens CH, Allender PS, Walker WG, Whelton PK, Williams RR. Angiotensinogen genotype, sodium reduction, weight loss, and prevention of hypertension: trials of hypertension prevention, phase II. *Hypertension* 1998; **32**: 393–401. II
1114 Arnett DK, Baird AE, Barkley RA, Basson CT, Boerwinkle E, Ganesh SK, Herrington DM, Hong Y, Jaquish C, McDermott DA, O'Donnell CJ, American Heart Association Council on Epidemiology and Prevention; American Heart Association Stroke Council; Functional Genomics and Translational Biology Interdisciplinary Working Group. Relevance of genetics and genomics for prevention and treatment of cardiovascular disease: a scientific statement from the American Heart Association Council on Epidemiology and Prevention, the Stroke Council, and the Functional Genomics and Translational Biology Interdisciplinary Working Group. *Circulation* 2007; **115**: 2878–2901. VI
1115 Ji W, Foo JN, O'Roak BJ, Zhao H, Larson MG, Simon DB, Newton-Cheh C, State MW, Levy D, Lifton RP. Rare independent mutations in renal salt handling genes contribute to blood pressure variation. *Nat Genet* 2008; **40**: 592–599. IVb
1116 Lifton RP, Gharavi AG, Geller DS. Molecular mechanisms of human hypertension. *Cell* 2001; **104**: 545–556. VI
1117 Boyden LM, Choi M, Choate KA, Nelson-Williams CJ, Farhi A, Toka HR, Tikhonova IR, Bjornson R, Mane SM, Colussi G, Lebel M, Gordon RD, Semmekrot BA, Poujol A, Välimäki MJ, De Ferrari ME, Sanjad SA, Gutkin M, Karet FE, Tucci JR, Stockigt JR, Keppler-Noreuil KM, Porter CC, Anand SK, Whiteford ML, Davis ID, Dewar SB, Bettinelli A, Fadrowski JJ, Belsha CW, Hunley TE, Nelson RD, Trachtman H, Cole TR, Pinsk M, Bockenhauer D, Shenoy M, Vaidyanathan P, Foreman JW, Rasoulpour M, Thameem F, Al-Shahrouri HZ, Radhakrishnan J, Gharavi AG, Goilav B, Lifton RP. Mutations in kelch-like 3 and cullin 3 cause hypertension and electrolyte abnormalities. *Nature* 2012; **482**: 98–102. IVb
1118 Choi M, Scholl UI, Yue P, Björklund P, Zhao B, Nelson-Williams C, Ji W, Cho Y, Patel A, Men CJ, Lolis E, Wisgerhof MV, Geller DS, Mane S, Hellman P, Westin G, Åkerström G, Wang W, Carling T, Lifton RP. K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. *Science* 2011; **331**: 768–772. IVb
1119 Ministry of Health, Labor, and Welfare. Ethical Guidelines for Human Genome/Gene Analysis Research. Revised on February 8, 2013. http://www.mhlw.go.jp/seisakunitsuite/bunya/hokabunya/kenkyujigyou/i-kenkyu/index.html. Japanese. VI
1120 Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA, American Heart Association. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. *Circulation* 2007; **115**: 1634–1642. GL
1121 Layton D, Souverein PC, Heerdink ER, Shakir SA, Egberts AC. Evaluation of risk profiles for gastrointestinal and cardiovascular adverse effects in nonselective NSAID and COX-2 inhibitor users: a cohort study using pharmacy dispensing data in The Netherlands. *Drug Saf* 2008; **31**: 143–158. E-II
1122 Strand V. Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin? *Lancet* 2007; **370**: 2138–2151. VI
1123 Arellano FM, Yood MU, Wentworth CE, Oliveria SA, Rivero E, Verma A, Rothman KJ. Use of cyclo-oxygenase 2 inhibitors (COX-2) and prescription non-steroidal anti-inflammatory drugs (NSAIDS) in UK and USA populations. Implications for COX-2 cardiovascular profile. *Pharmacoepidemiol Drug Saf* 2006; **15**: 861–872. E-II
1124 Fogari R, Zoppi A, Carretta R, Veglio F, Salvetti A, Italian Collaborative Study Group. Effect of indomethacin on the antihypertensive efficacy of valsartan and lisinopril: a multicentre study. *J Hypertens* 2002; **20**: 1007–1014. II
1125 Cosmetic Ingredient Review Expert Panel. Final report on the safety assessment of Glycyrrhetinic Acid, Potassium Glycyrrhetinate, Disodium Succinoyl Glycyrrhetinate, Glyceryl Glycyrrhetinate, Glycyrrhetinyl Stearate, Stearyl Glycyrrhetinate, Glycyrrhizic Acid, Ammonium Glycyrrhizate, Dipotassium Glycyrrhizate, Disodium Glycyrrhizate, Trisodium Glycyrrhizate, Methyl Glycyrrhizate, and Potassium Glycyrrhizinate. *Int J Toxicol* 2007; **26**(Suppl 2): 79–112. VI
1126 Homma M, Ishihara M, Qian W, Kohda Y. Effects of Long Term Administration of Shakuyaku-kanzo-To and Shosaiko-To on Serum Potassium Levels. *Yakugaku Zasshi* 2006; **126**: 973–978. Japanese. V
1127 Panoulas VF, Douglas KM, Stavropoulos-Kalinoglou A, Metsios GS, Nightingale P, Kita MD, Elisaf MS, Kitas GD. Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis. *Rheumatology (Oxford)* 2008; **47**: 72–75. E-II
1128 Sato A, Funder JW, Okubo M, Kubota E, Saruta T. Glucocorticoid-induced hypertension in the elderly. Relation to serum calcium and family history of essential hypertension. *Am J Hypertens* 1995; **8**: 823–828. E-II
1129 Saruta T. Mechanism of glucocorticoid-induced hypertension. *Hypertens Res* 1996; **19**: 1–8. VI
1130 Kelly JJ, Martin A, Whitworth JA. Role of erythropoietin in cortisol-induced hypertension. *J Hum Hypertens* 2000; **14**: 195–198. II
1131 Whitworth JA, Schyvens CG, Zhang Y, Andrews MC, Mangos GJ, Kelly JJ. The nitric oxide system in glucocorticoid-induced hypertension. *J Hypertens* 2002; **20**: 1035–1043. VI
1132 Iuchi T, Akaike M, Mitsui T, Ohshima Y, Shintani Y, Azuma H, Matsumoto T. Glucocorticoid excess induces superoxide production in vascular endothelial cells and elicits vascular endothelial dysfunction. *Circ Res* 2003; **92**: 81–87. VI
1133 Andoh TF, Johnson RJ, Lam T, Bennett WM. Subclinical renal injury induced by transient cyclosporine exposure is associated with salt-sensitive hypertension. *Am J Transplant* 2001; **1**: 222–227.
1134 Sander M, Lyson T, Thomas GD, Victor RG. Sympathetic neural mechanisms of cyclosporine-induced hypertension. *Am J Hypertens* 1996; **9**: 121S-138S. VI
1135 Zhang W, Victor RG. Calcineurin inhibitors cause renal afferent activation in rats: a novel mechanism of cyclosporine-induced hypertension. *Am J Hypertens* 2000; **13**: 999–1004.
1136 Lungu AO, Jin ZG, Yamawaki H, Tanimoto T, Wong C, Berk BC. Cyclosporin A inhibits flow-mediated activation of endothelial nitric-oxide synthase by altering cholesterol content in caveolae. *J Biol Chem* 2004; **279**: 48794–48800.
1137 Halimi JM, Giraudeau B, Buchler M, Al-Najjar A, Etienne I, Laouad I, Bruyère F, Lebranchu Y. Enalapril/amlodipine combination in cyclosporine-treated renal transplant recipients: a prospective randomized trial. *Clin Transplant* 2007; **21**: 277–284. II
1138 Suzuki M, Goya T. Survey regarding the preparation of guidelines for the use of EPO. Study report in 1992 by the Medical Research Business for Renal Failure by a scientific grant from the Ministry of Health and Welfare, 1993, pp. 165–172. Japanese. VI
1139 Sasagawa I, Nakada T, Hashimoto T, Kubota Y, Suzuki H, Sawamura T. Change in haemoglobin concentration, haematocrit and vasoactive hormones in haemodialysis patients with erythropoietin-associated hypertension. *Int Urol Nephrol* 1994; **26**: 237–243. III
1140 Okura Y, Oshima T, Yasunobu Y, Amano K, Mori M, Shinozaki K, Kajiyama G. Effect of erythropoietin treatment on blood pressure and intracellular cation concentrations in maintenance hemodialysis patients. *Hypertens Res* 1996; **19**: 91–95. III
1141 Shimada N, Saka S, Sekizuka K, Tanaka A, Takahashi Y, Nakamura T, Ebihara I, Koide H. Increased endothelin: nitric oxide ratio is associated with erythropoietin-induced hypertension in hemodialysis patients. *Ren Fail* 2003; **25**: 569–578. III
1142 Ishimitsu T, Tsukada H, Ogawa Y, Numabe A, Yagi S. Genetic predisposition to hypertension facilitates blood pressure elevation in hemodialysis patients treated with erythropoietin. *Am J Med* 1993; **94**: 401–406. E-Ib
1143 Miyashita K, Tojo A, Kimura K, Goto A, Omata M, Nishiyama K, Fujita T. Blood pressure response to erythropoietin injection in hemodialysis and predialysis patients. *Hypertens Res* 2004; **27**: 79–84. III
1144 Ohkubo M, Ishimitsu T, Kawaguchi T, Abe M, Yagi S. Efficacy and safety of long-term erythropoietin therapy in chronic hemodialysis patients with renal anemia. *Jpn J Nephrol Nihon Jinzo Gakkai Shi* 1993; **35**: 171–177. Japanese. V
1145 Du Y, Melchert HU, Schäfer-Korting M. Use of oral contraceptives in Germany: prevalence, determinants and use-associated health correlates. Results of National Health Surveys from 1984 to 1999. *Eur J Obstet Gynecol Reprod Biol* 2007; **134**: 57–66. E-II
1146 Hui KK. Hypertensive crisis induced by interaction of clonidine with imipramine. *J Am Geriatr Soc* 1983; **31**: 164–165. V
1147 Abo-Zena RA, Bobek MB, Dweik RA. Hypertensive urgency induced by an interaction of mirtazapine and clonidine. *Pharmacotherapy* 2000; **20**: 476–478. V
1148 Eisenhofer G, Rivers G, Rosas AL, Quezado Z, Manger WM, Pacak K. Adverse drug reactions in patients with phaeochromocytoma: incidence, prevention and management. *Drug Saf* 2007; **30**: 1031–1062. VI
1149 Feldman DR, Baum MS, Ginsberg MS, Hassoun H, Flombaum CD, Velasco S, Fischer P, Ronnen E, Ishill N, Patil S, Motzer RJ. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. *J Clin Oncol* 2009; **27**: 1432–1439. IVa
1150 Dienstmann R, Braña I, Rodon J, Tabernero J. Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs. *Oncologist* 2011; **16**: 1729–1740. VI
1151 Sane DC, Anton L, Brosnihan KB. Angiogenic growth factors and hypertension. *Angiogenesis* 2004; **7**: 193–201. VI
1152 Izzedine H, Ederhy S, Goldwasser F, Soria JC, Milano G, Cohen A, Khayat D, Spano JP. Management of hypertension in angiogenesis inhibitor-treated patients. *Ann Oncol* 2009; **20**: 807–815. VI